US 2026/0103471 A1Application

CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV

Publication Date:2026-04-16

•30 Claims

Abstract

The present disclosure provides, in part, cyclic urea thiazolyl compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

Metadata

Assignee

Assembly Biosciences, Inc.

Inventors

Hassan PAJOUHESH
Min ZHONG
Michael WALKER
Jiaxin YU
Jian ZHANG
Mark BURES

Application Information

Application Number:US 19/415,133

Filing Date:2025-12-10

Priority Date:2022-08-29

Classifications

IPC:

C07D491/107A61K31/427A61K31/513A61K31/527A61K31/5377A61K31/538A61K31/551A61P31/22C07D417/04C07D417/14C07D471/04C07D487/04C07D495/04C07D513/04

Patent Drawings

This patent does not have any drawings.

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is continuation of U.S. application Ser. No. 19/107,962, filed Feb. 28, 2025, which is a National Stage application of International Application No. PCT/US2023/031285, filed Aug. 28, 2023, which claims benefit of U.S. Provisional Application No. 63/401,877, filed Aug. 29, 2022, U.S. Provisional Application No. 63/445,427, filed Feb. 14, 2023, and U.S. Provisional Application No. 63/472,494, filed Jun. 12, 2023, the contents of each are hereby incorporated by reference.

BACKGROUND

[0002] Human herpes viruses are large-enveloped double-stranded DNA viruses that share the characteristic of establishing life-long infections in humans. This is accomplished by their ability to exist in the host either as a symptom free latent infection, where the virus lies dormant or, following activation, as a lytic infection with associated symptoms. These viral infections have widespread, worldwide prevalence and it is notable that over 90% of all humans are chronically infected with more than one human herpes virus.

[0003] Human herpes viruses are classified into three subfamilies (i.e., α, β and γ) based upon their biological characteristics and the family consists of eight members, i.e., Herpes Simplex Virus subtype type 1 and 2 (HSV1, HSV2), Varicella Zoster Virus (VZV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), and human herpes viruses 6-8 (HHV 6-8).

[0004] HSV1 and 2 infections can cause disease in immune competent individuals. Both subtypes cause cutaneous genital/anal and orolabial/nasal cavity (cold sore) lesions, although HSV2 is more commonly associated with the former and HSV1 the latter such that >80% of genital infections are believed to be caused by HSV2. Globally, over 500 million people have genital herpes infections. Symptoms vary but are typically most severe on first time of infection and can last for weeks to months. Approximately 50 to 80% of the world's population have orolabial HSV infection, which is the main cause of cold sores. HSV, and particularly HSV1, can also cause lesions on the fingers (Whitlows) and other areas of the skin.

[0005] The vast majority of HSV infected individuals will not experience any noticeable symptoms. However, some will experience recurrent outbreaks of infection. In the USA, 20 to 40% of the population will get recurrent labial HSV lesions. Significantly, orolabial cold sores and Whitlow's provide a very easy route for transmission of the virus to other individuals which can lead to rarer but much more serious HSV-related pathologies. For example, HSV-related ocular keratitis is a major cause of blindness. HSV can also cause encephalitis in neonates which is a life-threatening condition. Other disorders also believed to be caused by HSV include herpes gladiatorum, Mollaret's meningitis and possibly Bell's palsy.

[0006] Primary infection with, or reactivation of an existing herpes virus infection, can be a major cause of disease in immunocompromised individuals. Key at-risk immunocompromised populations include patients undergoing solid organ or stem cell transplantation, individuals with HIV/AIDS, and ICU patients.

[0007] Presently, there is no cure for HSV. Medicines have been developed that can to some degree prevent or shorten outbreaks, but there is a need for improved therapies for treating HSV infection and inhibiting viral replication.

[0008] Currently, nucleoside analogues, such as acyclovir and its prodrugs, e.g., valacyclovir and famciclovir, are used as agents against herpes viruses such as HSV. In order to exert their effects, these nucleoside analogues must first be phosphorylated by viral thymidine kinase (TK) and then subsequently converted by cellular kinases to the nucleoside triphosphate, which inhibits the activity of the viral DNA polymerase. If the virus has no functionally active TK, as is the case, for example, with resistant HHV1 mutants or with TK-negative viruses, the active substance is unable to exert its effects.

[0009] Nucleoside analogues are clinically administered at a dose as high as several hundred in mg to several grams per day and even in high doses, and over long treatment durations, these compounds do not completely prevent recurrent outbreaks of symptoms from HSV infection. High doses also lead to increased levels of adverse effects.

[0010] Viral shedding is also common in HSV patients and can asymptomatically facilitate the transmission of HSV to more individuals. Nucleoside analogues do little to address this and long-term suppressive treatment, e.g., with valacyclovir has been shown to reduce transmission risk only by 46%. Since the nucleoside analogues can incorporate into the genome DNA of a host via the host DNA polymerase, the mutagenicity of these agents is also a concern, as documented for the nucleoside analogue, ganciclovir.

[0011] Given the inadequacy of existing treatments, there is an urgent medical need to develop improved, well-tolerated anti-herpes treatments.

[0012] A class of compounds being investigated for HSV treatment are the helicase-primase inhibitors. Helicase-primase inhibitors are antiviral agents with a novel mechanism of action against HSV1 and 2. They inhibit the viral heterotrimeric complex consisting of helicase, primase, and cofactor subunits that have functions essential for viral DNA replication. They are not nucleoside analogues and do not require phosphorylation by TK to inhibit HSV replication and they are therefore potentially active against TK-deficient HSV, which as described above, is a major mechanism of resistance to nucleoside analogues, such as acyclovir.

[0013] Two examples of helicase-primase inhibitors are BILS-179 BS and amenamevir (Katsumata et al. (2018) Biochem Pharm 158 p 201-206). BILS-179 BS has been dosed orally but was suspended from early clinical trials due to adverse events.

[0014] One example of a helicase-primase inhibitor is pritelivir, a thiazolylamide derivative with the chemical name N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]acetamide. This compound has been disclosed in WO200053591. WO2001047904 discloses thiazolyl amide derivatives and their use as antiviral medicaments. WO2000053591 discloses thiazolyl derivatives and their utilization as antiviral agents. WO2017174640 discloses aminothiazole derivatives useful as antiviral agents. WO2019068817 discloses enantiomers of substituted thiazoles as antiviral compounds.

[0015] There is still a need for additional antiviral compounds for the treatment and prophylaxis of HSV infections that have an improved profile with respect to safety, potency, selectivity and/or bioavailability.

SUMMARY OF THE INVENTION

[0016] In one embodiment, the present disclosure provides a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein the variables are as described herein.

[0017] In another aspect, the disclosure provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0018] In another aspect, the disclosure provides a method of treating an HSV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof.

[0019] In another aspect, the disclosure provides a method of treating an HSV infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0020] In another aspect, the present invention provides a compound of Formula II

or a pharmaceutically acceptable salt thereof, wherein the variables are as described herein.

[0021] In another aspect, the disclosure provides pharmaceutical compositions comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0022] In another aspect, the disclosure provides a method of treating an HSV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound of Formula II, or a pharmaceutically acceptable salt thereof.

[0023] In another aspect, the disclosure provides a method of treating an HSV infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION OF THE INVENTION

[0024] The FDA-approved nucleoside drugs, acyclovir, and its prodrug valacyclovir, have been the mainstay of HSV treatment for many years There have been no regulatory approvals for small-molecule drugs to treat HSV in over two decades, making it an area of significant unmet medical need.

[0025] Pritelivir has entered Phase III clinical development by AiCuris for treatment of HSV. Bayer filed patent applications for two scaffolds related to Pritelivir. The first application, WO200053591 (filed on 24 Feb. 2000), relates to compounds with an acyclic urea core. The second application, WO2001047904 (filed on 12 Dec. 2000), relates to compounds, including Pritelivir, with an acyclic amide core. The discovery of Pritelivir (BAY 57-1293) is outlined in G. Kleymann, “Discovery, SAR and Medicinal Chemistry of Herpesvirus Helicase Primase Inhibitors,” Curr. Med. Chem.—Anti-Infective Agents, 2004, 3, 69-83 Of the 227 exemplified acyclic urea compounds disclosed in WO200053591, in vitro HSV-1 and HSV-2 biological assay data are provided for only four Examples: 43, 123, 94 and 2.

[0026] The structures of Examples 123 and 152 are shown below:

Likewise, of the 132 exemplified acyclic amide compounds in WO2001047904, in vitro HSV-1 and HSV-2 biological assay data are provided for only seven Examples: 14, 57, 8, 23, 38, 87 and 126. The structures of Examples 87 and 38 are shown below:

[0027] Example 5, described herein, is a preferred compound of the present invention. It has a solubility in water at ˜pH 7.0 (measured at room temperature) of less than 5 μg/ml. Animal studies were conducted to determine the half-life and clearance of Example 5. Intravenous dosing of a solution of the compound in rat, dog, monkey and mini-pig, at doses of 0.2 mg/kg, 0.15 mg/kg, 0.2 mg/kg and 0.25 mg/kg respectively, gave the terminal half-lives and clearances shown in the following table:


Species	Half-life (days)	Clearance (L/hr/kg)


Rat	0.8	0.02
Dog	2.3	0.002
Monkey	3.0	0.004
Mini-pig	5.6	0.0018

Based on the above pharmacokinetic data in multiple species, and using allometric scaling, the predicted human biological terminal half-life of the compound is 7.6 days (182 hours) with a clearance of 0.06 L/hr.

[0028] Table 1 shows comparison biological assay data for Example 5 of the present invention with the four prior art compounds shown above either lacking a substituent on the urea nitrogen atom between the carbonyl and phenyl moieties (acyclic ureas) or lacking a substituent on the carbon atom between the carbonyl and phenyl moieties (acyclic amides). The prior art compounds were prepared according to known procedures and all biological assay data presented in Table 1 was obtained using the biological assays described herein.

TABLE 1

Biological Activity Comparison of Example 5 with vs
Acyclic Urea and Amide Compounds in the Prior Art
		HSV-1	HSV-2
		EC50	EC50
COMPOUND	Core Moiety	(nM)	(nM)

Example 5	Cyclic Urea	19	10
Example 123 in WO200053591	Acyclic Urea	53	50
Example152 in WO200053591	Acyclic Urea	Not	132
		tested
Example 87 in WO2001047904	Acyclic Amide	17	17
Example 38 in WO2001047904	Acyclic Amide	70	40
(pritelivir)

[0029] The cyclic urea compounds of the present invention incorporate two novel structural changes absent in these prior art compounds. First, both nitrogen atoms have a covalent bond to a carbon atom making it a tetra-substituted urea. Second, the N-alkyl groups attached to the nitrogen atoms are linked to form a ring. These features are neither taught nor suggested in the Bayer patents referenced above.

[0030] Only one acyclic urea compound in WO200053591, Example 38, features a tetrasubstituted core ring (i.e., a core ring with substituents attached to both urea nitrogen atoms). More specifically, while all the exemplified compounds are substituted with a diverse group of substituents on the nitrogen which bears the thiazole heterocycle, only Example 38 is additionally substituted on the opposite urea nitrogen atom. Likewise, only one compound in WO2001047904, Example 45, has a substituent on the benzylic carbon atom next to the amide carbonyl, while there is a diverse set of substituents on the amide nitrogen.

No biological data is provided for either of these compounds and there is no teaching, suggestion or motivation recited in WO200053591 or WO2001047904 to cyclize the urea moiety. Nevertheless, Applicants have discovered that the novel cyclic urea compounds described herein, particularly tetrahydropyrimidin-2(1H)-ones, are surprisingly active relative to their acyclic counterparts and have differing physical and biological properties.

[0031] Since no biological data was provided in the prior art for Examples 38 and 45 discussed above, Applicants prepared a novel acyclic tetra-substituted urea Reference Compound A for direct comparison of biological activity relative to Example 5. Applicants note that a direct comparison to Example 38 of WO200053591 might result in ambiguous results due to the presence of a methyl ester moiety on the terminal phenyl group.

[0032] As shown in Table 2, Reference Compound A is 44-fold less active than Example 5 in the HSV-1 assay and 92-fold less active than Example 5 in the HSV-2 assay. Applicants also note that compared to the acyclic amide analog Example 87, shown above, Reference Compound A is 50-fold less active in the HSV-1 assay and 54-fold less active in the HSV-2 assay.

TABLE 2

Biological Activity Comparison of Example 5
of present invention with Novel Acyclic Analog
Substituted on BOTH Urea Nitrogen Atoms
		HSV-1 EC50	HSV-2 EC50
COMPOUND	Core Moiety	(nM)	(nM)

Example 5	Cyclic Urea	19	10
Reference Compound A	Acyclic Urea	844	925

[0033] Without specific teachings in the prior art, it was not possible to predict a priori the effect that alkylation of the urea nitrogen atom between the urea carbonyl and phenyl group, as in Reference Compound A, would have on activity. The comparison data presented above demonstrates substantial diminishment of biological activity for an acylic tetrasubstituted urea. Without structural information showing how the compound binds to the target it is not possible to know why methylation reduces activity. There are multiple hypotheses that might explain this observation. Without being bound by theory, these include the following: 1) if the urea NH forms an H-bond to the target, methylation would remove the H-bond donating NH; 2) there might not be enough space in the target to accommodate the methyl group; 3) if the urea carbonyl forms an H-bond to the target, methylation could sterically interfere and weak the interaction; 4) methylation might alter the conformational dynamics of the urea limiting its ability to form a favored bond-conformation; 5) methylation will alter the physical properties the molecule which might reduce its propensity to partition into the inhibitor binding pocket; and 6) methylation will alter the physical properties the molecule which might reduce its ability to enter the cell or access the target once inside the cell. Therefore, the behavior observed with Example 5, where the biological activity is significantly increased by cyclizing the urea moiety, can be considered unexpected and surprising from a medicinal chemistry point of view.

[0034] Applicants further point out that generally in medicinal chemistry, cyclization of an acyclic moiety results in diminished activity because the rotational freedom is limited to one conformer, which is statistically unlikely to be the preferred confirmation at the binding site. Without being bound by theory, additional potential explanations for surprising results presented herein include but are not limited to:

- [0035] 1. Conformational Preference: The cyclization of Compound 5 may lead to a specific conformation that aligns more favorably with the target binding site, allowing for stronger interactions and increased biological activity. This preferred conformation could enhance binding affinity and efficacy.
- [0036] 2. Structural Rigidity: The cyclized form of Compound 5 might exhibit greater structural rigidity, leading to improved stability and a reduced entropic cost of binding. This could facilitate a more optimal binding geometry and enhance target engagement.
- [0037] 3. Spatial Constraints: The cyclization may enable the compound to adopt a three-dimensional shape that complements the target's binding pocket, leading to improved molecular recognition and enhanced biological activity.

[0038] Applicants have further discovered that among the novel cyclic ureas of the present invention. 6-member core rings (i.e., tetrahydro-2(1H)-pyrimidinones) are generally more active than the corresponding 5-membered core rings (i.e., 2-imidazolidinones). Consider the following two sets of compounds: Examples 5/104 and Examples 259/324 with the following structures:

As shown in Table 3, Examples 5 is 91-fold more active than Example 104 (the 5-membered ring analog) in the HSV-1 assay and >200-fold more active in the HSV-2 assay. Similarly, Example 259 is 4-fold more active than Example 314 (the 5-membered ring analog).

TABLE 3

Biological Activity Comparison of Compounds
with 5- and 6-membered Cyclic Urea Cores
		HSV-1 EC50	HSV-2 EC50
COMPOUND	Core Ring Size	(nM)	(nM)

Example 5	6-membered Ring	19	10
Example 104	5-membered ring	1740	>2000 > 2
Example 259	6-membered ring	10	7
Example 314	5-membered ring	Not tested	28

[0039] The specific reasons behind this trend are unknown and would require a detailed analysis of the compounds' interactions with the target, including potential differences in conformational flexibility, binding affinity, and steric effects. Without being bound by theory, the larger size of the 6-membered core ring might contribute to improved binding interactions and enhanced potency compared to the 5-membered core ring, which could be a result of the increased conformational space accessible to the 6-membered ring.

[0040] The features and other details of the disclosure will now be more particularly described. Before further description of the present disclosure, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.

Definitions

[0041] The term “alkyl” as used herein refers to a saturated straight or branched hydrocarbon. Exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6 or 1-4 carbon atoms, referred to herein as C_1-6alkyl and C_1-4alkyl, respectively. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-butyl, 3-methyl-2-butyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.

[0042] The term “alkylene” as used herein refers to a biradical alkyl group.

[0043] The term “alkenyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups include, but are not limited to, a straight or branched group of 2-6 carbon atoms, referred to herein as C_2-6alkenyl. Examples include, but are not limited to, vinyl, allyl, butenyl, and pentenyl.

[0044] The term “alkynyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6 carbon atoms, referred to herein as C_2-6alkynyl. Examples include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and methylpropynyl.

[0045] The term “alkoxy” as used herein refers to a straight or branched alkyl group attached to oxygen (i.e., alkyl-O—). Exemplary alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 1-4 carbon atoms, referred to herein as C_1-6alkoxy and C_1-4alkoxy, respectively. Examples include, but are not limited to, methoxy, ethoxy, and isopropoxy.

[0046] The term “alkoxyalkyl” as used herein refers to an alkyl group substituted with an alkoxy group. Exemplary alkoxyalkyl groups include, but are not limited to, a C_1-6alkyl group substituted with a C_1-3alkoxy or C_1-4alkoxy group, referred to herein as C_1-3alkoxyC_1-6alkyl and C_1-4alkoxyC_1-6alkyl, respectively. Examples include, but are not limited to, CH₃CH₂OCH₂—, CH₃OCH₂CH₂— and CH₃OCH₂—.

[0047] The term “cyano” as used herein refers to CN.

[0048] The term “monocycloalkyl” as used herein refers to a saturated monocyclic hydrocarbon group of, for example, 3-6 carbons, referred to herein as C_3-6monocycloalkyl. Examples include, btu are not limited to, cyclooctyl, cycloheptyl. cyclohexyl, cyclopentenyl, cyclobutyl and cyclopropyl.

[0049] The terms “halo” or “halogen” as used herein refer to F, Cl, Br or I.

[0050] The term “haloalkyl” as used herein refers to an alkyl group substituted with one or more halogen atoms. Exemplary haloalkyl groups include, but are not limited to, a C_1-6alkyl or C_1-4alkyl substituted with one or more halo groups, referred to herein as haloC_1-6alkyl and haloC_1-4alkyl, respectively. For example, haloC_1-6alkyl refers to a straight or branched alkyl group of 1-6 carbon atoms substituted with one or more halogen atoms. Examples include, but are not limited to, —CH₂F, —CHCl₂, —CHF₂, —CF₃, CF₃CH₂—, CH₃CF₂—, CF₃CCl₂— and CF₃CF₂—.

[0051] The term “haloalkoxy” as used herein refers to an alkoxy group substituted with one or more halogen atoms. Exemplary alkoxy groups include, but are not limited to, a C_1-6alkoxy or C_1-4alkoxy substituted with one or more halo groups, referred to herein as haloC_1-6alkoxy and haloC_1-4alkoxy, respectively. Examples include, but are not limited to, CCl₃O—, CF₃O—, CHF₂O—CF₃CH₂O—, and CF₃CF₂O—.

[0052] The terms “hydroxy” and “hydroxyl” as used herein refer to OH.

[0053] The term “hydroxyalkyl” as used herein refers to an alkyl group substituted with one or more hydroxy groups. Exemplary hydroxyalkyl groups include, but are not limited to, a C_1-6alkyl or C_1-4alkyl substituted with one or more hydroxy groups, referred to herein as hydroxyC_1-6alkyl and hydroxyC_1-4alkyl, respectively. Examples include, but are not limited to, HOCH₂—, HOCH₂CH₂—, CH₃CH(OH)CH₂—, (CH₃)₂C(OH)CH₂—, and HOCH₂CH(OH)CH₂—.

[0054] The term “hydroxyalkoxy” as used herein refers to an alkoxy group substituted with one or more hydroxy groups. Exemplary hydroxyalkoxy groups include, but are not limited to, a C_1-6alkoxy or C_1-4alkoxy substituted with one or more hydroxy groups, referred to herein as hydroxyC_1-6alkoxy and hydroxyC_1-4alkoxy, respectively. Examples include, but are not limited, to HOCH₂O—, HOCH₂CH₂O—, CH₃CH(OH)CH₂O—, (CH₃)₂C(OH)CH₂O—, and HOCH₂CH(OH)CH₂O—.

[0055] The term “RⁿR^mNalkyl-,” as used herein refers to an alkyl group substituted with a RⁿR^mN— group, as defined herein. Exemplary RⁿR^mNalkyl- groups include, but are not limited to, a C_1-6alkyl or C_1-4alkyl substituted with one or more RⁿR^mN— group groups, referred to herein as RⁿR^mNC_1-6alkyl and RⁿR^mNC_1-4alkyl, respectively. Examples include, but are not limited to NH₂CH₂—, NH(CH₃)CH₂—, N(CH₃)₂CH₂CH₂— and CH₃CH(NH₂)CH₂—.

[0056] The term “RⁿR^mNalkoxy,” as used herein refers to an alkoxy group substituted with a RⁿR^mN— group, as defined herein. Exemplary RⁿR^mNalkoxy groups include, but are not limited to, a C_1-6alkoxy or C_1-4alkoxy substituted with one or more RⁿR^mN— groups, referred to herein as RⁿR^mNC_1-6alkoxy and RⁿR^mNC_1-4alkoxy, respectively. Examples include, but are not limited to, NH₂CH₂—, NH(CH₃)CH₂O—, N(CH₃)₂CH₂CH₂O—, and CH₃CH(NH₂)CH₂O—.

[0057] As used herein, when a bicyclic ring is shown with a floating point of attachment and/or floating substituents, for example as in

it signifies that the bicyclic ring can be attached via a carbon atom on either ring, and that the substituents (e.g., the R³³group(s)) can be independently attached to either or both rings.

[0058] The terms “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds or pharmaceutical compositions of the disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, dogs, primates, and the like). The mammal treated in the methods of the disclosure is desirably a mammal in which treatment of HSV infection is desired.

[0059] The term “modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.

[0060] The term “Pharmaceutically acceptable” includes molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.

[0061] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, fillers, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.

[0062] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable excipients.

[0063] The term “pharmaceutically acceptable salt(s)” as used herein refers to salts of acidic or basic groups that may be present in compounds used in the compositions. Compounds included in the present compositions that are basic in nature can form a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.

[0064] The term “therapeutically effective amount” or “effective amount” as used herein refers to the amount of the subject compound that will elicit the biological or medical response of a tissue, system or animal, (e.g., mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician. The compounds or pharmaceutical compositions of the disclosure are administered in therapeutically effective amounts to treat a disease. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect.

[0065] The term “treating” includes any effect, e.g., lessening, reducing, modulating, or eliminating, a viral infection, that results in the improvement of the disease.

[0066] The compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers. The term “stereoisomers” when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “(−),” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. The present disclosure encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.

[0067] The compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond. The symbol custom-character

denotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.

[0068] Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring. The arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers. Substituents around a carbocyclic or heterocyclic ring may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”

[0069] Individual enantiomers and diastereomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well-known methods, such as chiral-phase liquid chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art. Stereoselective syntheses encompass both enantiomeric and diastereoselective transformations and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.

[0070] The compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a single polymorph. In another embodiment, the compound is a mixture of polymorphs. In another embodiment, the compound is in a crystalline form.

[0071] The disclosure also embraces isotopically labeled compounds of the disclosure which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl, respectively. For example, a compound of the disclosure may have one or more H atom replaced with deuterium.

[0072] Certain isotopically labeled disclosed compounds (e.g., those labeled with ³H and ¹⁴C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e., ¹⁴C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0073] The term “prodrug” refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, et al., Nature Reviews Drug Discovery 2008, 7, 255).

Cyclic Urea Thiazolyl Compounds

[0074] In one aspect, the present disclosure provides a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein:

is selected from the group consisting of

- [0075] X is CR²or N;
- [0076] X⁰is O, S or NR^x;
- [0077] X¹, X², X³, X⁴and X⁶are independently selected from the group consisting of O and S;
- [0078] X⁵is CH₂, CF₂, O, S or NR^y,
- [0079] L is

- [0080] L¹is a bond; or L¹is —CH₂— or CH(CH₃)— when

- is

- [0081] L²is —CH₂—, —CH₂CH₂— or —CH₂CH₂CH₂—;
- [0082] R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, Rⁱand R^jare independently selected from the group consisting of hydrogen, halo, cyano, OH, NRⁿR^m, —C(O)OH, —C(O)OC_1-4alkyl, —C(O)NRⁿR^m, —SO₂NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, C_1-4alkoxy, and R¹³, provided that only one of R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, Rⁱand R^jcan be R¹³; or two R-groups together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,

- [0083] R^xand R^yare independently selected from the group consisting of is hydrogen, C_1-4alkyl, and acetyl;
- [0084] R¹is

- [0085] R²is hydrogen, halo, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy or haloC_1-4alkoxy;
- [0086] R³is independently selected for each occurrence from the group consisting of halo and cyano;
- [0087] R^3a, R^4a, R^11a, R^12aand R^14aare independently selected from the group consisting of hydrogen, C_1-4alkyl, halo C_1-4alkyl and hydroxyC_1-4alkyl;
- [0088] R⁴is independently selected for each occurrence from the group consisting of halo, CN, OH, NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl optionally substituted with hydroxyC_1-3alkyl, cyclopropyl optionally substituted with halo or cyano, and R^4b, provided that only one R⁴group can be R^4b;
- [0089] R^4bis selected from the group consisting of

- [0090] R⁷and R¹are independently selected from the group consisting of hydrogen, C_1-4alkyl, acetyl, C_3-6monocycloalkyl, phenyl, and pyridyl; or R⁷and R⁸together with the N atom to which they are attached form an arizidinyl, azetidinyl, pyrrolidinly, piperidinyl, morpholinyl or thiomorpholinyl group;
- [0091] R^7aand R^8aare independently selected from the group consisting of hydrogen, C_1-4alkyl and C_3-6monocycloalkyl, or R⁷and R⁸together with the N atom to which they are attached form an arizidinyl, azetidinyl, pyrrolidinyl, or piperidinyl morpholinyl or thiomorpholinyl group;
- [0092] R⁹and R^9aare independently selected from the group consisting or C_1-4alkyl and haloC_1-4alkyl;
- [0093] R¹⁰and R^10aare independently selected from the group consisting of hydrogen and C_1-4alkyl;
- [0094] R¹¹, R¹²and R¹⁴are independently selected for each occurrence from the group consisting of halo, CN, OH, NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, and cyclopropyl;
- [0095] R¹³is selected from the group consisting of

[0096] Rⁿand R^mare independently selected for each occurrence from the group consisting or hydrogen and C_1-4alkyl;

- [0097] j, p, q, r and x are independently selected from the group consisting of 0 and 1;
- [0098] k, n, s, w and z are independently selected from the group consisting of 0, 1 and 2; and
- [0099] m, t, u, v and y are independently selected from the group consisting of 0, 1, 2 and 3.

[0100] In another aspect, the present disclosure provides a compound of Formula Ia

or a pharmaceutically acceptable salt thereof, wherein:

- [0101] X is CR²or N;
- [0102] X⁵is CH₂, CF₂, O, S or NR^y;
- [0103] L is

- [0104] R^a, R^b, R^c, R^d, R^e, R^f, R^gand R^hare independently selected from the group consisting of hydrogen, halo, cyano, OH, NRⁿR^m, —C(O)OH, —C(O)OC_1-4alkyl, —C(O)NRⁿR^m, —SO₂NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, C_1-4alkoxy, and R¹³, provided that only one of R^a, R^b, R^c, R^d, R^e, R^f, R^gand R^hcan be R¹³; or two R-groups together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,

- [0105] R^yis hydrogen, C_1-4alkyl or acetyl;
- [0106] R¹is

- [0107] R²is hydrogen, halo, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy or haloC_1-4alkoxy;
- [0108] R³is independently selected for each occurrence from the group consisting of halo and cyano;
- [0109] R⁴is independently selected for each occurrence from the group consisting of halo, CN, OH, NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl optionally substituted with hydroxyC_1-3alkyl, and cyclopropyl optionally substituted with halo or cyano;
- [0110] R⁷and R¹are independently selected from the group consisting of hydrogen, C_1-4alkyl, acetyl, C_3-6monocycloalkyl, phenyl, and pyridyl; or R⁷and R⁸together with the N atom to which they are attached form an arizidinyl, azetidinyl, pyrrolidinly, piperidinyl, morpholinyl or thiomorpholinyl group;
- [0111] R^7aand R^8aare independently selected from the group consisting of hydrogen, C_1-4alkyl and C_3-6monocycloalkyl, or R⁷and R⁸together with the N atom to which they are attached form an arizidinyl, azetidinyl, pyrrolidinyl, or piperidinyl morpholinyl or thiomorpholinyl group;
- [0112] R⁹and R^9aare independently selected from the group consisting or C_1-4alkyl and haloC_1-4alkyl;
- [0113] R¹⁰and R^10aare independently selected from the group consisting of hydrogen and C_1-4alkyl;
- [0114] R¹³is selected from the group consisting of

- [0115] R¹⁴is independently selected for each occurrence from the group consisting of halo, CN, OH, NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, and cyclopropyl;
- [0116] R^14ais selected from the group consisting of hydrogen, C_1-4alkyl, halo C_1-4alkyl and hydroxyC_1-4alkyl;
- [0117] Rⁿand R^mare independently selected for each occurrence from the group consisting or hydrogen and C_1-4alkyl;
- [0118] j is selected from the group consisting of 0 and 1;
- [0119] k is selected from the group consisting of 0, 1 and 2; and
- [0120] m, u and v are independently selected from the group consisting of 0, 1, 2 and 3.

[0121] The following embodiments further describe a compound of Formula I, Formula Ia, or a pharmaceutically acceptable salt thereof. It will be appreciated that all chemically allowable combinations of the embodiments described herein are envisioned as further embodiments of the invention.

[0122] In certain embodiments,

[0123] In certain embodiments,

[0124] In certain embodiments,

[0125] In certain embodiments,

[0126] In certain embodiments,

is selected from the group consisting of

[0127] In certain embodiments,

is selected from the group consisting of

[0128] In certain embodiments,

is selected from the group consisting of

[0129] In certain embodiments,

[0130] In certain embodiments,

[0131] In certain embodiments,

[0132] In certain embodiments,

[0133] In certain embodiments,

is selected from the group consisting of

[0134] In certain embodiments,

is selected from the group consisting of

[0135] In certain embodiments,

is selected from the group consisting of

[0136] In certain embodiments, L is

[0137] In certain embodiments, L is

[0138] In certain embodiments, L is

[0139] In certain embodiments, L is

[0140] In certain embodiments, L is

[0141] In certain embodiments, L is

[0142] In certain embodiments, L is

[0143] In certain embodiments, L is

[0144] In certain embodiments, X is CR².

[0145] In certain embodiments, X is CR²and R²is Cl, F, CH₃or CF₃.

[0146] In certain embodiments, X is CR²and R²is CH₃.

[0147] In certain embodiments, R¹is

[0148] In certain embodiments, R¹is

[0149] In certain embodiments, R¹is

[0150] In certain embodiments, R¹is

[0151] In certain embodiments, R¹is

[0152] In certain embodiments, R¹is or

[0153] In certain embodiments, R¹is

[0154] In certain embodiments, R¹is

[0155] In certain embodiments, R¹is

[0156] In certain embodiments, R¹is

[0157] In certain embodiments, R³is halo for each occurrence and u is 1, 2 or 3.

[0158] In certain embodiments, R³is F for each occurrence and u is 1, 2 or 3.

[0159] In certain embodiments, R⁴is independently selected for each occurrence from the group consisting of halo, CN, methyl, CHF₂, CF₃, acetylenyl, and cyclopropyl.

[0160] In certain embodiments, R⁴is independently selected for each occurrence from the group consisting of halo, CN, OH, NH₂, NH(CH₃), N(CH₃)₂, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl optionally substituted with hydroxyC_1-3alkyl, and cyclopropyl optionally substituted with halo or cyano.

[0161] In certain embodiments, R^4bis selected from the group consisting of

[0162] In certain embodiments, R^4bis selected from the group consisting of

[0163] In certain embodiments, R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, Rⁱand R^jare independently selected from the group consisting of hydrogen, halo, cyano, OH, NH₂, NH(CH₃), N(CH₃)₂, —C(O)OH, —C(O)OC_1-4alkyl, —C(O)NH₂, —C(O)NH(CH₃), —C(O)N(CH₃)₂, —SO₂NH₂, —SO₂NH(CH₃), —SO₂N(CH₃)₂, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl and C_1-4alkoxy.

[0164] In certain embodiments, R¹³is selected from the group consisting of

[0165] In certain embodiments, R¹³is selected from the group consisting of

[0166] In another aspect, the present invention provides a compound of Formula II

or a pharmaceutically acceptable salt thereof, wherein:

is selected from the group consisting of

- [0167] X²and X⁴are independently selected from the group consisting of O and S;
- [0168] X⁵is CH₂, CF₂, O, S or NR^y,
- [0169] L is

- [0170] L¹is a bond; or L¹is —CH₂— when

- is

- [0171] R^a, R^b, R^c, R^d, R^e, R^f, R^gand R^hare independently selected from the group consisting of hydrogen, halo, CN, OH, NRⁿR^m, —C(O)OH, —C(O)OC_1-4alkyl, —C(O)NRⁿR^m, —SO₂NRⁿR^m, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, and C_1-4alkoxy; or two R-groups together with the carbon atom to which they are attached form a C_3-6monocycloalkyl,

- [0172] Rⁿand R^mare independently selected for each occurrence from the group consisting or hydrogen and C_1-4alkyl;
- [0173] R^yis hydrogen, C_1-4alkyl or acetyl;
- [0174] R¹is

- [0175] R²is hydrogen, halo, CN, OH, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, haloC_1-4alkyl, C_1-4alkoxy, hydroxyC_1-4alkyl or haloC_1-4alkoxy;
- [0176] R⁴is independently selected for each occurrence from the group consisting of halo, CN, OH, NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl optionally substituted with hydroxyC_1-3alkyl, cyclopropyl optionally substituted with halo or cyano, and R^4b, provided that only one R⁴group can be R^4b;
- [0177] R^4ais hydrogen, C_1-4alkyl, halo C_1-4alkyl and hydroxyC_1-4alkyl;
- [0178] R^4bis selected from the group consisting of

- [0179] R⁷and R⁸are independently selected from the group consisting of hydrogen, OH, acetyl, C_1-10alkyl, haloC_1-10alkyl, hydroxyC_1-10alkyl, C_1-4alkoxyC_1-10alkyl, C_3-6monocycloalkyl, phenyl, pyridyl or indolyl; or R⁷and R⁸together with the N-atom to which they are attached form an arizidinyl, azetidinyl, pyrrolidinly, piperidinyl, morpholinyl or thiomorpholinyl group, wherein the arizidinyl, azetidinyl, pyrrolidinly or piperidinyl group is optionally substituted with halo, CN or OH;
- [0180] R^7aand R^8aare independently selected from the group consisting of hydrogen, C_1-4alkyl and C_3-6monocycloalkyl, or R⁷and R⁸together with the N atom to which they are attached form an arizidinyl, azetidinyl, pyrrolidinyl, or piperidinyl morpholinyl or thiomorpholinyl group;
- [0181] R⁹and R^9aare independently selected from the group consisting or C_1-4alkyl and haloC_1-4alkyl;
- [0182] R¹⁰and R^10aare independently selected from the group consisting of hydrogen and C_1-4alkyl;
- [0183] R¹¹is independently selected from the group consisting of halo, CN, OH, NRⁿR^m, C_1-4alkyl, haloC_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, and C_3-6monocycloalkyl;
- [0184] R^11ais hydrogen, C_1-4alkyl, halo C_1-4alkyl and hydroxyC_1-4alkyl;
- [0185] q and x are independently selected from the group consisting of 0 and 1;
- [0186] w and z are independently selected from the group consisting of 0, 1 and 2; and
- [0187] v and y are independently selected from the group consisting of 0, 1, 2 and 3.

[0188] The following embodiments further describe a compound of Formula II, or a pharmaceutically acceptable salt thereof. It will be appreciated that all chemically allowable combinations of the embodiments described herein are envisioned as further embodiments of the invention.

[0189] In certain embodiments:

and

is selected from the group consisting of

[0190] In certain embodiments:

and

[0191] In certain embodiments:

[0192] is

and

is selected from the group consisting of

[0193] In certain embodiments:

is selected from the group consisting of

[0194] In certain embodiments:

and

[0195] In certain embodiments: L is

[0196] In certain embodiments, L is

[0197] In certain embodiments, L is

[0198] In certain embodiments: L is

[0199] In certain embodiments, L is

[0200] In certain embodiments: R²is H, Cl, F, CH₃or CF₃.

[0201] In certain embodiments: R²is CH₃.

[0202] In certain embodiments:

- [0203] R¹is

[0204] In certain embodiments: R¹is

[0205] In certain embodiments: R¹is

[0206] In certain embodiments: R¹is

[0207] In certain embodiments: R¹is

[0208] In certain embodiments: R¹is

[0209] In certain embodiments: R¹is

[0210] In certain embodiments: R¹is

[0211] In certain embodiments: R¹is

[0212] In certain embodiments: R³is halo for each occurrence and u is 0, 1, 2 or 3.

[0213] In certain embodiments: u is 0.

[0214] In certain embodiments: R⁴is independently selected for each occurrence from the group consisting of halo, CN, methyl, CHF₂, CF₃, acetylenyl, and cyclopropyl.

[0215] In certain embodiments: R⁴is independently selected from halo for all occurrences.

Methods of Use

[0216] The compounds according to the present invention are useful for the treatment and prophylaxis of disorders caused by herpes viruses, in particular Herpes simplex viruses.

[0217] In one aspect, the present invention provides a method for the treatment or prophylaxis of an HSV infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

[0218] In some embodiment, the infection is a Herpes simplex infection.

[0219] In some embodiment, the infection is an HSV-1 infection.

[0220] In some embodiment, the infection is an HSV-2 infection.

[0221] In some embodiments, the infection is a Herpes simplex infection and the subject displays symptoms such as Herpes labialis, Herpes genitalis, HSV-related keratitis, encephalitis, or pneumonia.

[0222] In another embodiment, the infection is a Herpes simplex infection and the subject displays symptoms such as suppressed immune system (for example AIDS patients, cancer patients, patients having a genetic immunodeficiency, transplant patients).

[0223] In another embodiment, the infection is a Herpes simplex infection, and the subject is a new-born child or infant.

[0224] In another aspect, the present invention provides a method for suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

[0225] In some embodiment, the infection is a Herpes simplex infection.

[0226] In some embodiment, the infection is an HSV-1 infection.

[0227] In some embodiment, the infection is an HSV-2 infection.

[0228] In some embodiment, the subject is a herpes-positive patient.

[0229] In some embodiment, the subject is a herpes-simplex-positive patient.

[0230] In another aspect, the present invention provides a method for the treatment or prophylaxis of an HSV infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, wherein: the infection is resistant to nucleosidic antiviral therapy.

[0231] In one embodiment, the infection is a Herpes simplex infection.

[0232] In some embodiment, the infection is a Herpes simplex infection.

[0233] In another embodiment, the subject is a herpes-positive patient.

[0234] In another embodiment, the nucleosidic antiviral therapy is selected from the group consisting of acyclovir, penciclovir, famciclovir, ganciclovir and valacyclovir.

[0235] In another aspect, the present invention provides a compound for the use as a medicament.

Combination Therapies

[0236] The compounds according to the present invention are also useful for the treatment and prophylaxis of disorders caused by herpes viruses, in particular Herpes simplex viruses, in combination with other active ingredients.

[0237] In one aspect, the present invention provides a method for the treatment or prophylaxis of an HSV infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, in combination with an antiviral agent.

[0238] In some embodiments, the antiviral agent is selected from the group consisting of acyclovir, penciclovir, famciclovir, ganciclovir and valacyclovir, foscarnet and trifluridine.

[0239] In some embodiment, the infection is a Herpes simplex infection.

[0240] In some embodiment, the infection is an HSV-1 infection.

[0241] In some embodiment, the infection is an HSV-2 infection.

[0242] In some embodiments, the infection is a Herpes simplex infection and the subject displays symptoms such as Herpes labialis, Herpes genitalis, HSV-related keratitis, encephalitis, or pneumonia.

[0243] In another embodiment, the infection is a Herpes simplex infection and the subject displays symptoms such as suppressed immune system (for example AIDS patients, cancer patients, patients having a genetic immunodeficiency, transplant patients).

[0244] In another embodiment, the infection is a Herpes simplex infection, and the subject is a new-born child or infant.

[0245] In another aspect, the present invention provides a method for suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, in combination with an antiviral agent.

[0246] In some embodiments, the antiviral agent is selected from the group consisting of acyclovir, penciclovir, famciclovir, ganciclovir and valacyclovir, foscarnet and trifluridine.

[0247] In some embodiment, the infection is a Herpes simplex infection.

[0248] In some embodiment, the infection is an HSV-1 infection.

[0249] In some embodiment, the infection is an HSV-2 infection.

[0250] In some embodiment, the subject is a herpes-positive patient.

[0251] In some embodiment, the subject is a herpes-simplex-positive patient.

[0252] In another aspect, the present invention provides a compound for the use as a medicament.

[0253] In another aspect, the present invention provides a method for the treatment or prophylaxis of an HSV infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, in combination with a corticosteroid.

[0254] In some embodiment, the infection is a Herpes simplex infection.

[0255] In some embodiment, the infection is an HSV-1 infection.

[0256] In some embodiment, the infection is an HSV-2 infection.

[0257] In some embodiments, the infection is a Herpes simplex infection and the subject displays symptoms such as Herpes labialis, Herpes genitalis, HSV-related keratitis, encephalitis, or pneumonia.

[0258] In another embodiment, the infection is a Herpes simplex infection and the subject displays symptoms such as suppressed immune system (for example AIDS patients, cancer patients, patients having a genetic immunodeficiency, transplant patients).

[0259] In another embodiment, the infection is a Herpes simplex infection, and the subject is a new-born child or infant.

[0260] In another aspect, the present invention provides a method for suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, in combination with a corticosteroid.

[0261] In some embodiment, the infection is a Herpes simplex infection.

[0262] In some embodiment, the infection is an HSV-1 infection.

[0263] In some embodiment, the infection is an HSV-2 infection.

[0264] In some embodiment, the subject is a herpes-positive patient.

[0265] In some embodiment, the subject is a herpes-simplex-positive patient.

[0266] In another aspect, the present invention provides a compound for the use as a medicament.

Formulations and Administration

[0267] The compounds on the invention can be converted in a known manner into the customary formulations, such as tablets, sugar-coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions, and solutions, using inert, nontoxic, pharmaceutically suitable carriers and solvents. Here, the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e., in amounts which are sufficient to achieve the dosage range indicated.

[0268] The formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, it being possible, for example, if the diluent used is water, to use, if appropriate, organic solvents as auxiliary solvents.

[0269] Administration is carried out in a customary manner, including orally, parenterally, topically, perlingually or intravenously.

[0270] In the case of parenteral administration, solutions or suspensions of the active compounds using suitable liquid carrier and excipients can be employed.

[0271] In general, it has proved advantageous in the case of intravenous administration to administer amounts of from approximately 0.001 to 20 mg/kg, preferably approximately 0.01 to 10 mg/kg, of bodyweight to achieve effective results, and in the case of oral administration the dose is approximately 0.01 to 30 mg/kg, preferably 0.1 to 20 mg/kg, of bodyweight.

[0272] In some instances, it may be necessary to depart from the amounts mentioned, namely depending on the bodyweight or on the type of administration route, on the individual response to the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned must be exceeded. In the case of the administration of relatively large amounts, it may be advisable to divide this into several individual administrations over the course of the day.

[0273] If appropriate, it may be useful to combine the compounds according to the invention with other active substances, in particular antiviral active substances.

[0274] The compounds used in the present invention can be in the form of a pharmaceutically acceptable salt, cocrystal or a solvate. The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids. In case the compounds of the present invention contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the present invention which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. The compounds of the present invention which contain one or more basic groups, i.e., groups which can be protonated, can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples of suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesuifonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the present invention simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts can be obtained by customary methods which are known to the person skilled in the art like, for example, by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the present invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.

[0275] Depending on the substitution pattern, the compounds according to the invention can exist in stereoisomeric forms which either behave as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers and their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform components in a known manner.

[0276] The scope of the invention includes those compounds which are only converted into the actual active compounds of the Formulas I and once inside the body (so-called prodrugs).

[0277] In practical use, the compounds used in the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, or parenteral {including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavouring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.

[0278] Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray or as eye drops.

[0279] The tablets, pills, capsules, and the like may also contain a binder such as hydroxypropyl methylcellulose, or polyvinylpyrrolidone; diluent or fillers such as microcrystalline cellulose, dicalcium phosphate, lactose, or mannitol; a disintegrating agent such as croscarmellose sodium, polyvinylpyrrolidone, or sodium starch glycolate; a lubricant such as magnesium stearate or sodium stearyl fumarate; a glidant such as silicon dioxide; and a sweetening agent such as sucrose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

[0280] Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

[0281] The compounds used in the present invention may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl cellulose, sodium lauryl sulfate, or polysorbate. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0282] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0283] Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral, rectal, topical, parenteral (including intravenous), ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Compounds of the present invention can be administered orally or as eye drop. The compounds of the present invention can also be administered orally. The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated, and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.

[0284] The compounds of the present invention can also be present in combination with additional active ingredients, in particular, with one or more active ingredients exhibiting advantageous effects in the treatment of any of the disorders or diseases as described herein. The compounds of the present invention can be present in a composition in combination with at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds), preferably a disease or disorder being associated with viral infections caused by herpes viruses, such as in particular by Herpes simplex viruses (i.e., combination therapy). The at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds) are preferably selected from the group consisting of nucleosidic drugs such as acyclovir, valacyclovir, penciclovir, ganciclovir, famciclovir and trifluridine, as well as compounds such as foscarnet and cidofovir.

[0285] Accordingly, the present invention further relates to a pharmaceutical composition comprising one or more of the compounds as described herein and at least one pharmaceutically acceptable carrier and/or excipient and/or at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds).

[0286] The novel active compounds can be converted in a known manner into customary formulations, such as tablets, caplets, sugar-coated tablets, pills, granules, aerosols, syrups, pharmaceutically suitable carriers, and solvents. Here, the therapeutically active compound should in each case be present in a concentration of about 0.1 to 90% by weight of the total mixture, i.e., in amounts which are sufficient to achieve the dosage range indicated.

[0287] The formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, if being possible, for example, if the diluent used is water, to use, if appropriate, organic solvents as auxiliary solvents.

[0288] Administration is carried out in a customary manner, preferably orally, parenterally or topically, in particular perlingually or intravenously.

[0289] In the case of parenteral administration, solutions or suspensions of the active compounds using suitable liquid carrier materials can be employed.

[0290] In general, it has proved advantageous in the case or intravenous administration to administer amounts of from approx. 0.001 to 20 mg/kg, preferably approx. 0.01 to 10 mg/kg of bodyweight to achieve effective results, and in the case of oral administration the dose is approx. 0.01 to 30 mg/kg, preferably 0.1 to 20 mg/kg of body weight.

[0291] In spite of this, it may be necessary, if appropriate, to depart from the amounts mentioned, namely depending on the bodyweight or on the type of the administration route, on the individual response to the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned must be exceeded. In the case of administration of relatively large amounts it may be advisable to divide this into several individual administrations over the course of the day.

EXAMPLES

[0292] The compounds described herein can be prepared in several ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials.

[0293] At least some of the compounds identified as “intermediates” herein are contemplated as compounds of the disclosure.


Abbreviations:


	AcOH	Acetic acid
	ACN	Acetonitrile
	Boc₂O	Di-tert-butyl dicarbonate
	nBuLi	n-Butyllithium
	DCM	Dichloromethane
	DIAD	Diisopropyl azodicarboxylate
	DIEA	Diisopropyl ethylamine
	DMF	N,N-Dimethylformamide
	DMSO	Dimethyl sulfoxide
	DPPF	1,1′-Bis(diphenylphosphino)ferrocene
	EtOAc	Ethyl acetate
	Et₃N	Triethylamine
	HATU	Hexafluorophosphate Azabenzotriazole
		Tetramethyl Uronium
	h, hr	Hour(s)
	HPLC	High performance liquid chromatography
	LCMS	Liquid chromatography-mass spectrometry
	MeOH	Methanol
	NMO/NMMO	N-Methyl morpholine-N-Oxide
	NBS	N-Bromosuccinimide
	PE	Petroleum ether
	iPrOH	Isopropanol
	rt, r.t.	Room temperature
	SFC	Supercritical Fluid Chromatography
	TEA	Triethylamine
	TBAI	Tetrabutylammonium iodide
	TBAB	Tetrabutylammonium bromide
	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
	TLC	Thin-layer chromatography
	XPhos	2-Dicyclohexylphosphino-2′,4′,6′-
		triisopropylbiphenyl

Following LCMS Method have been Used for the Analysis of Final Compounds:

- [0294] Method A: X-Bridge BEH C-18 (3×50 mm×2.5 mm); Mobile phase: A; 0.025% formic acid in H₂O; B; CH₃CN; Injection volume: 2 μL; Flow rate: 1.2 mL/min, column temperature: 50° C.; Gradient program: 2% B to 98% B in 2.2 min, held 3 min, at 3.2 min B conc. is held at 2% for 4 min.
- [0295] Method B: X-select CSH 18 (3×50 mm×2.5 mm); Mobile phase: A; 0.025% formic acid in H₂O; B; CH₃CN; Injection volume: 2 μL; Flow rate: 1.2 mL/min, column temperature: 50° C.; Gradient program: 0% B to 98% B in 2 min, hold for 3 min, at 3.2 min B conc. is held at 0% for 4 min.
- [0296] Method C: X-select CSH 18 (3×50 mm×2.5 mm); Mobile phase: A; 0.05% formic acid in H₂O:CH₃CN (95:5); B; 0.05% formic acid in CH₃CN; Injection volume: 2 μL; Flow rate: 1.2 mL/min, column temperature: 50° C.; Gradient program: 0% B to 98% B in 2 min, hold for 3 min, at 3.2 min B conc. is held at 0% for 4 min.
- [0297] Method D: X-select CSH C₁₈(3×50 mm×2.5 μm); Mobile phase: A; 2 mM in Ammonium Bicarbonate; B; CH₃CN; Injection volume: 2 μL; Flow rate: 1.2 mL/min, column temperature: 50° C.; Gradient program: 0% B to 98% B in 2 min, hold for 3 min, at 3.2 min B conc. is held at 0% for 4 min.
- [0298] Method E: X-select CSH 18 (3×50 mm×2.5 mm); Mobile phase: A; 0.05% formic acid in H₂O; B; CH₃CN; Injection volume: 2 μL; Flow rate: 1.5 mL/min, column temperature: 50° C.; Gradient program: 0% B to 100% B in 1.5 min, hold 2.2 min, at 2.6 min B conc. is held at 0% for 3 min.

Example 1. 4-Methyl-2-(2-oxo-3-(4-(pyridin-2-yl) phenyl) tetrahydropyrimidin-1(2H)-yl) thiazole-5-sulfonamide (1)

Step 1. Synthesis of 5-(benzylthio)-4-methylthiazol-2-amine (1-2)

[0299] Benzyl mercaptan (15.8 mL, 134.70 mmol) was added dropwise to a stirred solution of 1-1 (20 g, 103.62 mmol) in ethanol (200 mL) at 0° C. The resulting reaction mixture was slowly warmed to room temperature and stirred at 80° C. for 3 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in EtOAc and the organic layer washed with water. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 10-20% EtOAc in heptane) to afford 1-2 (25 g, 93.9%) as a dark brown colored sticky solid. TLC: 50% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₁₁H₁₂N₂S₂: 236.04; Found: 236.95 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.35-7.17 (m, 3H), 7.12 (dd, J=1.6, 7.8 Hz, 2H), 7.06 (s, 2H), 3.77 (s, 2H), 1.73 (s, 3H) ppm.

Step 2. Synthesis of 1-(5-(benzylthio)-4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (1-3)

[0300] A mixture of 1-chloro-3-isocyanatepropane (1.29 g, 10.847 mmol) and compound 1-2 (2 g, 8.474 mmol) in THF (100 mL) was heated at 65° C. for 7 h. TBAI (0.15 g, 0.423 mmol) and K₂CO₃(1.43 g, 11.016 mmol) were added portion wise to the resulting solution while maintaining the same temperature and stirring continued at 65° C. for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude compound was purified by CombiFlash chromatography (eluting with 60-70% EtOAc in heptane) to afford 1-3 (1.3 g, 48.1%) as an off-white solid. TLC: 70% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₅H₁₇N₃OS₂: 319.08; Found: 320.10 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.45 (br s, 1H), 7.30-7.20 (m, 3H), 7.19-7.03 (m, 2H), 3.93 (t, J=5.6 Hz, 2H), 3.84 (s, 2H), 3.23-3.17 (m, 2H), 1.89 (s, 3H) ppm.

Step 3. Synthesis of 1-(5-(benzylthio)-4-methylthiazol-2-yl)-3-(4-(pyridin-2-yl) phenyl) tetrahydropyrimidin-2(1H)-one (1-4)

[0301] To a stirred solution of 1-3 (0.8 g, 2.50 mmol) in 1,4-dioxane (12 mL) were added compound 1-7 (0.6 g, 2.75 mmol), K₂CO₃(0.7 g, 5.00 mmol) and 1,2-dimethylethylenediamine (0.11 g, 1.25 mmol). The reaction mixture was purged under nitrogen for 10 min. CuI (0.095 g, 0.50 mmol) was then added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through a Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc which was washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by reverse phase CombiFlash chromatography (eluting with 25% ACN in 0.01 M HCOOH in water) to afford 1-4 (0.5 g, 42.3%) as an off-white solid. TLC: 80% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₂₆H₂₄N₄OS₂: 472.14; Found: 473.2 [M+1]⁺.

Step 4. Synthesis of 2-(4-bromophenyl) pyridine (1-7)

[0302] To a stirred solution of 2-bromopyridine, 1-6 (3 g, 18.987 mmol) in toluene:H₂O:EtOH (1:1:0.2, 150 mL) were added (4-bromophenyl) boronic acid, 1-5 (4.9 g, 24.683 mmol) and Na₂CO₃(14.90 g, 140.50 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd (PPh₃)₄(0.66 g, 0.576 mmol) was the added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 1-7 (2 g, 45%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₁H₈BrN: 232.98; Found: 235.98 [M+2]⁺. ¹H NMR (400 MHz, CDCl₃): δ 8.69 (d, J=4.8 Hz, 1H), 7.92-7.84 (m, 2H), 7.80-7.73 (m, 1H), 7.73-7.69 (m, 1H), 7.63-7.57 (m, 2H), 7.30-7.23 (m, 1H) ppm.

Step 5. Synthesis of 4-methyl-2-(2-oxo-3-(4-(pyridin-2-yl) phenyl) tetrahydropyrimidin-1(2H)-yl) thiazole-5-sulfonamide (1)

[0303] To a stirred solution of 1-4 (0.3 g, 0.635 mmol) in AcOH/H₂O (2.8/0.15 mL), NCS (0.31 g, 2.38 mmol) was added, and the reaction mixture was stirred at room temperature for 15 min. After completion of the reaction (monitored by TLC) the reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in THF (5 mL) and aqueous ammonia (3 mL) was added while stirring was continued at room temperature for another 4 h. The reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in DCM and organic layer was washed with water. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by reverse phase CombiFlash chromatography (eluting with 10% ACN in 0.01M HCOOH in water) to afford 1 (26 mg, 9.5%) as an off-white solid. TLC: 100% EtOAc (R_f: 0.5).

Example 2. 2-(3-(5′-Ethynyl-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (17)

Step 1. Synthesis of 1-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (2-2)

[0304] A mixture of 2-1 (10 g, 87.71 mmol) and 1-chloro-3-isocyanatopropane (15.5 g, 131.57 mmol) in THF (150 mL) was heated at 70° C. for 6 h. To the resulting solution, TBAB (1.4 g, 4.38 mmol) and K₂CO₃(15.73 g, 114.02 mmol) were added portion wise maintaining the same temperature and stirring continued at 70° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 60-70% EtOAc in heptane) to afford 2-2 (10 g, 57.6%) as an off-white solid. TLC: 70% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₈H_iiN₃₀S: 197.06; Found: 198.17 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.30 (s, 1H), 6.60 (s, 1H), 3.99 (t, J=5.4 Hz, 2H), 3.20-3.19 (m, 2H), 2.28 (s, 3H), 1.99-1.89 (m, 2H) ppm.

Step 2. Synthesis of 1-(4-bromophenyl)-3-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (2-3)

[0305] To a stirred solution of 2-2 (5 g, 25.25 mmol) in 1, 4-dioxane (200 mL) were added 1-bromo-4-iodobenzene (14 g, 50.5 mmol), K₂CO₃(6.9 g, 50.5 mmol) and 1,2-dimethylethylenediamine (1 g, 12.62 mmol) the reaction mixture was purged under nitrogen for 10 min., CuI (0.95 g, 5.05 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-70% EtOAc in heptane) to afford 2-3 (2.5 g, 28.4%) as an off-white solid. TLC: 60% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₄H₁₄BrN₃OS: 351.00; Found: 354.09 [M+2]⁺.

Step 3. Synthesis of 2-(3-(4-bromophenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (2-4)

[0306] To a stirred solution of 2-3 (2 g, 5.68 mmol) in dry DCM (20 mL) at 0° C. in an inert atmosphere, was added chlorosulfuric acid (1.3 g, 11.363 mmol) and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid out was collected by filtration and dried in vacuo to afford 2-4 (2 g, 81.9%) as an off-white solid. TLC: 5% MeOH/DCM (R^f: 0.5) which was used in the next step without further purification. MS (ESI): calcd. for C₁₄H₄BrN₃O₄S₂: 430.96; Found: 434.00 [M+2]⁺

Step 4. Synthesis of 2-(3-(4-bromophenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (2-5)

[0307] A mixture of 2-4 (1 g, 2.315 mmol) and POCl₃(10 mL) was allowed to stir at 100° C. for 12 h. The reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in THF (10 mL) and aqueous ammonia (20 mL) was added at 0° C. while stirring was continued at room temperature for another 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 2-5 (0.8 g, 80.8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₄H₁₅BrN₄O₃S₂: 429.98; Found: 431.1 [M+1]⁺.

Step 5. Synthesis of 4-methyl-2-(2-oxo-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) tetrahydropyrimidin-1(2H)-yl) thiazole-5-sulfonamide (2-6)

[0308] To a stirred solution of 2-5 (0.6 g, 1.392 mmol) in 1, 4-dioxane (20 mL) were added bis(pinacolato)diborane (0.53 g, 2.088 mmol) and KOAc (0.27 g, 2.784 mmol) and the reaction mixture was purged under nitrogen for 10 min. PdCl₂(dppf) (0.1 g, 0.14 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 120° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 2-6 (0.8 g, 80.8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₀H₂₇BN₄O₅S₂: 478.15; Found: 479.2 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.70 (d, J=7.8 Hz, 2H), 7.55 (s, 2H), 7.42-7.38 (m, 2H), 4.17-4.09 (m, 2H), 3.82-3.74 (m, 2H), 2.44 (s, 3H), 2.26-2.15 (m, 2H), 1.30 (s, 9H) ppm.

Step 6. Synthesis of 2-(3-(5′-bromo-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (2-7)

[0309] To a stirred solution of 2-6 (0.4 g, 0.836 mmol) in 1, 4-dioxane and water (16:4 mL) were added 4-bromo-1-fluoro-2-iodobenzene (0.25 g, 0.836 mmol) and Na₂CO₃(0.17 g, 1.673 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf) C_1-2(61 mg, 0.083 mmol) was added under nitrogen atmosphere and the reaction mixture heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 2-7 (0.2 g, 45.5%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₀H₁₈BrFN₄O₃S₂: 524.00; Found: 525.00 [M+1]⁺.

Step 7. Synthesis of 2-(3-(5′-ethynyl-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (17)

[0310] To a stirred solution of 2-7 (0.1 g, 0.190 mmol) in DMF (5 mL) was added triethylamine (0.1 mL, 0.571 mmol) and CuI (4 mg, 0.019 mmol) and the reaction mixture purged under nitrogen for 10 min. Pd (PPh₃)₂Cl₂(27 mg, 0.038 mmol) and ethynyltrimethylsilane (56 mg, 0.571 mmol) were added under a nitrogen atmosphere and then the reaction mixture was heated at 120° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by preparative HPLC to afford 17 (5 mg, 5.61%) as an off-white solid. TLC: 50% EtOAc/heptane (R^f: 0.5).

Example 3. 2-(3-(5′-Fluoro-2′-(3-hydroxy-3-methylbut-1-yn-1-yl)-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (19)

Step 1. Synthesis of 4-(2-bromo-4-fluorophenyl)-2-methylbut-3-yn-2-ol (3-2)

[0311] To a stirred solution of compound 3-1 (1 g, 3.323 mmol) in DIPEA (10 mL) were added 2-methylbut-3-yn-2-ol (0.49 g, 4.984 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (63 mg, 0.332 mmol) and Pd(dppf)Cl₂(0.11 g, 0.166 mmol) were added under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 5-10% EtOAc in heptane) to afford 3-2 (0.8 g, 94.1%) as a brown oil. TLC: 10% EtOAc/Heptane (R_f: 0.5).

Step 2. Synthesis of 2-(3-(5′-fluoro-2′-(3-hydroxy-3-methylbut-1-yn-1-yl)-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (19)

[0312] To a stirred solution of 2-6 (0.2 g, 0.418 mmol) in 1, 4-dioxane:water (4:1, 10 mL) was added 4-(2-bromo-4-fluorophenyl)-2-methylbut-3-yn-2-ol (0.1 g, 0.418 mmol) followed by Na₂CO₃(88 mg, 0.836 mmol) and the resulting reaction mixture was purged under nitrogen for 20 min. To this resulting reaction mixture, Pd(dppf)Cl₂(30 mg, 0.0418 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by preparative HPLC to afford 19 (10 mg, 4.5%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5).

Example 4. 4-Methyl-2-(2-oxo-3-(3′-(thiazol-5-yl)-[1,1′-biphenyl]-4-yl)tetrahydropyrimidin-1(2H)-yl)thiazole-5-sulfonamide (30)

Step 1. Synthesis of 2-(3-bromophenyl)thiazole (4-2)

[0313] To a stirred solution of 4-1 (1 g, 6.097 mmol) in 1, 4-dioxane:water (4:1, 15 mL) was added (3-bromophenyl)boronic acid (1.34 g, 6.707 mmol) followed by K₃PO₄(3.18 g, 15.242 mmol) and the resulting reaction mixture was purged under nitrogen for 20 min. To this resulting reaction mixture, Pd(dppf)Cl₂(0.445 g, 0.6097 mmol) was added under nitrogen atmosphere and the reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 2-3% EtOAc in heptane) to afford 4-2 (0.2 g, 13.7%) as an off-white solid. TLC: 10% EtOAc/Heptane (R_f: 0.5).

Step 2. Synthesis of 4-methyl-2-(2-oxo-3-(3′-(thiazol-2-yl)-[1,1′-biphenyl]-4-yl)tetrahydropyrimidin-1(2H)-yl)thiazole-5-sulfonamide (30)

[0314] To a stirred solution of 8 (0.2 g, 0.418 mmol) in 1, 4-dioxane:water (4:1, 10 mL) was added 2-(3-bromophenyl)thiazole (0.1 g, 0.418 mmol) followed by K₃PO₄(0.221 g, 1.04 mmol) and the resulting reaction mixture was purged under nitrogen for 20 min. To this resulting reaction mixture, Pd(dppf)Cl₂(30.6 mg, 0.041 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by preparative HPLC to afford 30 (14 mg, 6.5%) as an off-white solid. TLC: 80% EtOAc/Heptane (R^f: 0.5).

Example 5. 4-Methyl-2-(2-oxo-3-(4-(thiazol-2-yl) phenyl) tetrahydropyrimidin-1(2H)-yl) thiazole-5-sulfonamide (42)

Step 1. Synthesis of 4-methyl-2-(2-oxo-3-(4-(thiazol-2-yl) phenyl) tetrahydropyrimidin-1(2H)-yl) thiazole-5-sulfonamide (42)

[0315] To a stirred solution of 2-6 (0.15 g, 0.313 mmol) in 1, 4-dioxane and water (8:2 mL) were added 2-bromothiazole (0.1 g, 0.626 mmol) and K₃PO₄(0.13 g, 0.626 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(23 mg, 0.0313 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford 42 (20 mg, 15.4%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Example 6. 2-(3-(4-(Benzo[d]thiazol-4-yl) phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (51)

Step 1. Synthesis of ethyl 4-(3-(4-methylthiazol-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl) benzoate (6-1)

[0316] To a stirred solution of 2-2 (3.1 g, 15.656 mmol) in 1, 4-dioxane (100 mL) were added ethyl 4-iodobenzoate (4.3 g, 15.656 mmol), K₂CO₃(4.3 g, 3.131 mmol) and 1,2-dimethylethylenediamine (0.7 g, 1.269 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (0.6 g, 3.131 mmol) was subsequently added under a nitrogen atmosphere and the resulting reaction mixture was heated at 100° C. for 24 h. After completion of the reaction, the reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-70% EtOAc in heptane) to afford the 6-1 (3 g, 57.6%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₁₇H₁₉N₃O₃S: 345.1; Found: 346.1 [M+1]⁺.

Step 2. Synthesis of 2-(3-(4-(ethoxycarbonyl)phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (6-2)

[0317] To a stirred solution of 6-1 (3 g, 8.695 mmol) in dry DCM (50 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (2 g, 17.39 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 6-2 (3 g, crude) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5) which was used in the next step without further purification. MS (ESI): calcd. for C₁₇H₁₉N₃O₆S₂: 425.1; Found: 426.1 [M+1]⁺.

Step 3. Synthesis of ethyl 4-(3-(4-methyl-5-sulfamoylthiazol-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl) benzoate (6-3)

[0318] A mixture of 6-2 (0.5 g, 1.176 mmol) and POCl₃(5 mL) was allowed to stir at 100° C. for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in THF (5 mL) and aqueous ammonia (8 mL) was added at 0° C. while stirring was continued at room temperature for another 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 6-3 (0.3 g, crude) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5) which was used in the next step without further purification. MS (ESI): calcd. for C₁₇H₂₀N₄O₅S₂: 424.09; Found: 424.92 [M+1]⁺.

Step 4. Synthesis of 4-(3-(4-methyl-5-sulfamoylthiazol-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl) benzoic acid (6-4)

[0319] To a stirred solution of 6-3 (0.2 g, 0.471 mmol) in THF:MeOH:H₂O (8:1:1 mL) at 0° C., Lithium hydroxide monohydrate (39 mg, 0.943 mmol) was added portion wise. The resulting reaction mixture was slowly warmed to room temperature and allowed to stir for 3 h. The reaction mixture was concentrated under reduced pressure to dryness. The residue was treated with saturated KHSO₄solution and the precipitated solid obtained out was collected by filtration and dried in vacuo to afford 6-4 (0.2 g, crude) as an off-white solid, which was used in the next step without further purification. TLC: 50% EtOAc/heptane (R_f: 0.5); MS (ESI): calcd. for C₁₅H₁₆N₄O₅S₂: 396.06; Found: 397.2 [M+1]⁺.

Step 5. Synthesis of 2-(3-(4-(1,3,4-oxadiazol-2-yl)phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (51)

[0320] To a stirred solution of 6-4 (0.2 g, 0.505 mmol) in DCM/EtOH (10/10 mL) was added (N-isocyanoimino)triphenylphosphorane (0.30 g, 1.010 mmol) and the resulting reaction mixture was allowed to stir at room temperature for 16 h. After completion of the reaction (monitored by TLC), the resulting reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude was purified by preparative HPLC to afford 51 (36 mg, 16.9%) as an off-white solid.

Example 7. 2-(3-(4-(Benzo[d]thiazol-7-yl) phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (67)

Step 1. Synthesis of 2-(3-(4-(benzo[d]thiazol-7-yl) phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (67)

[0321] To a stirred solution of 2-6 (0.2 g, 0.418 mmol) in 1, 4-dioxane and water (5/0.5 mL) was added 7-bromobenzo[d]thiazole (0.18 g, 0.836 mmol) followed by K₂CO₃(0.17 g, 0.836 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting solution, Pd(dppf)Cl₂(30 mg, 0.041 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 120° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford 67 (10 mg, 5%) as an off-white solid. TLC: 60% EtOAc/heptane (R^f: 0.5).

Example 8. 2-(3-(4-(Benzo[d]thiazol-4-yl) phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (71)

Step 1. Synthesis of 2-(3-(4-(benzo[d]thiazol-4-yl) phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (71)

[0322] To a stirred solution of 2-6 (0.2 g, 0.418 mmol) in 1, 4-dioxane and water (4:1, 10 mL) were added 4-bromobenzo[d]thiazole (0.13 g, 0.627 mmol) and Na₂CO₃(88 mg, 0.836 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting solution, Pd(dppf)Cl₂(30 mg, 0.0406 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford 71 (30 mg, 15%) as an off-white solid. TLC: 50% EtOAc/heptane (R^f: 0.5).

Example 9. 2-(3-(2,5-Difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (99)

Step 1. Synthesis of 1-(4-bromo-2,5-difluorophenyl)-3-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (9-1)

[0323] To a stirred solution of 2-2 (1.5 g, 7.614 mmol) in 1, 4-dioxane (30 mL) were added 1,4-dibromo-2,5-difluorobenzene (3.10 g, 11.42 mmol), K₂CO₃(2.1 g, 15.228 mmol) and 1,2-Dimethylethylenediamine (0.27 g, 3.045 mmol) the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (0.3 g, 1.522 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 120° C. for 24 h. The reaction mixture was filtered through Celite®545 bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-70% EtOAc in heptane) to afford 9-1 (0.8 g, 27.1%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₁₄H₁₂BrF₂N₃OS: 386.99; Found: 390.0 [M+2]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.86 (dd, J=6.4, 9.3 Hz, 1H), 7.67 (d, J=2.4 Hz, 1H), 6.72 (s, 1H), 4.16 (t, J=5.9 Hz, 2H), 3.69 (t, J=5.4 Hz, 2H), 2.25 (s, 3H), 2.23-2.17 (m, 2H) ppm.

Step 2. Synthesis of 2-(3-(4-bromo-2,5-difluorophenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (9-2)

[0324] To a stirred solution of 9-1 (0.89 g, 2.294 mmol) in dry DCM (20 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (0.38 g, 5.734 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 9-2 (0.75 g, crude) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5), which was used in the next step without further purification. MS (ESI): calcd. for C₁₄H₁₂BrF₂N₃O₄S₂: 466.94; Found: 469.85 [M+2]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.87 (t, J=7.1 Hz, 1H), 7.69 (t, J=7.1 Hz, 1H), 5.79 (br. s, 1H), 4.22-3.98 (m, 2H), 3.73-3.59 (m. 2H). 2.32 (s, 3H), 2.27-2.09 (m, 2H) ppm.

Step 3. Synthesis of 2-(3-(4-bromo-2,5-difluorophenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (9-3)

[0325] A mixture of 9-2 (1 g, 2.136 mmol) and POCl₃(10 mL) was allowed to stir at 100° C. for 12 h. The reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in THF (5 mL) and aqueous ammonia (5 mL) was added at 0° C. while stirring was continued at room temperature for another 2 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 9-3 (0.8 g, 80.8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₄H₁₃BrF₂N₄O₃S₂: 465.96; Found: 467.0 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.93-7.85 (m, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.57 (br. s, 2H), 4.21-4.12 (m, 2H), 3.77-3.67 (m, 2H), 2.44 (s, 3H), 2.27-2.17 (m, 2H) ppm.

Step 4. Synthesis of 2-(3-(2,5-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (99)

[0326] To a stirred solution of 9-3 (0.2 g, 0.428 mmol) in 1, 4-dioxane and water (4:1 mL) were added phenylboronic acid (78 mg, 0.642 mmol) and Na₂CO₃(90 mg, 0.856 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(31 mg, 0.043 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 110° C. for 12 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate, the resulting filtrate was concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 80-90% EtOAc in heptane) to afford 99 (0.12 g, 60.6%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Example 10. 2-(3-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-2-oxo-1,3-diazepan-1-yl)-4-methylthiazole-5-sulfonamide (101)

Step 1. Synthesis of 4-((4-methylthiazol-2-yl) amino) butan-1-ol (10-2)

[0327] To a stirred solution of 10-1 (5 g, 37.593 mmol) in DMSO (50 mL) were added K₂CO₃(7.78 g, 56.390 mmol), 4-aminobutan-1-ol (6.66 g, 75.186 mmol) followed by CuI (0.71 g, 3.759 mmol). The resulting reaction mixture was heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite®545 and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography [eluting with 20-30% EtOAc in heptane] to afford 10-2 (4 g, 28.7%) as a pale brown colored oil. TLC: 20% EtOAc/heptane (R^f: 0.2). MS (ESI): calcd. for C₈H₁₄N₂₀S: 186.27; Found: 187.0 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.37 (br s, 1H), 6.10 (s, 1H), 4.40 (t, J=4.6 Hz, 1H), 3.45-3.35 (m, 2H), 3.21-3.09 (m, 2H), 2.07 (s, 3H), 1.60-1.41 (m, 4H) ppm.

Step 2. Synthesis of 3-(4-bromophenyl)-1-(4-hydroxybutyl)-1-(4-methylthiazol-2-yl) urea (10-3)

[0328] To a stirred solution of 10-2 (1.5 g, 8.064 mmol) in 1,4 dioxane (30 mL) were added compound 1-bromo-4-isocyanatobenzene (1.6 g, 8.064 mmol). The resulting reaction mixture was allowed to stir at room temperature for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography [eluting with 30-40% EtOAc in heptane] to afford 10-3 (1.1 g, 38.8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.2). MS (ESI): calcd. for C₁₅H₁₈BrN₃O₂S: 383.03; Found: 386 [M+2]⁺.

Step 3. Synthesis of 4-(3-(4-bromophenyl)-1-(4-methylthiazol-2-yl) ureido) butyl 4-methylbenzenesulfonate (10-4)

[0329] To a stirred solution of 10-3 (1.0 g, 2.604 mmol) in DCM (20 mL) were added triethyl amine (0.55 mL, 3.906 mmol) followed by tosyl chloride (0.6 g, 3.125 mmol) at 0° C. The resulting reaction mixture was slowly warmed to room temperature and allowed to stir for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography [eluting with 30-40% EtOAc in heptane] to afford 10-4 (1 g, 71.4%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₂H₂₄BrN₃O₄S₂: 537.04; Found: 538.14 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 10.05 (s, 1H), 7.75 (d, J=8.3 Hz, 2H), 7.55-7.46 (m, 4H), 7.46-7.41 (m, 2H), 6.78 (s, 1H), 4.15-4.03 (m, 4H), 2.39 (s, 3H), 2.27 (s, 3H), 1.66-1.58 (m, 4H) ppm.

Step 4. Synthesis of 1-(4-bromophenyl)-3-(4-methylthiazol-2-yl)-1,3-diazepan-2-one (10-5)

[0330] To a stirred solution of 10-4 (1 g, 1.858 mmol) in dry DMF (10 mL) at 0° C. under a nitrogen atmosphere, NaH (60% w/w in mineral oil, 0.134 g, 2.788 mmol) was added in small portions and The resulting reaction mixture was slowly warmed to room temperature and stirred for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 15 min. The precipitated solid obtained was collected by filtration and dried in vacuo to afford 10-5 (0.6 g, 88.2%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5) which was used in the next step without further purification. MS (ESI): calcd. for C₁₅H₁₆BrN₃OS: 365.02; Found: 368 [M+2]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.55 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.8 Hz, 2H), 6.66 (s, 1H), 4.24-4.16 (m, 2H), 3.73-3.64 (m, 2H), 2.24 (s, 3H), 1.96-1.86 (m, 2H), 1.84-1.74 (m, 2H) ppm.

Step 5. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl)-1,3-diazepan-2-one (10-6)

[0331] To a stirred solution of 10-5 (0.6 g, 1.639 mmol) in 1,4 dioxane:H₂O (4:1, 20 mL) were added (2,5-difluorophenyl) boronic acid (0.38 g, 2.46 mmol) and Cs₂CO₃(1 g, 3.278 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd (PPh₃)₂Cl₂(0.12 g, 3.278 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 0-30% EtOAc in heptane) to afford 10-6 (0.6 g, 92.3%) as a yellow solid. TLC: 30% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₁H₁₉F₂N₃OS: 399.12; Found: 400.05 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.60 (d, J=7.8 Hz, 2H), 7.47 (d, J=7.8 Hz, 3H), 7.44-7.34 (m, 1H), 7.34-7.19 (m, 1H), 6.69 (s, 1H), 4.28-4.20 (m, 2H), 3.82-3.75 (m, 2H), 2.26 (s, 3H), 2.00-1.90 (m, 2H), 1.87-1.77 (m, 2H) ppm.

Step 6. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxo-1,3-diazepan-1-yl)-4-methylthiazole-5-sulfonic acid (10-7)

[0332] To a stirred solution of 10-6 (0.3 g, 0.751 mmol) in dry DCM (10 mL) at −5° C. in an inert atmosphere, chlorosulfuric acid (0.15 mL, 2.255 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 10-7 (0.6 g, 88.2%) as an off-white solid, which was used in the next step without further purification. TLC: 30% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₁H₁₉F₂N₃O₄S₂: 479.08; Found: 480.21 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.60 (d, J=7.8 Hz, 2H), 7.48 (d, J=8.3 Hz, 3H), 7.44-7.33 (m, 1H), 7.33-7.19 (m, 1H), 6.10 (br s, 1H), 4.23-4.13 (m, 2H), 3.82-3.73 (m, 2H), 2.34 (s, 3H), 2.00-1.89 (m, 2H), 1.88-1.75 (m, 2H) ppm.

Step 7. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxo-1,3-diazepan-1-yl)-4-methylthiazole-5-sulfonamide (101)

[0333] To a stirred solution of 2-7 (0.2 g, 0.417 mmol) in DCM (10 mL) at −10° C. in an inert atmosphere, oxalyl chloride (0.1 mL, 1.252 mmol) followed by DMF (cat.) were added. The resulting reaction mixture was slowly warmed to room temperature and allowed to stir at 60° C. for 2 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (5 mL) and aqueous ammonia (5 mL) was added at 0° C. while stirring was continued at room temperature for another 1 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) followed by preparative HPLC to afford 101 (40 mg, 20%) as an off-white solid. TLC: 50% EtOAc/heptane (R^f: 0.5).

Example 11. 2-(3-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-2-oxoimidazolidin-1-yl)-4-methylthiazole-5-sulfonamide (104)

Step 1. Synthesis of 4′-bromo-2,5-difluoro-1,1′-biphenyl (11-7)

[0334] To a stirred solution of 11-6 (5 g, 17.674 mmol) in 1,4 dioxane/H₂O (50 mL/5 mL) were added (2,5-difluorophenyl) boronic acid (11-5) (3.07 g, 19.441 mmol) and K₃PO₄(7.5 g, 35.348 mmol) and the reaction mixture was purged under nitrogen for 10 min. PdCl₂(dppf) (1.29 g, 1.767 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 80° C. for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite®545 and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 100% heptane) to afford 11-7 (2.3 g, 48.6%) as an off-white solid. TLC: 100% heptane (R_f: 0.5). ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J=8.3 Hz, 2H), 7.40 (d, J=7.3 Hz, 2H), 7.15-7.06 (m, 2H), 7.05-6.97 (m, 1H) ppm.

Step 2. Synthesis of 1-(4-methylthiazol-2-yl) imidazolidin-2-one (11-2)

[0335] A mixture of 2-1 (5 g, 43.859 mmol) and 1-chloro-2-isocyanatoethane (6.9 g, 65.79 mmol) in THF (100 mL) was heated at 65° C. for 5 h. To this resulting solution, TBAB (0.7 g, 2.192 mmol) and K₂CO₃(12.10 g, 87.718 mmol) were added portion wise maintaining the same temperature and stirring continued at 65° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 60-70% EtOAc in heptane) to afford 11-2 (6 g, 75%) as an off-white solid. TLC: 70% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₇H₉N₃OS: 183.05; Found: 184.00 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.52 (br s, 1H), 6.65 (s, 1H), 4.00 (t, J=7.8 Hz, 2H), 3.48 (t, J=8.1 Hz, 2H), 2.21 (s, 3H) ppm.

Step 3. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl) imidazolidin-2-one (11-3)

[0336] To a stirred solution of 11-2 (2 g, 10.752 mmol) in 1, 4-dioxane (50 mL) were added 11-7 (5.7 g, 21.505 mmol), K₂CO₃(2.96 g, 21.505 mmol) and 1,2-Dimethylethylenediamine (0.47 g, 5.376 mmol) the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (0.4 g, 2.150 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-70% EtOAc in heptane) to afford 11-3 (0.35 g, 17.5%) as an off-white solid. TLC: 60% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₁₉H₁₅F₂N₃OS: 371.09; Found: 372.35 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.77 (d, J=8.3 Hz, 2H), 7.69-7.57 (m, 2H), 7.49-7.30 (m, 2H), 7.30-7.19 (m, 1H), 6.79 (s, 1H), 4.21-4.05 (m, 4H), 2.28 (s, 3H) ppm.

Step 4. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxoimidazolidin-1-yl)-4-methylthiazole-5-sulfonic acid (11-4)

[0337] To a stirred solution of 11-3 (0.3 g, 0.808 mmol) in dry DCM (5 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (0.16 mL, 2.425 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 11-4 (0.2 g, 66.6%) as an off-white solid. TLC: 5% MeOH/DCM (R_f: 0.5) which was used in the next step without further purification.

Step 5. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxoimidazolidin-1-yl)-4-methylthiazole-5-sulfonamide (104)

[0338] To a stirred solution of 11-4 (0.2 g, 0.442 mmol) in DCM (5 mL) at 0° C. in an inert atmosphere, oxalyl chloride (0.1 mL, 1.327 mmol) followed by DMF (cat.) were added. The resulting reaction mixture was slowly warmed to room temperature and allowed to stir at 50° C. for 2 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (2 mL) and aqueous ammonia (5 mL) was added at 0° C. while stirring was continued at room temperature for another 1 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 0-1% MeOH in DCM) followed by preparative HPLC to afford 104 (8 mg, 4.2%) as an off-white solid.

Example 12. 2-(3-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-6-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (107)

Step 1. Synthesis of 3-((4-methylthiazol-2-yl)amino)butan-1-ol (12-1)

[0339] To a stirred solution of 10-1 (1 g, 7.518 mmol) in DMSO (10 mL) was added 3-aminobutan-1-ol (1.0 g, 11.278 mmol mmol) followed by K₂CO₃(2.5 g, 18.795 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (0.142 g, 0.751 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 120° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 30-70% EtOAc in heptane) to afford 12-1 (0.35 g, 25%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5).

Step 2. Synthesis of N-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-4-methylthiazol-2-amine (12-2)

[0340] To a stirred solution of 12-1 (1.5 g, 8.064 mmol) in dry DCM (20 mL) at 0° C. under a nitrogen atmosphere, Imidazole (1.09 g, 16.128 mmol) was added in small portions and the resulting reaction mixture was stirred at the same temperature for 10-15 min. To this reaction mixture, tert-butyldimethylsilyl chloride (1.38 g, 8.870 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 12-2 (1 g, 41.6%) as a yellow-colored oil. TLC: 30% EtOAc/heptane (R_f: 0.5).

Step 3. Synthesis of 3-(4-bromophenyl)-1-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-1-(4-methylthiazol-2-yl)urea (12-3)

[0341] To a stirred solution of 12-2 (1 g, 3.333 mmol) in 1,4 dioxane (10 mL) at 0° C. in an inert atmosphere, 1-bromo-4-isocyanatobenzene (0.78 g, 4.00 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography [eluting with 30-40% EtOAc in heptane] to afford 12-3 (1 g, 62.5%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Step 4. Synthesis of 3-(4-bromophenyl)-1-(4-hydroxybutan-2-yl)-1-(4-methylthiazol-2-yl)urea (12-4)

[0342] To a stirred solution of 12-3 (1 g, 2.012 mmol) in dry THF (5 mL) at 0° C. under a nitrogen atmosphere, Tetrabutylammonium fluoride (1M solution in THF, 4.02 mL, 4.024 mmol) was added dropwise. The resulting reaction mixture was slowly warmed to room temperature and stirred for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 12-4 (0.5 g, crude) as a pale-yellow oil. TLC: 50% EtOAc/heptane (R^f: 0.5).

Step 5. Synthesis of 1-(4-bromophenyl)-4-methyl-3-(4-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one (12-5)

[0343] To a stirred solution of 12-4 (0.5 g, 1.305 mmol) in Toluene (5 mL) at 0° C., was added triphenylphosphine (0.68 g, 2.610 mmol) followed by DEAD (0.52 g, 2.61 mmol). The resulting reaction mixture was slowly warmed to room temperature and stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 12-5 (0.3 g, 62.8) as a pale-yellow oil. TLC: 50% EtOAc/heptane (R_f: 0.5).

Step 6. Synthesis of 2-(3-(4-bromophenyl)-6-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (12-6)

[0344] To a stirred solution of 12-5 (0.3 g, 0.821 mmol) in dry DCM (5 mL) at 0° C. in an inert atmosphere, chlorosulfonic acid (0.19 g, 1.643 mmol) was added, and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford 12-6 (0.25 g, crude) as an off-white solid, TLC: 40% EtOAc/Heptane (R_f: 0.3), which was used in the next step without further purification.

Step 7. Synthesis of 2-(3-(4-bromophenyl)-6-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (12-7)

[0345] A mixture of 12-6 (0.25 g, 0.327 mmol) and POCl₃(3 mL) was allowed to stir at 80° C. for 12 h.

[0346] The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (3 mL) and aqueous ammonia (5 mL) was added at 0° C. while stirring was continued at room temperature for another 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced. The crude compound was purified by CombiFlash chromatography (eluting with 40-50% EtOAc in heptane) to afford 12-7 (0.15 g, 78%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Step 8. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-6-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (107)

[0347] To a stirred solution of 12-7 (0.15 g, 0.337 mmol) in 1,4 dioxane:H₂O (4:1, 10 mL) were added (2,5-difluorophenyl) boronic acid (0.8 g, 0.506 mmol) and K₃PO₄(0.143 g, 0.674 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(24.7 mg, 0.0337 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 100° C. for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite®545 and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography followed by preparative HPLC to afford 107 (90 mg, 55.9%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Example 13. 2-(7-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-6-oxo-5,7-diazaspiro [2.5]octan-5-yl)-4-methylthiazole-5-sulfonamide (110)

Step 1. Synthesis of 1-(5-(benzylthio)-4-methylthiazol-2-yl)-3-(4-bromophenyl) urea (13-1)

[0348] To a stirred solution of 1-2 (2.5 g, 10.593 mmol) in 1,4 dioxane (25 mL) at 0° C. in an inert atmosphere, 1-bromo-4-isocyanatobenzene (2.08 g, 10.593 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 13-1 (2 g, 44.7%) as an off-white solid. TLC: 50% EtOAc/heptane (R^f: 0.5), which was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-d₆): δ 10.56 (br s, 1H), 9.11 (s, 1H), 7.47 (s, 4H), 7.31-7.20 (m, 3H), 7.11 (d, J=6.8 Hz, 2H), 3.87 (s, 2H), 1.86 (s, 3H) ppm.

Step 2. Synthesis of 5-(5-(benzylthio)-4-methylthiazol-2-yl)-7-(4-bromophenyl)-5,7-diazaspiro [2.5]octan-6-one (13-2)

[0349] To a stirred solution of 13-1 (1.5 g, 3.464 mmol) in dry DMF (30 mL) at 0° C. under a nitrogen atmosphere, Cs₂CO₃(3.37 g, 10.392 mmol) was added in small portions and the resulting reaction mixture was stirred at room temperature for 30 min. To this reaction mixture, 1,1-bis(bromomethyl)cyclopropane (0.79 g, 3.464 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 13-2 (0.4 g, 23.5%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₃H₂₂BrN₃OS₂: 499.04; Found: 500.1 [M+1]. ¹H NMR (400 MHz, DMSO-d₆): δ 7.58 (d, J=7.8 Hz, 2H), 7.32 (d, J=8.3 Hz, 2H), 7.28-7.21 (m, 3H), 7.16-7.07 (m, 2H), 3.93 (s, 2H), 3.85 (s, 2H), 3.59 (s, 2H), 1.91 (s, 3H), 0.80-0.71 (m, 4H) ppm.

Step 3. Synthesis of 2-(7-(4-bromophenyl)-6-oxo-5,7-diazaspiro [2.5]octan-5-yl)-4-methylthiazole-5-sulfonamide (13-3)

[0350] To a stirred solution of 13-2 (0.1 g, 0.200 mmol) in AcOH/H₂O (2 mL/0.2 mL), NCS (0.1 g, 0.751 mmol) was added, and the reaction mixture was stirred at room temperature for 30 min. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (1 mL) and aqueous ammonia (2 mL) was added at 0° C. while stirring was continued at the same temperature for another 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 1-2% MeOH in DCM) to afford 13-3 (0.1 g, 55%) as an off-white solid. TLC: 5% MeOH/DCM (R^f: 0.3). ¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.54 (m, 4H), 7.34 (d, J=7.8 Hz, 2H), 3.98 (s, 2H), 3.62 (s, 2H), 2.41 (s, 3H), 0.78 (d, J=6.4 Hz, 4H) ppm.

Step 4. Synthesis of 2-(7-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-6-oxo-5,7-diazaspiro [2.5]octan-5-yl)-4-methylthiazole-5-sulfonamide (110)

[0351] To a stirred solution of 13-3 (90 mg, 0.197 mmol) in 1, 4-dioxane and water (2:0.4 mL) were added (2,5-difluorophenyl) boronic acid (46.74 mg, 0.296 mmol) and K₃PO₄(0.10 g, 0.492 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(14 mg, 0.0197 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 80° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by preparative HPLC to afford 110 (10 mg, 10.3%) as an off-white solid. TLC: 5% MeOH/DCM (R_f. 0.3).

Example 14. 4-Methyl-2-(7-(4-(1-methyl-1H-pyrazol-5-yl)phenyl)-6-oxo-5,7-diazaspiro[2.5]octan-5-yl)thiazole-5-sulfonamide (113)

Step 1. Synthesis of (1-(((4-methylthiazol-2-yl)amino)methyl)cyclopropyl)methanol (14-1)

[0352] To a stirred solution of 10-1 (3 g, 22.455 mmol) in DMSO (50 mL) was added compound 2 (3.4 g, 33.682 mmol mmol) followed by K₂CO₃(4.65 g, 33.682 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (0.43 g, 2.245 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 120° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 10-20-70% EtOAc in heptane) to afford 14-1 (0.8 g, 18%) as an off-white solid. TLC: 20% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₉H₁₄N₂₀S: 198.08; Found: 199.1 [M+1]⁺.

Step 2. Synthesis of N-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)methyl)-4-methylthiazol-2-amine (14-2)

[0353] To a stirred solution of 14-1 (0.4 g, 2.020 mmol) in dry DCM (20 mL) at 0° C. under a nitrogen atmosphere, Imidazole (0.20 g, 3.030 mmol) was added in small portions and the resulting reaction mixture was stirred at the same temperature for 10-15 min. To this reaction mixture, tert-Butyldimethylsilyl chloride (0.36 g, 2.424 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 14-2 (0.7 g, 55.5%) as a yellow-colored oil. TLC: 20% EtOAc/heptane (R_f: 0.5).

Step 3. Synthesis of 3-(4-bromophenyl)-1-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)methyl)-1-(4-methylthiazol-2-yl)urea (14-3)

[0354] To a stirred solution of 14-2 (0.35 g, 1.121 mmol) in 1,4 dioxane (10 mL) at 0° C. in an inert atmosphere, 1-bromo-4-isocyanatobenzene (0.22 g, 1.121 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography [eluting with 30-40% EtOAc in heptane] to afford 14-3 (0.5 g, 43.8%) as an off-white solid. TLC: 20-30% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₂₂H₃₂BrN₃O₂SSi: 509.12; Found: 512.13 [M+2]⁺.

Step 4. Synthesis of 3-(4-bromophenyl)-1-((1-(hydroxymethyl)cyclopropyl)methyl)-1-(4-methylthiazol-2-yl)urea (14-4)

[0355] To a stirred solution of 14-3 (0.25 g, 0.490 mmol) in dry THF (5 mL) at 0° C. under a nitrogen atmosphere, Tetrabutylammonium fluoride (1M solution in THF, 1 mL, 0.980 mmol) was added dropwise. The resulting reaction mixture was slowly warmed to room temperature and stirred for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 14-4 (0.4 g, crude) as an off-white solid. TLC: 30% EtOAc/heptane (R_f. 0.5). MS (ESI): calcd. for C₂₂H₃₂BrN₃O₂SSi: 395.03; Found: 396.1 [M+1]⁺.

Step 5. Synthesis of 5-(4-bromophenyl)-7-(4-methylthiazol-2-yl)-5,7-diazaspiro[2.5]octan-6-one (14-5)

[0356] To a stirred solution of 14-4 (0.2 g, 0.506 mmol) in Toluene (5 mL) at 0° C., was added triphenylphosphine (0.2 g, 0.759 mmol) followed by DEAD (0.13 g, 0.759 mmol). The resulting reaction mixture was slowly warmed to room temperature and stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 14-5 (0.24 g, 63.1%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₆H₁₆BrN₃OS: 377.02; Found: 377.90 [M+1]⁺.

Step 6. Synthesis of 2-(7-(4-bromophenyl)-6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-4-methylthiazole-5-sulfonic acid (14-6)

[0357] To a stirred solution of 14-5 (0.12 g, 0.317 mmol) in dry DCM (10 mL) at 0° C. in an inert atmosphere, Chlorosulfonic acid (0.11 g, 0.952 mmol) was added, and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford 14-6 (0.15 g, crude) as an off-white solid. TLC: 30% EtOAc/Heptane (R_f. 0.3) which was used in the next step without further purification. MS (ESI): calcd. for C₁₆H₁₆BrN₃O₄S₂: 456.98; Found: 459.7 [M+2]⁺.

Step 7. Synthesis of 2-(7-(4-bromophenyl)-6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-4-methylthiazole-5-sulfonamide (14-7)

[0358] A mixture of 14-6 (0.15 g, 0.327 mmol) and POCl₃(1.5 mL) was allowed to stir at 100° C. for 12 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (3 mL) and aqueous ammonia (5 mL) was added at 0° C. while stirring was continued at room temperature for another 1 h. The reaction mixture was concentrated under reduced pressure. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford 14-7 (0.1 g, crude) as a pale brown colored solid. TLC: 30% EtOAc/Heptane (R_f: 0.3) which was used in the next step without further purification. MS (ESI): calcd. for C₁₆H₁₇BrN₄O₃S₂: 455.99; Found: 458.7 [M+2]⁺.

Step 8. Synthesis of 4-methyl-2-(7-(4-(1-methyl-1H-pyrazol-5-yl)phenyl)-6-oxo-5,7-diazaspiro[2.5]octan-5-yl)thiazole-5-sulfonamide (113)

[0359] To a stirred solution of 14-7 (0.1 g, 0.218 mmol) in 1,4-dioxane:H₂O (4:1, 10 mL) were added 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (75 mg, 0.327 mmol) and Na₂CO₃(47 mg, 0.436 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd (dppf)Cl₂(16 mg, 0.0218 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography followed by preparative HPLC to afford 113 (20 mg, 20%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.3).

Example 15. 2-(3-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-N,4-dimethylthiazole-5-sulfonamide (116)

Step 1. Synthesis of 1-(5-(benzylthio)-4-methylthiazol-2-yl)-3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl) tetrahydropyrimidin-2(1H)-one (15-1)

[0360] To a stirred solution of 1-3 (0.5 g, 1.567 mmol) in 1, 4-dioxane (5 mL) were added compound 11-7 (0.46 g, 1.724 mmol), K₂CO₃(0.43 g, 3.134 mmol) and 1,2-dimethylethylenediamine (69 mg, 0.783 mmol) the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (60 mg, 0.313 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-70% EtOAc in heptane) to afford 15-1 (0.25 g, 31.6%) as an off-white solid. TLC: 60% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for Chemical Formula C₂₇H₂₃F₂N₃OS₂: 507.13; Found: 508.44 [M+1]⁺.

Step 2. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-N,4-dimethylthiazole-5-sulfonamide (116)

[0361] To a stirred solution of 15-1 (0.15 g, 0.295 mmol) in AcOH:H₂O (1.5:0.1 mL), NCS (0.15 g, 1.10 mmol) was added, and the reaction mixture was stirred at room temperature for 30 min. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (2 mL), to this resulting solution, Methyl amine (33 wt. % solution in methanol, 3 mL) was added at 0° C. and stirring continued at room temperature for another 1 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in ethyl acetate and the organic layer was washed with water. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford 116 (15 mg, 10.6%) as an off-white solid. TLC: 5% MeOH/DCM (R^f: 0.5)

Example 16. 1-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methyl-5-(S-methylsulfonimidoyl) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (139)

Step 1. Synthesis of 4-methyl-5-(methylthio) thiazol-2-amine (16-1)

[0362] To a stirred solution of 1-1 (1 g, 5.181 mmol) in methanol (10 mL) at 0° C., Sodium thiomethoxide (0.544 g, 7.77 mmol) was added drop wise. The resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in EtOAc and the organic layer was washed with water. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 10-20% EtOAc in heptane) to afford 16-1 (0.6 g, 72.3%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₅H₈N₂S₂: 160.01; Found: 160.75 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 7.08 (br s, 2H), 2.21 (s, 3H), 2.12 (s, 3H).

Step 2. Synthesis of 1-(4-methyl-5-(methylthio) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (16-2)

[0363] A mixture of 16-1 (0.6 g, 3.75 mmol) and 1-chloro-3-isocyanatopropane (0.58 g, 4.87 mmol) in THF (12 mL) was heated at 65° C. for 5 h. To this resulting solution, TBAI (69 mg, 0.187 mmol) and K₂CO₃(0.77 g, 5.62 mmol) were added portion wise maintaining the same temperature and stirring continued at 65° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 60-70% EtOAc in heptane) to afford 16-2 (0.5 g, 54.8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f. 0.5). MS (ESI): calcd. for C₉H₁₃N₃OS₂: 174.03; Found: 174.77 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.44 (s, 1H), 4.00-3.92 (m, 2H), 3.25-3.17 (m, 2H), 2.29 (s, 3H), 2.28 (s, 3H), 2.00-1.89 (m, 2H) ppm.

Step 3. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methyl-5-(methylthio) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (16-3)

[0364] To a stirred solution of 16-2 (0.5 g, 2.057 mmol) in 1, 4-dioxane (6 mL) were added 11-7 (0.66 g, 2.47 mmol), K₂CO₃(0.57 g, 4.11 mmol) and 1,2-Dimethylethylenediamine (90 mg, 1.028 mmol) the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (78 mg, 0.41 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 110° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-70% EtOAc in heptane) to afford 16-3 (0.4 g, 45%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₂₁H₁₉F₂N₃OS₂: 431.09; Found: 432.1 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.59 (m, 2H), 7.51-7.34 (m, 4H), 7.30-7.24 (m, 1H), 4.17-4.08 (m, 2H), 3.86-3.78 (m, 2H), 2.34-2.26 (m, 6H), 2.26-2.17 (m, 2H) ppm.

Step 4. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methyl-5-(S-methylsulfonimidoyl) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (139)

[0365] To a stirred solution of 16-3 (0.1 g, 0.23 mmol) in ACN:MeOH (2:2 mL) were added Ammonium carbamate (0.054 g, 0.69 mmol) and PhI(OAc)₂(0.34 g, 0.92 mmol). The resulting reaction mixture was allowed to stir at room temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude residue obtained was dissolved in ethyl acetate and washed with water. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 0-70% EtOAc in heptane) followed by preparative HPLC to afford 139 (15 mg, 14%) as an off-white solid. TLC: 80% EtOAc/heptane (R_f: 0.5).

Example 17. (R)-1-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methyl-5-(S-methylsulfonimidoyl) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (140) and (S)-1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methyl-5-(S-methylsulfonimidoyl)thiazol-2-yl)tetrahydropyrimidin-2(1H)-one (141)

[0366] Compound 139 chiral separation under the condition below afforded 140 and 141 as an off-white solid.

Chiral Separation Condition for 140

[0367] Chiral HPLC: Rt 14.02 min, 100%

[0368] CHIRAL PAK IC (150×4.6 mm, 3 μm); MOBILE PHASE A: n-Hexane; MOBILE PHASE B: DCM:MEOH (50:50); PROGRAM-AB 40:60; FLOW RATE: 1.0 mL/min.

Chiral Separation Condition for 141

[0369] Chiral HPLC: Rt 16.02 min, 99.05%

[0370] CHIRAL PAK IC (150×4.6 mm, 3 μm); MOBILE PHASE A: n-Hexane; MOBILE PHASE B: DCM:MEOH (50:50); PROGRAM-AB 40:60; FLOW RATE: 1.0 mL/min.

[0371] The stereochemistry of 140 and 141 was arbitrarily assigned, respectively.

Example 18. 1-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-3-(5-(isopropylsulfonyl)-4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (162)

Step 1. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (18-1)

[0372] To a stirred solution of 2-2 (5 g, 25.380 mmol) in 1, 4-dioxane (100 mL) were added 4′-bromo-2,5-difluoro-1,1′-biphenyl (8.16 g, 30.456 mmol), K₂CO₃(8.75 g, 63.45 mmol) followed by CuI (0.96 g, 5.076 mmol) and the resulting reaction mixture was purged under nitrogen for 20 min. To this resulting reaction mixture, 1,2-dimethylethylenediamine (0.9 g, 10.152 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 120° C. for 16 h in a sealed tube. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 18-1 (4.1 g, 41.9%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5). MS (ESI): calcd. for C₂₀H₁₇F₂N₃OS: 385.11; Found: 385.90 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.61 (d, J=7.8 Hz, 2H), 7.54-7.35 (m, 4H), 7.35-7.21 (m, 1H), 6.70 (s, 1H), 4.17 (t, J=5.6 Hz, 2H), 3.81 (t, J=4.9 Hz, 2H), 2.26 (s, 3H), 2.24-2.21 (m, 2H) ppm.

Step 2. Synthesis of 1-(5-bromo-4-methylthiazol-2-yl)-3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl) tetrahydropyrimidin-2(1H)-one (18-2)

[0373] To a stirred solution of 18-1 (1 g, 2.597 mmol) in DCM (10 mL) was added NBS (0.6 g, 3.37 mmol) and the resulting reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 18-2 (0.7 g, 58.3%) as an off-white solid. TLC: 50% EtOAc/Heptane (R^f: 0.5). MS (ESI): calcd. for C₂₀H₁₆BrF₂N₃OS: 463.02; Found: 466.0 [M+2]⁺.

Step 3. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(5-(isopropylsulfonyl)-4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (162)

[0374] To a stirred solution of 18-2 (0.5 g, 1.079 mmol) in DMF (10 mL) were added propane-2-sulfinate sodium salt (0.56 g, 4.319 mmol) and CS₂CO₃(0.87 g, 2.69 mmol) and then was subsequently added CuI (21 mg, 0.1079 mmol) followed by L-proline (25 mg, 0.216 mmol). The resulting reaction mixture was heated at 80° C. for 12 h. The reaction mixture was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by preparative HPLC to afford 162 (8 mg, 1.5%) as an off-white solid.

Example 19. 2-(3-(2′,5′-Difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethyl) thiazole-5-sulfonamide (169)

Step 1. Synthesis of 4-(trifluoromethyl) thiazol-2-amine (19-2)

[0375] To a stirred solution of 19-1 (2.7 g, 14.210 mmol) in ethanol (50 mL) was added thiourea (2.16 g, 28.42 mmol) and the resulting reaction mixture was stirred at 60° C. for 2 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 19-2 (3 g, crude) as a sticky liquid. TLC: 20% EtOAc/heptane (R_f: 0.2). MS (ESI): calcd. for C₄H₃F₃N₂S: 168.00; Found: 169.00 [M+1]⁺.

Step 2. Synthesis of 1-(4-(trifluoromethyl) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (19-3)

[0376] To a mixture of 19-2 (4 g, 23.809 mmol) and 1-chloro-3-isocyanatopropane (4.2 g, 35.714 mmol) in THF (60 mL) were added TBAI (0.38 g, 1.190 mmol) and K₂CO₃(4.28 g, 30.951 mmol) portion wise the resulting reaction mixture was stirred at 70° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 19-3 (2.7 g, 45.2%) as an off-white solid. TLC: 40% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₈H₈F₃N₃OS: 251.03; Found: 251.80 [M+1]⁺.

Step 3. Synthesis of 1-(4-bromophenyl)-3-(4-(trifluoromethyl) thiazol-2-yl) tetrahydropyrimidin-2(1H)-one (19-4)

[0377] To a stirred solution of 19-3 (2.7 g, 10.756 mmol) in ACN (50 mL) were added 1-bromo-4-iodobenzene (3.65 g, 12.908 mmol), CS₂CO₃(6.99 g, 21.512 mmol) followed by CuI (0.81 g, 4.302 mmol) and the resulting reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, 1,2-Dimethylethylenediamine (0.378 g, 4.302 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h in a sealed tube. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 19-4 (2 g, 45.9%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₄H₁₁BrF₃N₃OS: 404.98; Found: 405.80 [M+1]⁺.

Step 4. Synthesis of 2-(3-(4-bromophenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethyl) thiazole-5-sulfonic acid (19-5)

[0378] To a stirred solution of 19-4 (0.5 g, 1.234 mmol) in dry DCM (8 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (0.4 mL, 4.938 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 48 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford 19-5 (0.5 g, crude) as an off-white solid. TLC: 30% EtOAc/Heptane (R_f: 0.3). MS (ESI): calcd. for C₁₄H₁₁BrF₃N₃O₄S₂: 484.93; Found: 485.65 [M+1]⁺.

Step 5. Synthesis of 2-(3-(4-bromophenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethyl) thiazole-5-sulfonamide (19-6)

[0379] A stirred solution of 19-5 (0.5 g, 1.030 mmol) in POCl₃(6 mL) was allowed to stir at 100° C. for 2 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (3 mL) and aqueous ammonia (6 mL) was added at 0° C. while stirring was continued at room temperature for another 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford 19-6 (0.2 g, 40.1%) as an off-white solid. MS (ESI): calcd. for C₁₄H₁₂BrF₃N₄O₃S₂: 483.95; Found: 484.85 [M+1]⁺.

Step 6. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethyl) thiazole-5-sulfonamide (169)

[0380] To a stirred solution of 19-6 (0.2 g, 0.413 mmol) in 1,4 dioxane:H₂O (5:1 mL) were added (2,5-difluorophenyl) boronic acid (0.1 g, 0.619 mmol) and K₃PO₄(0.21 g, 1.032 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf) C_1-2(30 mg, 0.041 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 10-30% EtOAc in heptane) to afford 169 (25 mg, 11.6%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.3).

Example 20. 2-(3-((2′,5′-Difluoro-[1,1′-biphenyl]-3-yl) methyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (172)

Step 1. Synthesis of 1-(3-bromobenzyl)-3-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (20-1)

[0381] To a stirred solution of 2-2 (4 g, 20.304 mmol) in dry THF (80 mL) at 0° C. under a nitrogen atmosphere, NaH (60% w/w in mineral oil, 1.21 g, 30.456 mmol) was added in small portion and the resulting reaction mixture was stirred at the same temperature for 30 min. To this reaction mixture, 1-bromo-4-(bromomethyl) benzene (6 g, 24.36 mmol) was added at 0° C. and The resulting reaction mixture was stirred at the same temperature for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (using a gradient method of 50-60% EtOAc in heptane) to afford 20-1 (5.21 g, 70.3%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₅H₁₆BrN₃OS: 365.02; Found: 368 [M+2]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.51-7.46 (m, 2H), 7.36-7.27 (m, 2H), 6.66 (s, 1H), 4.57 (s, 2H), 4.07 (t, J=5.6 Hz, 2H), 3.36-3.33 (m, 2H), 2.23 (s, 3H), 2.06-1.99 (m, 2H) ppm

Step 2. Synthesis of 2-(3-(3-bromobenzyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (20-2)

[0382] To a stirred solution of 20-1 (1 g, 2.739 mmol) in dry DCM (10 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (0.63 g, 5.48 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and stirred for 5-10 min. The precipitated solid obtained out was collected by filtration and dried in vacuo to afford 20-2 (1.02 g, crude) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.2) which was used in the next step without further purification. MS (ESI): calcd. for C₁₅H₁₆BrN₃O₄S₂: 444.98; Found: 446 [M+1]. ¹H NMR (400 MHz, DMSO-d₆): δ 7.52-7.45 (m, 2H), 7.35-7.28 (m, 2H), 4.57 (s, 2H), 4.04-3.97 (m, 2H), 3.41-3.25 (m, 2H), 2.32 (s, 3H), 2.08-1.96 (m, 2H) ppm.

Step 3. Synthesis of 2-(3-(3-bromobenzyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (20-3)

[0383] To a stirred solution of 20-2 (1 g, 2.242 mmol) in POCl₃(10 mL) was allowed to stir at 80° C. for 12 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (5 mL) and aqueous ammonia (10 mL) was added at 0° C. while stirring was continued at room temperature for another 12 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (using a gradient method of 1-2% MeOH in DCM) to afford 20-3 (0.60 g, 60.6%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₅H₁₇BrN₄O₃S₂: 443.99; Found: 447.1 [M+2]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.55-7.50 (m, 4H), 7.31 (s, 2H), 4.58 (s, 2H), 4.11-4.00 (m, 2H), 3.39-3.33 (m, 2H), 2.42 (s, 3H), 2.10-2.01 (m, 2H) ppm.

Step 4. Synthesis of 2-(3-((2′,5′-difluoro-[1,1′-biphenyl]-3-yl) methyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (172)

[0384] To a stirred solution of 20-3 (0.3 g, 0.677 mmol) in 1, 4-dioxane and water (4:1.5 mL) were added (2,5-difluorophenyl) boronic acid (0.16 g, 1.015 mmol) and K₃PO₄(0.36 g, 1.692 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(50 mg, 0.0677 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 80° C. for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and, extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 1-2% MeOH in DCM) to afford 172 (0.14 g, 45.6%) as an off-white solid. TLC: 5% MeOH/DCM (R_f: 0.5).

Example 21. 2-(3-(1-(2′,5′-Difluoro-[1,1′-biphenyl]-3-yl) ethyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (174)

Step 1. Synthesis of 1-(3-bromophenyl) ethan-1-ol (21-2)

[0385] To a stirred solution of 21-1 (5 g, 25.119 mmol) in methanol (35 mL) at 0° C. under a nitrogen atmosphere, NaBH₄(1.43 g, 37.68 mmol) was added in small portions and then the reaction mixture was slowly warmed to room temperature and stirred for 3 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The resulting residue was suspended in ice cold water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to afford 21-2 (4.5 g, crude) as a yellow-colored sticky solid, which was used in the next step without further purification.

Step 2. Synthesis of 1-bromo-3-(1-bromoethyl) benzene (21-3)

[0386] To a stirred solution of 21-2 (4.5 g, 22.38 mmol) in DCM (20 mL) at 0° C. in an inert atmosphere, Phosphorus tribromide (2.13 mL, 22.38 mmol) was added dropwise and the reaction mixture was stirred at the same temperature for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated NaHCO₃solution and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford 21-3 (4 g, crude) as a pale green solid, which was used in the next step without further purification. TLC: 10% EtOAc/heptane (R^f: 0.5).

Step 3. Synthesis of 1-(1-(3-bromophenyl) ethyl)-3-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (21-4)

[0387] To a stirred solution of 2-2 (0.8 g, 4.060 mmol) in dry DMF (8 mL) at 0° C. under a nitrogen atmosphere, NaH (60% w/w in mineral oil, 0.24 g, 6.091 mmol) was added in small portions and the resulting reaction mixture was stirred at the same temperature for 15 min. To this reaction mixture, 21-3 (1.6 g, 6.091 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred at 50° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford 21-4 (1.2 g, 77.9%) as a yellow solid. TLC: 40% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₁₆H₁₈BrN₃OS: 379.04; Found: 379.9 [M+1]⁺.

Step 4. Synthesis of 2-(3-(1-(3-bromophenyl) ethyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (21-5)

[0388] To a stirred solution of 21-4 (1.2 g, 3.165 mmol) in dry DCM (12 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (0.42 mL, 6.331 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford 21-5 (0.8 g, crude) as a pale brown colored solid. TLC: 50% EtOAc/heptane (R_f: 0.3). MS (ESI): calcd. for C₁₆H₁₈BrN₃O₄S₂: 458.99; Found: 461.7 [M+2]⁺.

Step 5. Synthesis of 2-(3-(1-(3-bromophenyl) ethyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonyl chloride (21-6)

[0389] A stirred solution of 21-5 (0.8 g, 1.742 mmol) in POCl₃(8 mL) was allowed to stir at 80° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and concentrated under reduced pressure to afford 21-6 (0.7 g, crude) as an orange colored solid, which was used without further purification.

Step 6. Synthesis of 2-(3-(1-(3-bromophenyl) ethyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (21-7)

[0390] To a stirred solution of 21-6 (0.6 g 1.257 mmol) in THF (6 mL) at 0° C., aqueous ammonia (1 mL) was added dropwise. The resulting reaction mixture was slowly warmed to room temperature and allowed to stir for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted, with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 20-50% EtOAc in heptane) to afford the title compound 21-7 (0.16 g, 29.8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.3). MS (ESI): calcd. for C₁₆H₁₉BrN₄O₃S₂: 458.01; Found: 460.7 [M+2]⁺.

Step 7. Synthesis of 2-(3-(1-(2′,5′-difluoro-[1,1′-biphenyl]-3-yl) ethyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (174)

[0391] To a stirred solution of 21-7 (0.15 g, 0.327 mmol) in 1, 4-dioxane and water (2.5:0.5 mL) were added (2,5-difluorophenyl) boronic acid (0.13 g, 0.818 mmol) and K₃PO₄(0.17 g, 0.818 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(25 mg, 0.038 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 80° C. for 10 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford 174 (80 mg) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Example 22. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (5)

Step 1. Synthesis of 1-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (5-2)

[0392] A mixture of compound 5-1 (6 g, 52.632 mmol) and 1-chloro-3-isocyanatopropane (6.26 g, 52.632 mmol) in THF (60 mL) was heated at 70° C. for 6 h. To the resulting solution, TBAB (1.7 g, 5.263 mmol) and K₂CO₃(18.15 g, 131.58 mmol) were added portion wise maintaining the same temperature and stirring continued at 70° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 60-70% EtOAc in heptane) to afford the title compound 5-2 (5.1 g, 49.2%) as an off-white solid. TLC: 70% EtOAc/heptane (R_f: 0.5). MS (ESI): calcd. for C₈H_iiN₃₀S: 197.06; Found: 198.17 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.30 (s, 1H), 6.60 (s, 1H), 3.99 (t, J=5.4 Hz, 2H), 3.20-3.19 (m, 2H), 2.28 (s, 3H), 1.99-1.89 (m, 2H) ppm.

Step 2. Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl) tetrahydropyrimidin-2(1H)-one (5-3)

[0393] To a stirred solution of compound 5-2 (5 g, 25.380 mmol) in 1, 4-dioxane (100 mL) were added Int #5A (8.16 g, 30.456 mmol), K₂CO₃(8.75 g, 63.45 mmol) followed by CuI (0.96 g, 5.076 mmol) and the resulting reaction mixture was purged under nitrogen for 20 min. To this resulting reaction mixture, 1,2-Dimethylethylenediamine (0.9 g, 10.152 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 120° C. for 24 h in a sealed tube. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and, extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 30-40% EtOAc in heptane) to afford the title compound 5-3 (4.1 g, 41.9%) as an off-white solid. TLC: 50% EtOAc/Heptane (R^f: 0.5). MS (ESI): calcd. for C₂₀H₁₇F₂N₃OS: 385.11; Found: 385.90 [M+1]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 7.61 (d, J=7.8 Hz, 2H), 7.54-7.35 (m, 4H), 7.35-7.21 (m, 1H), 6.70 (s, 1H), 4.17 (t, J=5.6 Hz, 2H), 3.81 (t, J=4.9 Hz, 2H), 2.26 (s, 3H), 2.24-2.21 (m, 2H) ppm.

Step 3. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (5-4)

[0394] To a stirred solution of compound 5-3 (4 g, 10.389 mmol) in dry DCM (40 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (2.07 mL, 31.168 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford the title compound 5-4 (3.35 g, crude) as an off-white solid. TLC: 100% EtOAc (R_f: 0.2). MS (ESI): calcd. for C₂₀H₁₇F₂N₃O₄S₂: 465.06; Found: 466 [M+1]⁺.

Step 4. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (5)

[0395] A stirred solution of compound 5-4 (3.3 g, 7.096 mmol) in POCl₃(33 mL) was allowed to stir at 90° C. for 5 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (66 mL), and aqueous ammonia (33 mL) was added at −5° C. while stirring was continued at room temperature for another 12 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 100% EtOAc) to afford the desired product as a white solid 5 (1.1 g, 44.6%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 7.65-7.59 (m, 2H), 7.55 (br s, 2H), 7.53-7.48 (m, 2H), 7.48-7.36 (m, 2H), 7.31-7.25 (m, 1H), 4.17 (t, J=6.1 Hz, 2H), 3.82 (t, J=5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm.

Step 5. Synthesis of 4′-bromo-2,5-difluoro-1,1′-biphenyl (Int. 5A)

[0396] To a stirred solution of compound 5A (5 g, 17.674 mmol) in 1,4 dioxane:H₂O (50:5 mL) were added (2,5-difluorophenyl) boronic acid (3.07 g, 19.441 mmol) and K₃PO₄(7.5 g, 35.348 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd(dppf)Cl₂(1.29 g, 1.767 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 80° C. for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 100% heptane) to afford the title compound Int. 5A (2.3 g, 48.6%) as an off-white solid. TLC: 100% heptane (R^f: 0.5). ¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.3 Hz, 2H), 7.40 (d, J=7.3 Hz, 2H), 7.15-7.06 (m, 2H), 7.05-6.97 (m, 1H) ppm.

Example 23. Synthesis of 2-(3-(3′-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (228)

Synthesis of 4-(3-bromo-2,5-difluorophenyl)-1H-pyrazole (23-2)

[0397] To a stirred solution of 1,3-dibromo-2,5-difluorobenzene (23-1) (1215 mg, 4.47 mmol) and (1H-pyrazol-4-yl) boronic acid (500 mg, 4.47 mmol) in DME (10 mL), water (4.00 mL) was added K₂CO₃(1.853 g, 13.41 mmol) and Pd(dppfcl2)DCM (365 mg, 0.447 mmol) and purged with nitrogen for 10 min. The reaction mixture was heated at 80° C. for 3 h. The reaction was monitored by UPLC. After completion, the reaction mixture was diluted with cold water (10 mL) and extracted with ethyl acetate (2×15 mL). The combined organic layer was washed with brine (1×15 mL), dried over anhydrous sodium sulfate, and concentrated on a rotary evaporator (bath temperature 45° C.) under reduced pressure to afford 4-(3-bromo-2,5-difluorophenyl)-1H-pyrazole (23-2) (200 mg, 0.749 mmol, 16.7% yield) as a crude compound. LCMS: 1.704 min, 97.65%, 259.0 (M+H)⁺, (Column: Atlantis dC18 (50*4.6) 5 μm), Mobile phase A: 0.1% Formic acid in H₂O, Mobile phase B: ACN, Flow Rate: 1.5 ml/min)

Synthesis of 4-(3-bromo-2,5-difluorophenyl)-1-(difluoromethyl)-1H-pyrazole (23-3)

[0398] To a stirred solution of 4-(3-bromo-2,5-difluorophenyl)-1H-pyrazole (23-2) (200 mg, 0.772 mmol) and potassium fluoride (90 mg, 1.544 mmol) in Acetonitrile (10 mL), were added Diethyl (bromodifluoromethyl)phosphonate (0.275 mL, 1.544 mmol) and the reaction mixture was stirred at RT for 16 h. After completion, the reaction mixture was diluted with cold water (10 mL) and extracted with ethyl acetate (2×15 mL). The combined organic layer was washed with brine (1×15 mL), dried over anhydrous sodium sulfate, and concentrated on a rotary evaporator (bath temperature 45° C.) under reduced pressure to afford crude. The obtained crude was purified by Isolera column chromatography Technique using 230˜400 silica gel, eluted in 20% Ethyl acetate:Pet ether. The combined pure fractions are concentrated on a rota evaporator under reduced pressure to afford pure 4-(3-bromo-2,5-difluorophenyl)-1-(difluoromethyl)-1H-pyrazole (23-3) (20 mg, 0.062 mmol, 8% yield) as a pale-yellow liquid. LCMS: 2.044 min, 97.65%, 310.9 (M+H)⁺, (Column: XBridge C18 (50×4.6 mm) 3.5 μm, Mobile phase A: 0.1% TFA in H2O, Mobile phase B: ACN, Flow Rate: 2.0 ml/min).

Synthesis of 2-(3-(3′-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (228)

[0399] To a stirred solution of 4-(3-bromo-2,5-difluorophenyl)-1-(difluoromethyl)-1H-pyrazole (23-3) (20 mg, 0.065 mmol) and 4-methyl-2-(2-oxo-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahydropyrimidin-1(2H)-yl)thiazole-5-sulfonamide (2-6) (31.0 mg, 0.065 mmol) in THF (10 mL), water (4.00 mL) was added K₂CO₃(26.8 mg, 0.194 mmol) and XPhos Pd G2 (5.09 mg, 6.47 μmol) and purged with nitrogen for 10 min. The reaction mixture was heated at 80° C. for 3 h. The reaction was monitored by LCMS. The reaction mixture was diluted with water (5 mL) and extracted with Ethyl acetate (2×5 mL). The combined organic layer was washed with water (5 mL) followed by brine solution, dried over sodium sulfate, and concentrated. The resulting crude compound was purified by Prep HPLC (FA method) to afford 2-(3-(3′-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (228) (4.25 mg, 7.25 μmol, 11.2% yield) as an off white solid.

Example 24: Synthesis of 2-(3-(4-(4,6-difluoropyridin-2-yl)phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (235)

Synthesis of Synthesis of 2-(3-(4-(4,6-difluoropyridin-2-yl)phenyl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (235)

[0400] To a stirred solution of compound 2-6 (0.18 g, 0.386 mmol) in 1, 4-dioxane and water (4:1 mL) was added 2-bromo-4,6-difluoropyridine (50 mg, 0.257 mmol) followed by K₃PO₄(0.10 g, 0.515 mmol) and the reaction mixture was purged under nitrogen for 10 min. To this resulting solution, PdCl₂(dppf) (19 mg, 0.0257 mmol) was added under a nitrogen atmosphere and the reaction mixture was heated at 110° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford the title compound 235 (20 mg, 16.5%) as an off-white solid.

Example 25: Synthesis of 2-(8-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-7-oxo-2-oxa-6,8-diazaspiro[3.5]nonan-6-yl)-4-methylthiazole-5-sulfonamide (339)

Synthesis of 3-(5-(benzylthio)-4-methylthiazol-2-yl)-1-(4-bromophenyl)-1-((3-(hydroxymethyl)oxetan-3-yl)methyl)urea (25-1)

[0401] To a stirred solution of compound 13-1 (4 g, 9.259 mmol) in DMF (40 mL) at 0° C., was added CS₂CO₃(7.54 g, 23.147 mmol) followed by (3-(bromomethyl)oxetan-3-yl)methanol (2.51 g, 13.888 mmol). The resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by Combi Flash chromatography (eluting with 40-50% EtOAc in heptane) to afford the title compound 25-1 (1 g, 20.2%) as a pale-yellow solid.

Synthesis of 6-(5-(benzylthio)-4-methylthiazol-2-yl)-8-(4-bromophenyl)-2-oxa-6,8-diazaspiro[3.5]nonan-7-one (25-2)

[0402] To a stirred solution of compound 25-1 (0.9 g, 1.70 mmol) in Toluene (10 mL) at 0° C., was added triphenylphosphine (0.66 g, 2.50 mmol) and DEAD (0.44 g, 2.50 mmol). The resulting reaction mixture was slowly warmed to room temperature and stirred at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by Combi Flash chromatography (eluting with 40-50% EtOAc in heptane) to afford the title compound 25-2 (0.55 g, 63%) as a pale-yellow solid.

Synthesis of 6-(5-(benzylthio)-4-methylthiazol-2-yl)-8-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxa-6,8-diazaspiro[3.5]nonan-7-one (25-3)

[0403] To a stirred solution of compound 25-2 (0.5 g., 0.968 mmol) in 1,4 dioxane:H₂O (7:2 mL) was added (2,5-difluorophenyl)boronic acid (0.23 g, 1.45 mmol) followed by K₃PO₄(0.4 g, 1.94 mmol) and the reaction mixture was purged under nitrogen for 10 min. PdCl₂(dppf) (35 mg., 0.0484 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by Combi Flash chromatography (eluting with 50-60% EtOAc in heptane) to afford the title compound 25-3 (0.11 g, 21.6%) as an off-white solid.

Synthesis of 2-(8-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-7-oxo-2-oxa-6,8-diazaspiro[3.5]nonan-6-yl)-4-methylthiazole-5-sulfonamide (339)

[0404] To a stirred solution of compound 25-3 (0.110 g, 0.200 mmol) in AcOH:H₂O (3:0.1 mL) was added N-chlorosuccinimide (93 mg, 0.701 mmol mmol) and then the reaction mixture was stirred at room temperature for 30 min. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (1 mL) and aqueous ammonia (2 mL) was added at 0° C. while stirring was continued at room temperature for another 1 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered. The crude compound obtained was purified by Combi Flash chromatography (eluting with 70-80% EtOAc in heptane) followed by preparative HPLC to afford the title compound 339 (13 mg, 13%) as an off-white solid.

Example 26. Synthesis of (S)-2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-(2-hydroxypropan-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (343) and (R)-2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-(2-hydroxypropan-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (344)

Synthesis of ethyl (E)-3-ethoxy-2-(ethoxymethyl)acrylate (26-2)

[0405] To a stirred solution of compound 26-1 (10 g, 68.493 mmol) in Toluene (120 mL) at 0° C. under a nitrogen atmosphere, Sodium ethoxide (9.3 g, 136.98 mmol) and ethyl formate (10 g, 136.98 mmol) were added, and the resulting reaction mixture was stirred at the same temperature for 2 h. To this reaction mixture, dimethyl sulfate (13 mL, 136.98 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred at 50° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the title compound 26-2 (11 g, crude) as yellow oil. TLC: 20% EtOAc/heptane (R_f: 0.2).

Synthesis of ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (26-3)

[0406] To a stirred solution of compound 26-2 (11 g, 54.455 mmol) in ethanol (120 mL) was added urea (3.2 g, 54.455 mmol mmol) followed by conc. HCl (2.4 mL) and the resulting reaction mixture was heated at 80° C. for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with ethanol. The obtained solid was filtered off and dried in vacuo to afford the title compound 26-3 (2.0 g, crude) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.3) which was used in the next step without further purification.

Synthesis of ethyl 2-oxohexahydropyrimidine-5-carboxylate (26-4)

[0407] An autoclave was charged with a solution of compound 26-3 (1.6 g, 9.090 mmol) in ethanol (50 mL) and the solution was purged under a nitrogen atmosphere for 10 min. 10% Pd/C (0.6 g) was added at room temperature under an inert atmosphere. The resulting reaction mixture was stirred at room temperature for 16 h under hydrogen atmosphere at 100 Psi. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated under reduced pressure to dryness to afford the title compound 26-4 (1.2 g, crude) as an off-white solid. TLC: 70% EtOAc/heptane (R_f: 0.5).

Synthesis of ethyl 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxohexahydropyrimidine-5-carboxylate (26-5)

[0408] To a stirred solution of compound 26-4 (1.2 g, 6.976 mmol) in toluene (20 mL) was added 4′-bromo-2,5-difluoro-1,1′-biphenyl (1.5 g, 5.581 mmol) and K₂CO₃(2.4 g, 17.44 mmol) and the reaction mixture was purged under nitrogen for 10 min. XPhos (0.66 g, 1.395 mmol) and Pd₂(dba)₃(0.63 g, 0.697 mmol) were added under a nitrogen atmosphere. The reaction mixture was heated at 110° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 60-80% EtOAc in heptane) to afford the title compound 26-5 (0.7 g, 28%) as an off white solid. TLC: 70% EtOAc/heptane (R_f: 0.5).

Synthesis of ethyl 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl)-2-oxohexahydropyrimidine-5-carboxylate (26-6)

[0409] To a stirred solution of compound 26-5 (0.7 g, 1.944 mmol) in toluene (12 mL) was added 2-bromo-4-methylthiazole (0.27 g, 1.555 mmol) and K₂CO₃(0.64 g, 4.86 mmol) and the reaction mixture was purged under nitrogen for 10 min. XPhos (0.37 g, 0.777 mmol) and Pd₂(dba)₃(0.35 g, 0.388 mmol) were added under a nitrogen atmosphere. The reaction mixture was heated at 110° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 10-40% EtOAc in heptane) to afford the title compound 26-6 (0.5 g, 62.5%) as an off white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl)-2-oxohexahydropyrimidine-5-carboxamide (26-7)

[0410] A solution of compound 26-6 (0.2 g, 0.437 mmol) in 7M ammonia in methanol (10 mL) was heated at 70° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 60-80% EtOAc in heptane) to afford the title compound 26-7 (0.14 g, 74.8%) as an off white solid. TLC: 70% EtOAc/heptane (R_f: 0.5).

Synthesis of 2-(5-carbamoyl-3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (26-8)

[0411] To a stirred solution of compound 26-7 (0.2 g, 0.467 mmol) in dry DCM (5 mL) at 0° C. in an inert atmosphere, Chlorosulfonic acid (0.1 g, 0.934 mmol) was added, and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford the title compound 26-8 (0.13 g, crude) as an off-white solid. TLC: 70% EtOAc/heptane (R_f: 0.3) which was used in the next step without further purification.

Synthesis of 2-(5-cyano-3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonyl chloride (26-9)

[0412] To a stirred solution of compound 26-8 (0.1 g, 0.196 mmol) in 1,2-dichloroethane (2 mL) was added POCl₃(1 mL) and the resulting reaction mixture was allowed to stir at 80° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness to afford the title compound 26-9 (0.1 g, crude) as a brown colored oil. TLC: 70% EtOAc in heptane (R_f: 0.5). This compound was used as such without further purification.

Synthesis of 2-(5-cyano-3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (360)

[0413] To a stirred solution of compound 26-9 (0.1 g 0.196 mmol) in THF (2 mL) at 0° C., aqueous ammonia (1 mL) was added dropwise. The resulting reaction mixture was slowly warmed to room temperature and allowed to stir for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford the title 360 (15 mg, 15.6%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Synthesis of methyl 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methyl-5-(methylsulfonyl)thiazol-2-yl)-2-oxohexahydropyrimidine-5-carboxylate (384)

[0414] To a stirred solution of compound 360 (0.2 g, 0.409 mmol) in MeOH:H₂O (4:1 mL) was added H₂SO₄(2 mL) and the resulting reaction mixture was heated at 100° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 0-80% EtOAc in heptane) followed by preparative HPLC to afford the title compound 384 (0.15 g, 70.4%) as an off white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Synthesis of (R)-2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-(2-hydroxypropan-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (343) and (R)-2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-(2-hydroxypropan-2-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (344)

[0415] To a stirred solution of compound 384 (0.15 g, 0.287 mmol) in dry THF (5 mL) at −78° C. under an Argon atmosphere, Methyllithium solution (1.6 M in diethyl ether, 0.89 mL, 1.436 mmol) was added dropwise and the reaction mixture was stirred at the same temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 0-70% EtOAc in heptane) to give 26-10. Preparative HPLC and SFC chiral separation of 26-10 afforded compound 343 (0.13 g, 86.6%) and compound 344 as an off-white solid, respectively. The stereochemistry was arbitrarily assigned. TLC: 70% EtOAc/heptane (R_f: 0.5).

Example 27. Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-hydroxy-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (353)

Synthesis of 5-hydroxytetrahydropyrimidin-2(1H)-one (27-2)

[0416] To a stirred solution of compound 27-1 (10 g, 111.11 mmol) in 1,5,7-Triazabicyclodec-5-ene (0.77 g, 5.555 mmol) at 0° C. in an inert atmosphere, diethyl carbonate (1.57 g, 133.33 mmol) was added, and the resulting reaction mixture was slowly warmed to room temperature and stirred at 130° C. for 1 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with DCM and stirred for 1 h. The obtained solid was filtered off and dried in vacuo to afford the title compound 27-2 (5 g, crude) as an off-white solid. TLC: 100% EtOAc (R^f: 0.2).

Synthesis of 5-((tert-butyldiphenylsilyl)oxy)tetrahydropyrimidin-2(1H)-one (27-3)

[0417] To a stirred solution of compound 27-2 (5 g, 43.103 mmol) in DMF (80 mL) at 0° C. under a nitrogen atmosphere, Imidazole (5.8 g, 86.206 mmol) was added in small portions and the resulting reaction mixture was stirred at the same temperature for 10-15 min. To this reaction mixture, tert-butyl(chloro)diphenylsilane (17.7 g, 64.654 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 40-50% EtOAc in heptane) to afford the title compound 27-3 (10 g, 65.5%) as an off white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Synthesis of 5-((tert-butyldimethylsilyl)oxy)-1-(4-methylthiazol-2-yl)tetrahydropyrimidin-2(11)-one (27-4)

[0418] To a stirred solution of compound 27-3 (3.7 g, 10.451 mmol) in Toluene (10 mL) was added 2-bromo-4-methylthiazole (1.67 g, 9.406 mmol) followed by K₂CO₃(3.6 g, 26.127 mmol) and the reaction mixture was purged under nitrogen for 10 min. Pd₂(dba)₃(0.95 g, 1.045 mmol) and Xphos (0.24 g, 0.522 mmol) were added under a nitrogen atmosphere and the reaction mixture was heated at 110° C. for 24 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 40-50% EtOAc in heptane) to afford the title compound 27-4 (1 g, 21.2%) as an off-white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Synthesis of 5-((tert-butyldimethylsilyl)oxy)-1-(4-iodophenyl)-3-(4-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one (27-5)

[0419] To a stirred solution of compound 27-41.0 g, 2.217 mmol) in 1, 4-dioxane (15 mL) were added 1-bromo-4-iodobenzene (0.941 g, 3.325 mmol), K₂CO₃(0.61 g, 4.434 mmol) and 1,2-Dimethylethylenediamine (0.039 g, 0.443 mmol) the reaction mixture was purged under nitrogen for 10 min. To this resulting reaction mixture, CuI (42 mg, 0.221 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 16 h. The reaction mixture was filtered through Celite bed and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford the title compound 27-5 (1.0 g, 68.96%) as an off white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Synthesis of 5-((tert-butyldiphenylsilyl)oxy)-1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-3-(4-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one (27-6)

[0420] To a stirred solution of compound 27-5 (1 g, 1.531 mmol) in 1, 4-dioxane and water (15:4 mL) were added (2,5-difluorophenyl)boronic acid (0.36 g, 2.296 mmol) and K₃PO₄(0.811 g, 3.827 mmol) and the reaction mixture was purged under nitrogen for 10 min. PdCl₂(dppf) (0.11 g, 0.153 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 110° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford the title compound 27-6 (0.7 g, 71.5%) as an off white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-hydroxy-3-(4-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one (27-7)

[0421] To a stirred solution of compound 27-6 (0.7 g, 1.095 mmol) in dry THF (10 mL) at 0° C. under a nitrogen atmosphere, Tetrabutylammonium fluoride (1M solution in THF, 0.572 mL, 2.190 mmol) was added dropwise. The resulting reaction mixture was slowly warmed to room temperature and stirred for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford the title compound 27-7 (0.4 g, 91.1%) as an off white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-methoxy-3-(4-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one (27-8)

[0422] To a stirred solution of compound 27-7 (0.4 g, 0.997 mmol) in THF (5 mL) at 0° C. under a nitrogen atmosphere, NaH (60% w/w in mineral oil, 79.8 mg, 1.995 mmol) was added in small portions and the resulting reaction mixture was stirred at the same temperature for 5-10 min. To this reaction mixture, Methyl iodide (0.28 g, 1.995 mmol) was added at 0° C. and then the reaction mixture was slowly warmed to room temperature and stirred for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 20-30% EtOAc in heptane) to afford the title compound 27-8 (0.2 g, 48.3%) as an off white solid. TLC: 30% EtOAc/heptane (R_f: 0.5).

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-methoxy-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (27-9)

[0423] To a stirred solution of compound 27-8 (0.15 g, 0.361 mmol) in dry DCM (4 mL) at 0° C. in an inert atmosphere, Chlorosulfonic acid (84 mg, 0.722 mmol) was added, and the resulting reaction mixture was slowly warmed to room temperature and stirred for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford the title compound 27-9 (0.15 g, crude) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.3) which was used in the next step without further purification.

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-methoxy-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (357)

[0424] A mixture of compound 27-9 (0.15 g, 0.303 mmol) and POCl₃(2 mL) was allowed to stir at 90° C. for 6 h. The reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (1 mL) and aqueous ammonia (2 mL) was added at 0° C. while stirring was continued at room temperature for another 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford the title compound 357 (12 mg, 8%) as an off-white solid. TLC: 50% EtOAc/heptane (R_f: 0.5).

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-5-hydroxy-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (353)

[0425] To a stirred solution of 357 (0.32 g, 0.646 mmol) in DMF (1 mL) at 0° C. under a nitrogen atmosphere, Boron tribromide solution (1.0 M in DCM, 10 mL 10.343 mmol) was added dropwise. The resulting reaction mixture was slowly warmed to room temperature and stirred at 100° C. for 48 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The crude compound was purified by CombiFlash chromatography (eluting with 2-5% MeOH in DCM) followed by preparative HPLC to afford the title compound 353 (10 mg, 3.2%) as an off white solid. TLC: 5% MeOH/DCM (R_f: 0.3).

Example 28: Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-N-(2-hydroxyethyl)-4-methylthiazole-5-sulfonamide (388)

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonic acid (28-1)

[0426] To a stirred solution of compound 18-1 (4 g, 10.389 mmol) in dry DCM (40 mL) at 0° C. in an inert atmosphere, chlorosulfuric acid (2.07 mL, 31.168 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to dryness. The crude residue obtained was purified by trituration with diethyl ether. The obtained solid was filtered off and dried in vacuo to afford the title compound 28-1 (3.35 g, crude) as an off-white solid. TLC: 100% EtOAc (R^f0.2).

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonyl chloride (28-2)

[0427] A stirred solution of compound 28-1 (4 g, 8.602 mmol) in POCl₃(20 mL) was allowed to stir at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness to afford the title compound 28-2 (3.5 g, crude) as a brown colored solid. TLC: 50% EtOAc in heptane (R_f: 0.5). This compound was used as such for the next step without further purification.

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-N-(2-hydroxyethyl)-4-methylthiazole-5-sulfonamide (388)

[0428] To a stirred solution of compound 28-2 (0.6 g, 1.242 mmol) in THF (6 mL) at 0° C. was added DIPEA (0.65 mL, 3.726 mmol) followed by 2-aminoethan-1-ol (0.14 g, 1.863 mmol). The resulting reaction mixture was slowly warmed to room temperature and stirred for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-60% EtOAc in heptane) followed by preparative HPLC to afford the title compound 388 (16 mg, 2.5%) as an off-white solid. TLC: 50% EtOAc/Heptane (R_f: 0.5).

Example 29: Synthesis of 1-(5-((difluoromethyl)sulfonyl)-4-methylthiazol-2-yl)-3-(2′-fluoro-[1,1′-biphenyl]-4-yl)tetrahydropyrimidin-2(1H)-one (412)

Synthesis of sodium 2-(3-(2′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfinate (29-2)

[0429] A stirred solution of sodium sulfite (62.1 mg, 0.483 mmol) in water (10 ml) was stirred at RT for 10 minutes. sodium bicarbonate (83 mg, 0.966 mmol) was added, and the resulting solution was stirred at 50° C. for 1 h. Compound 29-1 (300 mg, 0.483 mmol) was added portion wise to the solution and the reaction mixture was continued to stir at 50° C. for 16 h. After completion of the reaction, as monitored by TLC, the reaction mixture was concentrated under a vacuum to remove the solvent. To the residue was added Methanol (5 mL) and stirred for 30 minutes. The solids formed were removed through filtration, and the filtrate was concentrated under a vacuum to afford sodium salt of compound 29-2 (300 mg, 90%) as a yellow solid.

[0430] LCMS: 1.26 min, 66.06%, 433.0 [M+H]⁺, (Column: Acquity BEH C₁₈(50×2.1 mm) 1.7 μm), Mobile phase A: 0.1% Formic acid in H₂O, Mobile phase B: 0.05% Formic acid in ACN, Flow Rate: 1.0 mL/min.

[0431] Note: Sulfonic acid mass was observed by LCMS.

Synthesis of 1-(5-((difluoromethyl)sulfonyl)-4-methylthiazol-2-yl)-3-(2′-fluoro-[1,1′-biphenyl]-4-yl)tetrahydropyrimidin-2(1H)-one (412)

[0432] To a stirred solution of KOH (247 mg, 4.41 mmol) in water (3.00 mL) was added compound 29-2 (100 mg, 0.221 mmol) in Acetonitrile (3 mL). Then the reaction mixture was cooled to 0-5° C. and stirred for 10 minutes vigorously and diethyl (bromodifluoromethyl)phosphonate (177 mg, 0.662 mmol) and the reaction mixture was allowed to stir at RT for 16 h. The reaction was monitored by TLC. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2×20 mL). The combined organic extract was washed with brine solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude was purified by preparative HPLC (ABC method) to afford compound 412 (1.9 mg, 1.8%) as an off white solid.

[0433] LCMS: 2.22 min, 98.02%, 482.0 (M+H)⁺, (Column: XBridge C8 (50×4.6 mm) 3.5 μm, Mobile phase: A: 0.1% TFA in H₂O, Mobile phase: B: Acetonitrile, Flow Rate: 2.0 ml/min)

[0434] HPLC: 6.86 min, 98.90%, (Column: XBridge C8 (50×4.6 mm) 3.5 μm, Mobile phase: A: 5 mM Ammonium acetate in H₂O, Mobile phase: B: Acetonitrile, Flow Rate: 2.0 ml/min)

Example 30: Synthesis of Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(fluoromethyl)thiazole-5-sulfonamide (441)

Synthesis of 1-(4-bromophenyl)-3-(3-chloropropyl)urea (30-2)

[0435] To a stirred solution of compound 30-1 (5 g, 28.089 mmol) in TIFF (80 mL) at 0° C. under a nitrogen atmosphere, 1-chloro-3-isocyanatopropane (5 g, 42.134 mmol) was added and the resulting reaction mixture was slowly warmed to room temperature and stirred at 85° C. for 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the title compound 30-2 (6 g, crude) as an off-white solid, which was used in the next step without further purification.

Synthesis of 1-(4-bromophenyl)tetrahydropyrimidin-2(1H)-one (30-3)

[0436] To a stirred solution of compound 30-2 (6 g, 20.689 mmol) in acetonitrile (90 mL) was added K₂CO₃(5.7 g, 41.379 mmol) followed by TBAB (3.3 g, 10.344 mmol). The resulting reaction mixture was heated at 90° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 70-80% EtOAc in heptane) to afford the title compound 30-3 (4 g, 76.9%) as an off-white solid.

Synthesis of 1-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)tetrahydropyrimidin-2(1H)-one (30-4)

[0437] To a stirred solution of compound 30-3 (2.7 g, 11.00 mmol) in 1,4 dioxane. H₂O (20:5 mL) was added (2,5-difluorophenyl)boronic acid (2 g, 13.00 mmol) followed by K₃PO₄(6.7 g, 32 mmol) and the reaction mixture was purged under nitrogen for 10 min. PdCl₂(dppf) (0.81 g, 1.1 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 100° C. for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography [eluting with 70-80% EtOAc in heptane] to afford the title compound 30-4 (1 g, 33%) as an off-white solid.

Synthesis of methyl 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)thiazole-4-carboxylate (30-5)

[0438] To a stirred solution of compound 30-4 (2 g, 6.937 mmol) in 1,4-dioxane (40 mL) was added compound 7 (2.31 g, 10.41 mmol) followed by CS₂CO₃(5.65 g, 17.34 mmol) and the reaction mixture was purged under nitrogen for 10 min. Xantphos (0.4 g, 0.693 mmol) and Pd₂(dba)₃(0.6 g, 0.693 mmol) were added under a nitrogen atmosphere. The reaction mixture was heated at 120° C. for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 50-100% EtOAc in heptane) to afford the title compound 30-5 (1.55 g, 52%) as an off-white solid.

Synthesis of methyl 5-bromo-2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)thiazole-4-carboxylate (30-6)

[0439] To a stirred solution of compound 30-5 (1.5 g, 3.50 mmol) in DCM (30 mL) was added N-Bromosuccinimide (1.3 g, 7.00 mmol). The resulting reaction mixture was heated at 55° C. for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, diluted with water, and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography (eluting with 40-50% EtOAc in heptane) to afford the title compound 30-6 (1.60 g, 90%) as an off-white solid.

Synthesis of methyl 5-(benzylthio)-2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)thiazole-4-carboxylate (30-7)

[0440] To a stirred solution of compound 30-6 (1.5 g, 3.00 mmol) in 1,4-dioxane (25 mL) was added phenylmethanethiol (0.92 g, 7.4 mmol) followed by DIPEA (1.2 g, 8.90 mmol) and the reaction mixture was purged under nitrogen for 10 min. Xantphos (0.18 g, 0.30 mmol) and Pd₂(dba)₃(0.14 g, 0.15 mmol) were added under a nitrogen atmosphere. The reaction mixture was heated at 110° C. for 36 h. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through a pad of Celite and washed with ethyl acetate. The filtrate was diluted with water and extracted with EtOAc then washed with brine. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound obtained was purified by CombiFlash chromatography (eluting with 60-70% EtOAc in heptane) to afford the title compound 30-7 (1.4 g, 86%) as a yellow solid.

Synthesis of methyl 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-5-sulfamoylthiazole-4-carboxylate (30-8)

[0441] To a stirred solution of compound 30-7 (1 g, 1.80 mmol) in AcOH:H₂O (8:0.1 mL) was added N-chlorosuccinimide (0.75 g, 5.40 mmol) and then the reaction mixture was stirred at room temperature for 30 min. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to dryness. The resulting residue was dissolved in THF (20 mL) and aqueous ammonia (10 mL) was added at 0° C. while stirring was continued at room temperature for another 2 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na₂SO₄, filtered to afford the title compound 30-8 (0.5 g, 54%) as an off-white solid.

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(hydroxymethyl)thiazole-5-sulfonamide (440)

[0442] To a stirred solution of compound 30-8 (0.15 g, 0.295 mmol) in THF (4 mL) at 0° C. under a nitrogen atmosphere, Lithium borohydride (14 mg, 0.590 mmol) was added. The resulting reaction mixture was stirred at the same temperature for 5-10 min and then the reaction mixture was slowly warmed to room temperature and stirred for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford the title compound 440 (10 mg, 7%) as an off-white solid.

Synthesis of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-(fluoromethyl)thiazole-5-sulfonamide (441)

[0443] To a stirred solution of compound 440 (0.2 g, 0.416 mmol) in DCM (7 mL) at 0° C. under a nitrogen atmosphere, DAST (0.21 g, 1.249 mmol) was added. The resulting reaction mixture was stirred at the same temperature for 5-10 min and then the reaction mixture was slowly warmed to room temperature and stirred for 2 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative HPLC to afford the title compound 441 (10 mg, 4.9%) as an off-white solid.

[0444] Table 1 shows structures and analytical data of representative exemplified compounds of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art.

TABLE 1

Representative exemplified compounds of the present invention
Com-
pound		MS
Number	Structure	[M + 1]⁺	¹H NMR

1		429.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.65-8.64 (m, 1H), 8.12 (d, J = 8.0 Hz, 2H), 7.97-7.83 (m, 2H), 7.56 (s, 2H), 7.50 (d, J = 8.4 Hz, 2H), 7.40- 7.31 (m, 1H), 4.15-4.14 (m, 2H), 3.80-3.70 (m, 2H), 2.45 (s, 3H), 2.30- 2.2-0 (m, 2H) ppm

2		430.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.92 (s, 1H), 8.58 (d, J = 4.9 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 8.3 Hz, 2H), 7.56 (s, 2H), 7.54- 7.49 (m, 3H), 4.17 (t, J = 5.6 Hz, 2H), 3.85-3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm

3		429.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.69-8.60 (m, 2H), 7.86 (d, J = 8.6 Hz, 2H), 7.79-7.68 (m, 2H), 7.61-7.49 (m, 4H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H) ppm

4		430.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.68 (dd, J = 0.8, 4.8 Hz, 1H), 8.12 (t, J = 1.8 Hz, 1H), 8.02- 7.96 (m, 2H), 7.93-7.88 (m, 1H), 7.57-7.51 (m, 3H), 7.47-7.42 (m, 1H), 7.42-7.34 (m, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.30-2.20 (m, 2H) ppm

5		464.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.65-7.59 (m, 2H), 7.55 (br s, 2H), 7.53-7.48 (m, 2H), 7.48- 7.36 (m, 2H), 7.31-7.25 (m, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm

6		465.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (d, J = 7.5 Hz, 2H), 7.58-7.50 (m, 4H), 7.48-7.29 (m, 3H), 4.23-4.09 (m, 2H), 3.86-3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm

7		483.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.68-7.63 (m, 2H), 7.63-7.49 (m, 5H), 7.40-7.32 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.20 (m, 2H) ppm

8		446.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.53 (m, 5H), 7.52-7.41 (m, 3H), 7.36-7.29 (m, 2H), 4.17 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.19 (m, 2H) ppm

9		463.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.60-7.55 (m, 3H), 7.52-7.37 (m, 7H), 4.17 (t, J = 5.9 Hz, 2H), 3.86-3.79 (m, 2H), 2.45 (s, 3H), 2.30-2.16 (m, 2H) ppm

10		459.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.57-7.54 (m, 2H), 7.54-7.47 (m, 2H), 7.42-7.30 (m, 4H), 7.13 (d, J = 7.6 Hz, 1H), 7.07-7.01 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.83- 3.80 (m, 2H), 3.79 (s, 3H), 2.45 (s, 3H), 2.26- 2.19 (m, 2H) ppm

11		475.5	¹H NMR (400 MHz, DMSO-d₆): δ 7.57 (s, 2H), 7.47-7.35 (m, 6H), 7.26-7.20 (m, 2H), 4.17 (t, J = 6.1 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.39 (s, 3H), 2.27- 2.19 (m, 2H) ppm

12		479.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.78-7.70 (m, 1H), 7.66-7.52 (m, 4H), 7.52-7.44 (m, 2H), 7.43-7.34 (m, 3H), 6.98- 6.64 (t, J = 54 Hz, 1H), 4.19-4.10 (m, 2H), 3.86- 3.77 (m, 2H), 2.43 (s, 3H), 2.27-2.18 (m, 2H) ppm

13		446.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.75 (d, J = 8.6 Hz, 2H), 7.61-7.44 (m, 7H), 7.25-7.16 (m, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29- 2.17 (m, 2H) ppm

14		479.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.92-7.83 (m, 2H), 7.75 (d, J = 8.5 Hz, 2H), 7.67-7.61 (m, 1H), 7.60-7.54 (m, 3H), 7.54-7.48 (m, 2H), 7.10 (t, J = 56 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.27-2.20 (m, 2H) ppm

15		497.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.04-7.97 (m, 2H), 7.82-7.78 (m, 2H), 7.78-7.68 (m, 2H), 7.56 (s, 2H), 7.54-7.49 (m, 2H), 4.17 (t, J = 6.0 Hz., 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.27-2.21 (m, 2H) ppm

16		464.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.61 (s, 1H), 7.58-7.36 (m, 7H), 7.36-7.22 (m, 1H), 4.16 (t, J = 5.6 Hz, 2H), 3.92- 3.75 (m, 2H), 2.44 (s, 3H), 2.29-2.17 (m, 2H) ppm

17		471.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.67-7.58 (m, 3H), 7.57-7.48 (m, 5H), 7.37 (dd, J = 8.5, 10.6 Hz, 1H), 4.23 (s, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29- 2.18 (m, 2H) ppm

18		471.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.70-7.61 (m, 3H), 7.56 (s, 2H), 7.53-7.44 (m, 2H), 7.36- 7.30 (m, 1H), 7.29- 7.22 (m, 1H), 4.22-4.11 (m, 3H), 3.83 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H) ppm

19		527.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.76-7.61 (m, J = 8.0 Hz, 2H), 7.55 (s, 3H), 7.52-7.43 (m, 2H), 7.40-7.30 (m, 1H), 7.29-7.15 (m, 1H), 5.34 (s, 1H), 4.23-4.11 (m, 2H), 3.88-3.76 (m, 2H), 2.45 (s, 3H), 2.29-2.15 (m, 2H), 1.36 (s, 6H) ppm

20		480.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.87 (d, J = 7.8 Hz, 1H), 7.62-7.42 (m, 7H), 7.42-7.32 (m, 3H), 6.48 (d, J = 16.6 Hz, 1H), 4.23-4.13 (m, 2H), 3.91-3.79 (m, 2H), 2.45 (s, 3H), 2.32-2.16 (m, 2H) ppm

21		480.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.96 (d, J = 7.3 Hz, 1H), 7.62-7.52 (m, 4H), 7.52-7.47 (m, 3H), 7.42-7.33 (m, 2H), 7.26-7.20 (m, 1H), 5.94 (d, J = 11.7 Hz, 1H), 4.20- 4.14 (m, 2H), 3.87- 3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm

22		487.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.55 (s, 2H), 7.52-7.45 (m, 4H), 7.14-7.00 (m, 3H), 4.17 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H), 1.86-1.76 (m, 1H), 0.88-0.81 (m, 2H), 0.69- 0.64 (m, 2H) ppm

23		494.5	¹H NMR (400 MHz, DMSO-d₆): δ 7.60-7.30 (m, 10H), 4.17 (t, J = 5.9 Hz, 2H), 3.86 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 2H), 1.50- 1.39 (m, 2H), 1.24- 1.10 (m, 2H) ppm

24		472.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.08 (dd, J = 5.6, 8.6 Hz, 1H), 7.71- 7.64 (m, 2H), 7.61-7.54 (m, 5H), 7.53-7.43 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28- 2.20 (m, 2H) ppm

25		526.6	¹H NMR (400 MHz, DMSO-d₆): δ 7.74 (dd, J = 2.5, 6.9 Hz, 1H), 7.65- 7.58 (m, 3H), 7.56 (s, 2H), 7.54-7.47 (m, 2H), 7.34 (dd, J = 8.9, 10.4 Hz, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.32-2.15 (m, 2H) ppm

26		477.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.64-7.58 (m, 2H), 7.56 (s, 2H), 7.51-7.46 (m, 2H), 7.29- 7.21 (m, 1H), 7.10- 7.03 (m, 1H), 7.00-6.92 (m, 1H), 4.20-4.14 (m, 2H), 3.86-3.81 (m, 2H), 3.80 (s, 3H), 2.45 (s, 3H), 2.28-2.18 (m, 2H) ppm

27		481.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (d, J = 7.3 Hz, 3H), 7.56 (brs, 2H), 7.53-7.45 (m, 3H), 7.44-7.35 (m, 1H), 4.21- 4.12 (m, 2H), 3.86- 3.78 (m, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H) ppm

28		510.7	¹H NMR (400 MHz, DMSO-d₆): δ 7.75-7.68 (m, 4H), 7.55 (s, 2H), 7.52-7.44 (m, 4H), 5.48 (s, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.26-2.19 (m, 2H), 1.48 (s, 6H) ppm

29		489.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.67-7.62 (m, 2H), 7.62-7.55 (m, 3H), 7.55-7.49 (m, 3H), 4.68 (s, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.26-2.21 (m, 2H) ppm

30		512.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.20 (s, 1H), 8.00-7.92 (m, 2H), 7.86-7.77 (m, 4H), 7.66- 7.59 (m, 1H), 7.58- 7.49 (m, 4H), 4.21-4.13 (m, 2H), 3.86-3.80 (m, 2H), 2.45 (s, 3H), 2.29- 2.20 (m, 2H) ppm

31		512.2	¹H NMR (400 MHz, DMSO-d₆): δ 9.13 (s, 1H), 8.46 (s, 1H), 7.97 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.74-7.63 (m, 2H), 7.60-7.47 (m, 5H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.21 (m, 2H) ppm

32		509.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.81-7.73 (m, 4H), 7.64-7.58 (m, 1H), 7.58-7.52 (m, 3H), 7.52-7.46 (m, 3H), 6.51 (d, J = 1.9 Hz, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.91 (s, 3H), 3.82 (t, J = 5.7 Hz, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H) ppm

33		445.2	¹H NMR (400 MHz, CD₃OD-d₄): δ 7.99 (dd, J = 7.4, 8.8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 8.6 Hz, 2H), 7.22- 7.17 (m, 1H), 6.99 (d, J = 8.9 Hz, 1H), 4.29 (t, J = 6.1 Hz, 2H), 3.91 (t, J = 5.7 H7, 2H), 2.53 (s, 3H), 2.40-2.28 (m, 2H) ppm

34		545.1	¹H NMR (400 MHz, DMSO-d₆): δ 9.76 (s, 1H), 8.11 (d, J = 8.8 Hz, 2H), 7.87-7.78 (m, 1H), 7.76-7.70 (m, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.56 (s, 2H), 7.53-7.45 (m, 2H), 4.16 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.1 Hz, 2H), 2.45 (s, 3H), 2.28- 2.18 (m, 2H), 1.49 (s, 9H) ppm

35		448.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.57-8.55 (m, 1H), 7.96 (dd, J = 1.4, 8.6 Hz, 2H), 7.92- 7.78 (m, 1H), 7.61-7.46 (m, 5H), 4.17 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.30-2.19 (m, 2H) ppm

36		448.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (dd, J = 5.6, 9.1 Hz, 1H), 8.20- 8.14 (m, 2H), 7.95 (dd, J = 2.4, 11.1 Hz, 1H), 7.58- 7.48 (m, 4H), 7.32-7.27 (m, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.23 (quin, J = 5.8 Hz, 2H) ppm

37		481.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.52 (d, J = 4.9 Hz, 1H), 7.95 (d, J = 7.3 Hz, 2H), 7.77-7.72 (m, 1H), 7.57 (d, J = 8.3 Hz, 2H), 4.17 (t, J = 5.4 Hz, 2H), 3.85 (t, J = 5.1 Hz, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm(Note: -NH₂not observed)

38		481.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.79 (s, 1H), 8.35 (d, J = 5.9 Hz, 1H), 8.13 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 4.21-4.12 (m, 2H), 3.88-3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H) ppm. (Note: -NH₂ not observed)

39		431.0	¹H NMR (400 MHz, DMSO-d₆): δ 9.28 (s, 1H), 8.73 (s, 1H), 8.62 (s, 1H), 8.19 (d, J = 8.8 Hz, 2H), 7.57 (s, 4H), 4.22- 4.13 (m, 2H), 3.93-3.80 (m, 2H), 2.45 (s, 3H), 2.29-2.19 (m, 2H) ppm

40		433.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.60-7.55 (m, 4H), 7.53-7.45 (m, 3H), 6.42 (d, J = 1.9 Hz, 1H), 4.16 (t, J = 5.6 Hz, 2H), 3.88 (s, 3H), 3.86- 3.79 (m, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm

41		420.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.23 (d, J = 0.6 Hz, 1H), 8.04-7.98 (m, 2H), 7.61-7.52 (m, 4H), 7.42-7.36 (m, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.29-2.18 (m, 2H) ppm

42		435.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.00-7.97 (m, 2H), 7.94 (d, J = 3.3 Hz, 1H), 7.80 (d, J = 3.1 Hz, 1H), 7.59-7.49 (m, 4H), 4.16 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29- 2.18 (m, 2H) ppm

43		450.5	¹H NMR (400 MHz, DMSO-d₆): δ 7.97-7.91 (m, 2H), 7.56 (s, 2H), 7.54-7.47 (m, 2H), 7.33 (d, J = 1.0 Hz, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.43 (s, 3H), 2.28- 2.17 (m, 2H) ppm

44		450.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.95-7.84 (m, 2H), 7.64-7.58 (m, 1H), 7.56 (s, 2H), 7.52- 7.48 (m, 2H), 4.16 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.27-2.18 (m, 2H) ppm (Note: -3H merged in solvent peak)

45		503.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.54 (d, J = 1.3 Hz, 1H), 8.09-8.03 (m, 2H), 7.63-7.54 (m, 4H), 4.16 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29- 2.19 (m, 2H) ppm

46		504.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.56 (d, J = 0.9 Hz, 1H), 8.06-8.00 (m, 2H), 7.61-7.54 (m, 4H), 4.16 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.30- 2.18 (m, 2H) ppm

47		460.9	¹H NMR (400 MHz, DMSO-d₆): δ 9.28 (s, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.62 (d, J = 8.3 Hz, 2H), 7.57 (brs, 2H), 4.23- 4.11 (m, 2H), 3.91- 3.80 (m, 2H), 2.45 (s, 3H), 2.27-2.20 (m, 2H) ppm

48		460.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.91 (s, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.8 Hz, 2H), 4.19-4.12 (m, 2H), 3.89-3.80 (m, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm (Note: -NH₂not observed)

49		436.0	¹H NMR (400 MHz, DMSO-d₆): δ 9.09 (s, 1H), 8.33 (s, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.56 (s, 2H), 7.51-7.42 (m, 2H), 4.19-4.12 (m, 2H), 3.84- 3.76 (m, 2H), 2.44 (s, 3H), 2.28-2.17 (m, 2H) ppm

50		450.2	¹H NMR (400 MHz, DMSO-d₆): δ 9.01 (s, 1H), 7.58-7.52 (m, 4H), 7.51-7.47 (m, 2H), 4.19- 4.13 (m, 2H), 3.85- 3.79 (m, 2H), 2.45 (s, 3H), 2.27-2.20 (m, 2H) ppm

51		421.2	¹H NMR (400 MHz, DMSO-d₆): δ 9.35 (s, 1H), 8.08-8.04 (m, 2H), 7.66-7.62 (m, 2H), 7.57 (s, 2H), 4.16 (t, J = 6.1 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm

52		483.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.17 (s, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.4 Hz, 1H), 7.59-7.47 (m, 5H), 7.35-7.24 (m, 1H), 4.18 (t, J = 5.9 Hz, 2H), 4.10 (s, 3H), 3.85 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.32-2.20 (m, 2H) ppm

53		483.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.44 (s, 1H), 8.09 (d, J = 8.3 Hz, 2H), 7.74-7.68 (m, 1H), 7.55 (s, 2H), 7.53-7.43 (m, 3H), 7.15 (t, J = 7.6 Hz, 1H), 4.21 (s, 3H), 4.20-4.15 (m, 2H), 3.87- 3.80 (m, 2H), 2.45 (s, 3H), 2.32-2.17 (m, 2H) ppm

54		469.1	¹H NMR (400 MHz, DMSO-d₆): δ 13.24 (br s, 1H), 8.19 (s, 1H), 7.82- 7.71 (m, 3H), 7.59-7.51 (m, 4H), 7.48-7.40 (m, 1H), 7.29-7.19 (m, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.31-2.19 (m, 2H) ppm

55		483.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.17 (d, J = 0.9 Hz, 1H), 7.81-7.76 (m, 2H), 7.66 (d, J = 8.5 Hz, 1H), 7.59-7.47 (m, 5H), 7.29 (d, J = 6.6 Hz, 1H), 4.18 (t, J = 6.0 Hz, 2H), 4.10 (s, 3H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 2H) ppm

56		511.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.18 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.74-7.70 (m, 1H), 7.59-7.52 (m, 4H), 7.50- 7.45 (m, 1H), 7.27 (d, J = 7.2 Hz, 1H), 5.09-5.03 (m, 1H), 4.18 (t, J = 6.2 Hz, 2H), 3.85 (t, J = 5.3 Hz, 2H), 2.45 (s, 3H), 2.29-2.22 (m, 2H), 1.52 (d, J = 6.6 Hz, 6H) ppm

57		547.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (s, 1H), 8.07-7.96 (m, 1H), 7.83-7.70 (m, 3H), 7.62- 7.52 (m, 5H), 4.24- 4.12 (m, 2H), 3.90-3.81 (m, 2H), 3.51 (s, 3H), 2.46 (s, 3H), 2.30-2.20 (m, 2H) ppm

58		513.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.09 (s, 1H), 7.73-7.66 (m, 2H), 7.55 (br.s, 2H), 7.52- 7.46 (m, 2H), 7.19-7.12 (m, 1H), 6.98-6.91 (m, 1H), 4.27 (s, 3H), 4.21- 4.14 (m, 2H), 3.99 (s, 3H), 3.88-3.78 (m, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm

59		511.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.56 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 8.7 Hz, 1H), 7.57 (s, 2H), 7.55- 7.49 (m, 2H), 7.36-7.30 (m, 1H), 7.18 (d, J = 6.6 Hz, 1H), 4.91-4.84 (m, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29- 2.22 (m, 2H), 1.57 (d, J = 6.6 Hz, 6H) ppm

60		541.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.20-8.16 (m, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.76-7.69 (m, 1H), 7.60-7.51 (m, 4H), 7.50-7.41 (m, 1H), 7.26 (d, J = 6.8 Hz, 1H), 4.68 (s, 1H), 4.36 (s, 2H), 4.18 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.31-2.19 (m, 2H), 1.16 (s, 6H) ppm

61		483.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.26 (s, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.61-7.52 (m, 3H), 7.52-7.44 (m, 3H), 7.44- 7.32 (m, 1H), 4.23- 4.13 (m, 2H), 3.89 (s, 3H), 3.86-3.81 (m, 2H), 2.45 (s, 3H), 2.31-2.18 (m, 2H) ppm

62		483.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.92 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.57 (s, 2H), 7.55- 7.52 (m, 4H), 7.52-7.44 (m, 1H), 7.32-7.26 (m, 1H), 4.18 (t, J = 5.8 Hz, 2H), 3.86 (t, J = 5.2 Hz, 2H), 3.52 (s, 3H), 2.45 (s, 3H), 2.29-2.22 (m, 2H) ppm

63		483.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.15 (s, 1H), 7.80 (dd, J = 1.8, 7.3 Hz, 1H), 7.56 (s, 2H), 7.54-7.50 (m, 4H), 7.27- 7.17 (m, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.87 (t, J = 5.5 Hz, 2H), 3.63 (s, 3H), 2.45 (s, 3H), 2.32-2.20 (m, 2H) ppm

64		469.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.09-7.92 (m, 3H), 7.75 (d, J = 8.8 Hz, 1H), 7.62-7.49 (m, 4H), 7.40-7.25 (m, 1H), 7.05 (d, J = 6.8 Hz, 1H), 6.74 (s, 1H), 4.22-4.14 (m, 2H), 3.91-3.83 (m, 2H), 2.46 (s, 3H), 2.34- 2.17 (m, 2H) ppm

65		469.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.51 (s, 1H), 8.38 (d, J = 7.1 Hz, 1H), 7.80-7.76 (m, 2H), 7.59-7.49 (m, 5H), 6.92 (d, J = 6.1 Hz, 1H), 6.82- 6.77 (m, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.7 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 2H) ppm

66		482.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.72-7.67 (m, 2H), 7.56 (s, 2H), 7.53-7.45 (m, 3H), 7.45- 7.39 (m, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.16-7.13 (m, 1H), 6.58-6.55 (m, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.88-3.80 (m, 5H), 2.45 (s, 3H), 2.28-2.21 (m, 2H) ppm

67		486.0	¹H NMR (400 MHz, DMSO-d₆): δ 9.48 (s, 1H), 8.13 (d, J = 7.3 Hz, 1H), 7.83-7.74 (m, 2H), 7.73-7.65 (m, 1H), 7.65- 7.53 (m, 5H), 4.23- 4.14 (m, 2H), 3.91-3.82 (m, 2H), 2.45 (s, 3H), 2.30-2.20 (m, 2H) ppm

68		500.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.94 (dd, J = 1.0, 8.0 Hz, 1H), 7.77- 7.72 (m, 2H), 7.64-7.49 (m, 6H), 4.18 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.82 (s, 3H), 2.45 (s, 3H), 2.30-2.20 (m, 2H) ppm

69		501.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.67 (d, J = 8.5 Hz, 2H), 7.56 (s, 2H), 7.55-7.49 (m, 4H), 7.37- 7.31 (m, 2H), 7.12 (dd, J = 2.6, 6.1 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.48- 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm

70		504.3	¹H NMR (400 MHz, DMSO-d₆): δ 9.41 (s, 1H), 8.11 (dd, J = 2.5, 8.4 Hz, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.63-7.48 (m, 5H), 4.18 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.29- 2.22 (m, 2H) ppm

71		484.3	¹H NMR (400 MHz, DMSO-d₆): δ 9.44 (s, 1H), 8.20 (d, J = 7.8 Hz, 1H), 7.90 (d, J = 8.3 Hz, 2H), 7.70-7.66 (m, 1H), 7.63-7.54 (m, 3H), 7.54- 7.48 (m, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.22 (m, 2H) ppm

72		499.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.08-8.02 (m, 1H), 7.88-7.81 (m, 2H), 7.59-7.54 (m, 3H), 7.53-7.45 (m, 3H), 4.22- 4.15 (m, 2H), 3.88- 3.81 (m, 2H), 2.82 (s, 3H), 2.45 (s, 3H), 2.29- 2.21 (m, 2H) ppm

73		499.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.74 (d, J = 7.8 Hz, 3H), 7.59-7.52 (m, 4H), 7.50-7.41 (m, 1H), 7.40-7.30 (m, 1H), 7.24 (s, 1H), 4.21-4.14 (m, 2H), 3.89-3.80 (m, 2H), 2.56 (s, 3H), 2.45 (s, 3H), 2.29-2.20 (m, 2H) ppm

74		469.1	¹H NMR (400 MHz, DMSO-d₆): δ 13.25 (s, 1H), 8.20 (s, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.59- 7.50 (m, 5H), 7.50-7.40 (m, 1H), 7.26 (d, J = 6.9 Hz, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.30-2.21 (m, 2H) ppm

75		483.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.17 (d, J = 0.9 Hz, 1H), 7.81-7.75 (m, 2H), 7.66 (d, J = 8.5 Hz, 1H), 7.59-7.46 (m, 5H), 7.29 (d, J = 6.6 Hz, 1H), 4.18 (t, J = 6.0 Hz, 2H), 4.10 (s, 3H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 2H) ppm

76		484.1	¹H NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 7.61 (d, J = 7.8 Hz, 2H), 7.57-7.53 (m, 2H), 7.51-7.38 (m, 2H), 7.31- 7.24 (m, 1H), 7.03 (d, J = 7.8 Hz, 1H), 6.82 (d, J = 7.3 Hz, 1H), 4.19-4.11 (m, 2H), 3.84-3.76 (m, 2H), 3.63 (s, 2H), 2.43 (s, 3H), 2.26-2.17 (m, 2H) ppm

77		498.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.66-7.61 (m, J = 8.5 Hz, 2H), 7.56 (s, 2H), 7.47 (d, J = 8.5 Hz, 2H), 7.45-7.36 (m, 1H), 7.13 (d, J = 7.4 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.72 (s, 2H), 3.16 (s, 3H), 2.45 (s, 3H), 2.28- 2.18 (m, 2H) ppm

78		502.2	¹H NMR (400 MHz, DMSO-d₆): δ 12.04 (s, 1H), 7.65-7.59 (m, 2H), 7.58-7.51 (m, 4H), 7.44- 7.38 (m, 1H), 7.25 (dd, J = 0.9, 7.7 Hz, 1H), 7.15 (dd, J = 0.9, 7.9 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H) ppm

79		516.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.64-7.59 (m, 2H), 7.58-7.46 (m, 5H), 7.37-7.29 (m, 2H), 4.19-4.10 (m, 2H), 3.86- 3.76 (m, 2H), 3.44 (s, 3H), 2.43 (s, 3H), 2.28- 2.18 (m, 2H) ppm

80		508.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.77 (d, J = 8.6 Hz, 2H), 7.61-7.48 (m, 5H), 7.45-7.39 (m, 1H), 7.37-7.30 (m, 1H), 4.17 (t, J = 5.7 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm

81		473.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.86-7.65 (m, J = 8.3 Hz, 2H), 7.56 (s, 2H), 7.52-7.41 (m, 2H), 7.14 (d, J = 6.8 Hz, 1H), 7.03-6.85 (m, 2H), 6.08 (s, 2H), 4.15 (t, J = 5.4 Hz, 2H), 3.83-3.78 (m, 2H), 2.43 (s, 3H), 2.27-2.16 (m, 2H) ppm

82		480.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.93 (d, J = 2.4 Hz, 1H), 8.47 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 7.3 Hz, 1H), 7.81 (d, J = 6.4 Hz, 1H), 7.75-7.66 (m, 3H), 7.63-7.54 (m, 3H), 7.50-7.46 (m, 2H), 4.19 (t, J = 5.2 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.31-2.22 (m, 2H) ppm

83		480.3	¹H NMR (400 MHz, DMSO-d₆): δ 9.21 (s, 1H), 8.56 (d, J = 5.6 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 5.3 Hz, 1H), 7.91-7.83 (m, 1H), 7.68-7.52 (m, 7H), 4.24- 4.14 (m, 2H), 3.97- 3.83 (m, 2H), 2.46 (s, 3H), 2.34-2.24 (m, 2H) ppm

84		480.5	¹H NMR (400 MHz, DMSO-d₆): δ 8.98-8.93 (m, 1H), 8.25 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.85 (t, J = 7.8 Hz, 1H), 7.61-7.52 (m, 8H), 4.22-4.15 (m, 2H), 3.92-3.83 (m, 2H), 2.46 (s, 3H), 2.31-2.21 (m, 2H) ppm

85		480.6	¹H NMR (400 MHz, DMSO-d₆): δ 9.41 (s, 1H), 8.52 (d, J = 6.0 Hz, 1H), 8.19 (dd, J = 2.7, 6.7 Hz, 1H), 7.81-7.75 (m, 2H), 7.75-7.68 (m, 1H), 7.57 (s, 6H), 4.19 (t, J = 6.0 Hz, 2H), 3.88 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.33-2.21 (m, 2H) ppm

86		480.4	¹H NMR (400 MHz, DMSO-d₆): δ 8.68-8.52 (m, 1H), 8.08 (br s, 2H), 7.94-7.77 (m, 2H), 7.76- 7.65 (m, 3H), 7.63- 7.47 (m, 4H), 4.33-4.09 (m, 2H), 3.98-3.79 (m, 2H), 2.46 (s, 3H), 2.33- 2.23 (m, 2H) ppm

87		470.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.22 (d, J = 8.3 Hz, 2H), 7.84-7.75 (m, 2H), 7.68-7.60 (m, 2H), 7.56 (s, 2H), 7.43- 7.38 (m, 2H), 4.19-4.10 (m, 2H), 3.90-3.82 (m, 2H), 2.43 (s, 3H), 2.29- 2.17 (m, 2H) ppm

88		486.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.19-8.11 (m, 3H), 8.10-8.05 (m, 1H), 7.66-7.53 (m, 5H), 7.52-7.45 (m, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.87 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.30-2.19 (m, 2H) ppm

89		487.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (dd, J = 1.6, 4.6 Hz, 1H), 8.69- 8.63 (m, 1H), 8.20 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 8.6 Hz, 2H), 7.58 (s, 2H), 7.52-7.46 (m, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.88 (t, J = 5.4 Hz, 2H), 2.44 (s, 3H), 2.30-2.22 (m, 2H) ppm

90		504.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.15 (d, J = 8.8 Hz, 2H), 8.00 (dd, J = 0.8, 7.9 Hz, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.59- 7.55 (m, 2H), 7.53-7.46 (m, 1H), 7.45-7.34 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.87 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.32- 2.19 (m, 2H) ppm

91		469.1	¹H NMR (400 MHz, DMSO-d₆): δ 13.26 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 8.06-8.00 (m, 2H), 7.66-7.49 (m, 6H), 7.45- 7.39 (m, 1H), 7.27- 7.19 (m, 1H), 4.24-4.13 (m, 2H), 3.90-3.78 (m, 2H), 2.45 (s, 3H), 2.30- 2.20 (m, 2H) ppm

92		483.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.10 (d, J = 8.3 Hz, 1H), 8.01 (d, J = 8.6 Hz, 2H), 7.71 (d, J = 8.5 Hz, 1H), 7.59-7.45 (m, 5H), 7.28-7.23 (m, 1H), 4.18 (t, J = 5.9 Hz, 2H), 4.12 (s, 3H), 3.84 (t, J = 5.8 Hz, 2H), 2.45 (s, 3H), 2.28-2.21 (m, 2H) ppm

93		469.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.39 (s, 1H), 7.94-7.77 (m, 4H), 7.62-7.45 (m, 5H), 7.32- 7.22 (m, 1H), 4.21- 4.12 (m, 2H), 3.89-3.78 (m, 2H), 2.43 (s, 3H), 2.31-2.17 (m, 2H) ppm

94		469.6	¹H NMR (400 MHz, DMSO-d₆): δ 8.61 (s, 1H), 7.81-7.78 (m, 1H), 7.77-7.71 (m, 2H), 7.69- 7.61 (m, 3H), 7.57 (s, 2H), 7.39-7.31 (m, 2H), 4.19 (t, J = 6.0 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.34-2.21 (m, 2H) ppm

95		465.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.58 (s, 2H), 7.54-7.45 (m, 4H), 7.40-7.29 (m, 3H), 4.19- 4.12 (m, 2H), 3.89- 3.80 (m, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H) ppm

96		465.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.54 (m, 5H), 7.50-7.43 (m, 2H), 7.42-7.28 (m, 2H), 4.23-4.14 (m, 2H), 3.80 (m, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm

97		447.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (d, J = 4.4 Hz, 1H), 8.00-7.90 (m, 2H), 7.81 (d, J = 7.8 Hz, 1H), 7.58 (s, 2H), 7.49-7.36 (m, 3H), 4.16 (t, J = 5.6 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H) ppm

98		466.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.77-8.73 (m, 1H), 7.99-7.93 (m, 1H), 7.89-7.83 (m, 2H), 7.64 (dd, J = 6.3, 11.4 Hz, 1H), 7.58 (s, 2H), 7.50-7.44 (m, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.78 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H) ppm

99		465.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.64-7.43 (m, 9H), 4.18 (t, J = 5.9 Hz, 2H), 3.77 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.32-2.17 (m, 2H) ppm

100		437.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.42 (d, J = 2.5 Hz, 1H), 8.06 (s, 1H), 7.85-7.78 (m, 1H), 7.58 (s, 2H), 7.51-7.34 (m, 3H), 4.16 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.8 Hz, 2H), 2.44 (s, 3H), 2.26- 2.17 (m, 2H) ppm

101		479.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (d, J = 7.8 Hz, 2H), 7.60-7.55 (m, 2H), 7.53-7.35 (m, 4H), 7.33-7.22 (m, 1H), 4.28-4.21 (m, 2H), 3.84- 3.78 (m, 2H), 2.45 (s, 3H), 2.02-1.93 (m, 2H), 1.89-1.81 (m, 2H) ppm

102		461.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.53 (m, 5H), 7.52-7.38 (m, 3H), 7.38-7.27 (m, 2H), 4.29-4.21 (m, 2H), 3.87- 3.77 (m, 2H), 2.45 (s, 3H), 2.03-1.92 (m, 2H), 1.90-1.79 (m, 2H) ppm

103		444.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.67 (d, J = 4.4 Hz, 1H), 8.12 (d, J = 8.3 Hz, 2H), 8.00-7.96 (m, 1H), 7.95-7.83 (m, 1H), 7.56 (br s, 2H), 7.53- 7.45 (m, 2H), 7.45- 7.27 (m, 1H), 4.32-4.17 (m, 2H), 3.86-3.75 (m, 2H), 2.45 (s, 3H), 2.04- 1.93 (m, 2H), 1.91-1.80 (m, 2H) ppm

104		450.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.77 (d, J = 8.9 Hz, 2H), 7.64 (dd, J = 1.4, 8.7 Hz, 2H), 7.47- 7.33 (m, 2H), 7.27-7.17 (m, 1H), 6.16 (br.s, 2H), 4.17-4.08 (m, 4H), 2.40 (s, 3H) ppm

105		475.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.53 (m, 5H), 7.52-7.40 (m, 3H), 7.39-7.27 (m, 2H), 3.94 (s, 2H), 3.60 (s, 2H), 2.44 (s, 3H), 1.17 (s, 6H) ppm

106		493.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (d, J = 7.1 Hz, 2H), 7.55 (s, 2H), 7.52-7.36 (m, 4H), 7.32- 7.25 (m, 1H), 3.93 (s, 2H), 3.60 (s, 2H), 2.44 (s, 3H), 1.17 (s, 6H) ppm

107		479.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.64 (d, J = 7.8 Hz, 2H), 7.59-7.51 (m, 4H), 7.50-7.34 (m, 2H), 7.32-7.23 (m, 1H), 5.17-5.08 (m, 1H), 4.13- 4.02 (m, 1H), 3.74- 3.65 (m, 1H), 2.45 (s, 3H), 2.40-2.30 (m, 1H), 2.11-2.02 (m, 1H), 1.43 (d, J = 6.8 Hz, 3H) ppm

108	Single enantiomer, arbitrarily assigned stereochemistry	479.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (m, 2H), 7.58-7.51 (m, 4H), 7.50-7.36 (m, 2H), 7.32- 7.25 (m, 1H), 5.16- 5.07 (m, 1H), 4.13-4.03 (m, 1H), 3.74-3.65 (m, 1H), 2.46 (s, 3H), 2.42- 2.30 (m, 1H), 2.10-2.01 (m, 1H), 1.43 (d, J = 6.4 Hz, 3H) ppm

109	Single enantiomer, arbitrarily assigned stereochemistry	478.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.66-7.61 (m, 2H), 7.58-7.50 (m, 4H), 7.49-7.42 (m, 1H), 7.41-7.34 (m, 1H), 7.32- 7.24 (m, 1H), 5.16- 5.06 (m, 1H), 4.14-4.01 (m, 1H), 3.73-3.64 (m, 1H), 2.45 (s, 3H), 2.39- 2.30 (m, 1H), 2.10-2.02 (m, 1H), 1.43 (d, J = 6.4 Hz, 3H) ppm

110		490.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (d, J = 8.3 Hz, 2H), 7.57-7.53 (m, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.46-7.35 (m, 2H), 7.31-7.23 (m, 1H), 4.01 (s, 2H), 3.69 (s, 2H), 2.42 (s, 3H), 0.81 (d, J = 4.9 Hz, 4H) ppm

111		473.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.61-7.49 (m, 5H), 7.49-7.39 (m, 3H), 7.34-7.28 (m, 2H), 3.99 (s, 2H), 3.67 (s, 2H), 2.41 (s, 3H), 0.79 (d, J = 5.9 Hz, 4H) ppm.

112		473.9	¹H NMR (400 MHz, DMSO-d₆): δ 8.56 (br s, 1H), 7.96 (d, J = 8.3 Hz, 2H), 7.91-7.79 (m, 1H), 7.62-7.50 (m, 5H), 4.02 (s, 2H), 3.71 (s, 2H), 2.44 (s, 3H), 0.86-0.77 (m, 4H) ppm

113		459.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.60-7.53 (m, 4H), 7.53-7.44 (m, 3H), 6.42 (d, J = 1.9 Hz, 1H), 4.01 (s, 2H), 3.88 (s, 3H), 3.69 (s, 2H), 2.43 (s, 3H), 0.87-0.75 (m, 4H) ppm

114		476.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.93 (d, J = 8.3 Hz, 2H), 7.57 (s, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.33 (s, 1H), 4.00 (s, 2H), 3.68 (s, 2H), 2.45-2.42 (m, 6H), 0.80 (d, J = 5.4 Hz, 4H) ppm

115		452.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.22 (br s, 2H), 7.67-7.61 (m, 2H), 7.55-7.36 (m, 4H), 7.32- 7.25 (m, 1H), 4.27 (t, J = 6.0 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.35-2.26 (m, 2H) ppm

116		479.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.65-7.56 (m, 3H), 7.54-7.36 (m, 4H), 7.33-7.22 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.50-2.47 (m, 3H) merged in solvent peak, 2.45 (s, 3H), 2.54-2.21 (m, 2H) ppm

117		505.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.03 (brs, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.46-7.35 (m, 2H), 7.35-7.22 (m, 1H), 4.22- 4.15 (m, 2H), 3.87- 3.79 (m, 2H), 2.46 (s, 3H), 2.28-2.17 (m, 3H), 0.59-0.45 (m, 2H), 0.45- 0.40 (m, 2H) ppm

118		444.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.70-8.65 (m, 1H), 8.13 (d, J = 8.3 Hz, 2H), 7.98 (d, J = 7.8 Hz, 1H), 7.95-7.84 (m, 1H), 7.58 (br s, 1H), 7.55- 7.47 (m, 2H), 7.46- 7.26 (m, 1H), 4.24-4.13 (m, 2H), 3.88-3.79 (m, 2H), 2.48-2.44 (m, 6H), 2.28-2.21 (m, 2H) ppm

119		470.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.68 (d, J = 3.9 Hz, 1H), 8.13 (d, J = 8.3 Hz, 2H), 8.05-8.01 (m, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.96-7.83 (m, 1H), 7.51 (d, J = 8.8 Hz, 2H), 7.47-7.26 (m, 1H), 4.19 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.46 (s, 3H), 2.28-2.18 (m, 3H), 0.59-0.45 (m, 2H), 0.45-0.40 (m, 2H) ppm

120		461.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.53 (m, 4H), 7.52-7.47 (m, 2H), 7.46-7.40 (m, 1H), 7.38-7.27 (m, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.5 Hz, 2H), 2.48- 2.47 (m, 3H), 2.45 (s, 3H), 2.29-2.20 (m, 2H) ppm

121		462.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (dd, J = 5.6, 9.1 Hz, 1H), 8.17 (d, J = 8.6 Hz, 2H), 7.95 (dd, J = 2.3, 11.1 Hz, 1H), 7.61-7.55 (m, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.34-7.27 (m, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.49- 2.47 (m, 3H), 2.45 (s, 3H), 2.30-2.19 (m, 2H) ppm

122		462.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.57 (s, 1H), 7.97 (d, J = 6.8 Hz, 2H), 7.91-7.80 (m, 1H), 7.63-7.46 (m, 4H), 4.23- 4.14 (m, 2H), 3.89- 3.80 (m, 2H), 2.50 (s, 3H), 2.46 (s, 3H), 2.30- 2.20 (m, 2H) ppm

123		459.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.00 (d, J = 7.3 Hz, 2H), 7.58 (s, 1H), 7.43 (d, J = 7.3 Hz, 3H), 7.07 (d, J = 7.3 Hz, 1H), 6.42 (d, J = 7.3 Hz, 1H), 5.99 (s, 2H), 4.21-4.14 (m, 2H), 3.84-3.77 (m, 2H), 2.50 (s, 3H), 2.45 (s, 3H), 2.28-2.18 (m, 2H) ppm

124		473.4	¹H NMR (400 MHz, DMSO-d₆): δ 8.31-8.17 (m, J = 8.0 Hz, 2H), 7.97- 7.88 (m, 1H), 7.87- 7.72 (m, 4H), 7.37 (d, J = 7.3 Hz, 1H), 6.90 (br s, 1H), 4.44 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.2 Hz, 2H), 2.92 (s, 3H), 2.75- 2.70 (m, 6H), 2.25-2.22 (m, 2H) ppm

125		559.1	¹H NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 8.11 (d, J = 8.6 Hz, 2H), 7.85-7.79 (m, 1H), 7.75-7.71 (m, 1H), 7.64- 7.54 (m, 2H), 7.54- 7.44 (m, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.49-2.48 (m, 3H), 2.45 (s, 3H), 2.28-2.19 (m, 2H), 1.50 (s, 9H) ppm

126		450.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.99 (d, J = 8.3 Hz, 2H), 7.96-7.91 (m, 1H), 7.80 (d, J = 3.4 Hz, 1H), 7.61-7.56 (m, 1H), 7.56-7.49 (m, 2H), 4.17 (t, J = 5.6 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.49-2.47 (m, 3H), merged in solvent peak, 2.45 (s, 3H), 2.27-2.20 (m, 2H) ppm

127		476.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (d, J = 2.6 Hz, 1H), 8.02-7.97 (m, 2H), 7.97-7.92 (m, 1H), 7.81 (d, J = 3.3 Hz, 1H), 7.58-7.50 (m, 2H), 4.19 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.47 (s, 3H), 2.28-2.18 (m, 3H), 0.57-0.50 (m, 2H), 0.46-0.39 (m, 2H) ppm

128		462.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.73 (d, J = 4.0 Hz, 1H), 8.00-7.89 (m, 2H), 7.81 (d, J = 7.9 Hz, 1H), 7.60 (d, J = 4.6 Hz, 1H), 7.49-7.35 (m, 3H), 4.17 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.49-2.47 (m, 3H), merged in solvent peak, 2.46 (s, 3H), 2.30-2.20 (m, 2H) ppm

129		488.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.76-8.72 (m, 1H), 8.07-8.03 (m, 1H), 8.03-7.90 (m, 2H), 7.84-7.79 (m, 1H), 7.49- 7.38 (m, 3H), 4.19 (t, J = 5.9 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.48 (s, 3H), 2.30-2.20 (m, 3H), 0.56- 0.50 (m, 2H), 0.46-0.40 (m, 2H) ppm

130		479.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.57 (m, 3H), 7.56-7.51 (m, 1H), 7.50-7.44 (m, 2H), 7.40-7.29 (m, 2H), 4.21 (t, J = 6.0 Hz, 2H), 3.76 (t, J = 5.6 Hz, 2H), 2.48- 2.47 (m, 3H), 2.46 (s, 3H), 2.25 (t, J = 5.6 Hz, 2H) ppm

131		505.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.05 (d, J = 2.3 Hz, 1H), 7.55-7.41 (m, 4H), 7.41-7.31 (m, 3H), 4.18 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.47 (s, 3H), 2.28- 2.18 (m, 3H), 0.56-0.50 (m, 2H), 0.45-0.40 (m, 2H) ppm

132		479.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.54 (m, 1H), 7.54-7.42 (m, 4H), 7.42-7.29 (m, 3H), 4.17 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.49-2.47 (m, 3H), 2.45 (s, 3H), 2.27-2.19 (m, 2H) ppm

133		505.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (s, 1H), 7.64-7.58 (m, 2H), 7.57-7.52 (m, 1H), 7.52- 7.44 (m, 2H), 7.40- 7.28 (m, 2H), 4.22 (t, J = 5.9 Hz, 2H), 3.77 (t, J = 5.6 Hz, 2H), 2.47 (s, 3H), 2.29-2.18 (m, 3H), 0.56- 0.49 (m, 2H), 0.46- 0.39 (m, 2H) ppm

134		541.1	¹H NMR (400 MHz, DMSO-d₆): δ 10.39 (brs, 1H), 7.62 (dd, J = 1.4, 8.5 Hz, 2H), 7.51-7.36 (m, 4H), 7.31-7.24 (m, 3H), 7.16-7.04 (m, 3H), 4.11 (t, J = 6.1 Hz, 2H), 3.78 (t, J = 5.6 Hz, 2H), 2.32 (s, 3H), 2.24-2.15 (m, 2H) ppm

135		534.6	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (d, J = 7.8 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.46-7.36 (m, 2H), 7.35-7.20 (m, 1H), 4.24-4.15 (m, 2H), 3.88-3.78 (m, 2H), 2.92- 2.84 (m, 4H), 2.77- 2.69 (m, 4H), 2.50 (s, 3H), 2.31-2.21 (m, 3H) ppm

136		535.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (d, J = 7.8 Hz, 2H), 7.53-7.49 (m, 2H), 7.47-7.35 (m, 2H), 7.32-7.24 (m, 1H), 4.20 (t, J = 5.6 Hz, 2H), 3.87-3.78 (m, 2H), 3.69- 3.63 (m, 4H), 3.00- 2.94 (m, 4H), 2.50 (s, 3H), 2.29-2.21 (m, 2H) ppm

137		507.0	¹H NMR (400 MHz, DMSO-d₆): δ 12.57- 11.87 (m, 1H), 7.66- 7.58 (m, 2H), 7.54-7.48 (m, 2H), 7.48-7.35 (m, 2H), 7.31-7.23 (m, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.46 (s, 3H), 2.26-2.19 (m, 2H), 1.85 (s, 3H) ppm

138		458.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.67 (d, J = 4.5 Hz, 1H), 8.12 (d, J = 8.6 Hz, 2H), 7.98 (d, J = 8.0 Hz, 1H), 7.94-7.84 (m, 1H), 7.60 (br s, 1H), 7.49 (d, J = 8.6 Hz, 2H), 7.36 (dd, J = 5.2, 6.8 Hz, 1H), 4.31-4.21 (m, 2H), 3.87-3.78 (m, 2H), 2.50- 2.49 (m, 3H, merged in solvent peak), 2.45 (s, 3H), 2.04-1.93 (m, 2H), 1.90-1.81 (m, 2H) ppm

139		463.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.66-7.60 (m, 2H), 7.54-7.49 (m, 2H), 7.48-7.42 (m, 1H), 7.42-7.35 (m, 1H), 7.32- 7.24 (m, 1H), 5.32 (brs, 1H), 4.19 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.30 (s, 3H), 2.51 (s, 3H), 2.28-2.21 (m, 2H) ppm

140	Single enantiomer, arbitrarily assigned stereochemistry	463.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (d, J = 7.8 Hz, 2H), 7.54-7.34 (m, 4H), 7.28 (s, 1H), 4.59 (s, 1H), 4.22-4.11 (m, 2H), 3.89-3.76 (m, 2H), 3.12 (s, 3H), 2.50 (s, 3H), 2.29-2.18 (m, 2H) ppm

141	Single enantiomer, arbitrarily assigned stereochemistry	463.10	¹H NMR (400 MHz, DMSO-d₆): δ 7.66-7.59 (m, 2H), 7.54-7.34 (m, 4H), 7.33-7.22 (m, 1H), 4.59 (s, 1H), 4.20-4.12 (m, 2H), 3.88-3.76 (m, 2H), 3.12 (s, 3H), 2.50 (s, 3H), 2.29-2.18 (m, 2H) ppm

142		445.7	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.54 (m, 3H), 7.54-7.41 (m, 3H), 7.36-7.29 (m, 2H), 4.63-4.52 (m, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.83 (t, J = 5.7 Hz, 2H), 3.12 (d, J = 1.1 Hz, 3H), 2.27- 2.20 (m, 2H) ppm

143	Single enantiomer, arbitrarily assigned stereochemistry	445.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.60-7.54 (m, 3H), 7.49-7.42 (m, 3H), 7.36-7.29 (m, 2H), 4.57 (s, 1H), 4.21-4.13 (m, 2H), 3.86-3.78 (m, 2H), 3.11 (s, 3H), 2.50 (s, 3H), 2.28-2.17 (m, 2H) ppm

144	Single enantiomer, arbitrarily assigned stereochemistry	445.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.54 (m, 3H), 7.52-7.38 (m, 3H), 7.36-7.29 (m, 2H), 4.57 (s, 1H), 4.21-4.13 (m, 2H), 3.86-3.78 (m, 2H), 3.11 (s, 3H), 2.50 (s, 3H), 2.28-2.17 (m, 2H) ppm.

145		459.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.54 (m, 3H), 7.52-7.40 (m, 3H), 7.37-7.28 (m, 2H), 4.22-4.15 (m, 2H), 3.87- 3.79 (m, 2H), 3.23 (s, 3H), 2.57 (s, 3H), 2.45 (s, 3H), 2.29-2.18 (m, 2H) ppm

146	Single enantiomer, arbitrarily assigned stereochemistry	459.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.53 (m, 3H), 7.52-7.40 (m, 3H), 7.38-7.28 (m, 2H), 4.22-4.14 (m, 2H), 3.86- 3.78 (m, 2H), 3.16 (s, 3H), 2.55 (s, 3H), 2.45 (s, 3H), 2.29-2.20 (m, 2H) ppm

147	Single enantiomer, arbitrarily assigned stereochemistry	459.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.53 (m, 3H), 7.52-7.38 (m, 3H), 7.38-7.27 (m, 2H), 4.21-4.12 (m, 2H), 3.87- 3.75 (m, 2H), 3.16 (s, 3H), 2.55 (s, 3H), 2.45 (s, 3H), 2.29-2.17 (m, 2H) ppm

148		477.6	¹H NMR (400 MHz, DMSO-d₆): δ 7.64-7.60 (m, 2H), 7.52-7.36 (m, 4H), 7.31-7.24 (m, 1H), 4.54 (s, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.17 (q, J = 7.2 Hz, 2H), 2.48 (s, 3H), 2.27-2.20 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H) ppm

149	Single enantiomer, arbitrarily assigned stereochemistry	477.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (d, J = 8.3 Hz, 2H), 7.53-7.35 (m, 4H), 7.32-7.23 (m, 1H), 4.56 (s, 1H), 4.20- 4.14 (m, 2H), 3.85-3.80 (m, 2H), 3.25-3.09 (m, 2H), 2,49 (s, 3H), 2.27- 2.20 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H) ppm

150	Single enantiomer, arbitrarily assigned stereochemistry	477.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.58 (m, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.45-7.32 (m, 2H), 7.30-7.21 (m, 1H), 4.53 (s, 1H), 4.19-4.12 (m, 2H), 3.84-3.76 (m, 2H), 3.19-3.11 (m, 2H), 2.49 (s, 3H), 2.25-2.18 (m, 2H), 1.14 (t, J = 7.3 Hz, 3H) ppm

151		477.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (dd, J = 1.5, 8.5 Hz, 2H), 7.54- 7.36 (m, 4H), 7.32-7.25 (m, 1H), 4.19 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.60 (s, 3H), 2.47 (s, 3H), 2.33-2.20 (m, 2H) ppm

152	Single enantiomer, arbitrarily assigned stereochemistry	477.6	¹H NMR (400 MHz, DMSO-d₆): δ 7.64 (d, J = 7.8 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.49-7.45 (m, 1H), 7.45-7.36 (m, 1H), 7.35-7.25 (m, 1H), 4.20 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.1 Hz, 2H), 3.19 (s, 3H), 2.57 (s, 3H), 2.46 (s, 3H), 2.32-2.19 (m, 2H) ppm

153	Single enantiomer, arbitrarily assigned stereochemistry	477.7	¹H NMR (400 MHz, DMSO-d₆): δ 7.63 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.47-7.42 (m, 1H), 7.41-7.34 (m, 1H), 7.30-7.23 (m, 1H), 4.22-4.14 (m, 2H), 3.86- 3.79 (m, 2H), 3.16 (s, 3H), 2.54 (s, 3H), 2.44 (s, 3H), 2.28-2.19 (m, 2H) ppm

154		477.5	¹H NMR (400 MHz, DMSO-d₆): δ 7.62 (d, J = 8.3 Hz, 2H), 7.55-7.34 (m, 4H), 7.33-7.22 (m, 1H), 4.29-4.21 (m, 2H), 3.84-3.77 (m, 2H), 3.13 (s, 3H), 2.03-1.93 (m, 2H), 1.89-1.79 (m, 2H) ppm (Note: -NH and -CH₃protons not observed)

155		489.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.60 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.44-7.32 (m, 2H), 7.30-7.21 (m, 1H), 4.56 (s, 1H), 3.99 (s, 2H), 3.67 (s, 2H), 3.12- 3.11 (m, 3H), 2.45 (s, 3H), 0.79-0.78 (m, 4 H) ppm

156	Single enantiomer, arbitrarily assigned stereochemistry	489.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.65-7.59 (m, 2H), 7.51-7.36 (m, 4H), 7.33-7.22 (m, 1H), 4.57 (s, 1H), 4.01 (s, 2H), 3.69 (s, 2H), 3.15-3.09 (m, 3H), 2.47 (s, 3H), 0.81 (d, J = 4.4 Hz, 4H) ppm

157	Single enantiomer, arbitrarily assigned stereochemistry	489.5	¹H NMR (400 MHz, DMSO-d₆): δ 7.64-7.59 (m, 2H), 7.51-7.36 (m, 4H), 7.31-7.24 (m, 1H), 4.57 (s, 1H), 4.01 (s, 2H), 3.69 (s, 2H), 3.12 (d, J = 0.9 Hz, 3H), 2.47 (s, 3H), 0.81 (d, J = 4.5 Hz, 4H) ppm

158		471.3	¹H NMR (400 MHz, DMSO-d₆): δ 7.61-7.52 (m, 3H), 7.51-7.40 (m, 3H), 7.38-7.27 (m, 2H), 4.57 (s, 1H), 4.02 (s, 2H), 3.69 (s, 2H), 3.11 (m, 3H), 2.47 (s, 3H), 0.81 (d, J = 4.4 Hz, 4H) ppm

159	Single enantiomer, arbitrarily assigned stereochemistry	471.6	¹H NMR (400 MHz, DMSO-d₆): δ 7.61-7.53 (m, 3H), 7.51-7.40 (m, 3H), 7.38-7.27 (m, 2H), 4.57 (s, 1H), 4.01 (s, 2H), 3.69 (s, 2H), 3.12 (s, 3H), 2.47 (s, 3H), 0.81 (d, J = 4.1 Hz, 4H) ppm

160	Single enantiomer, arbitrarily assigned stereochemistry	471.4	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.51 (m, 3H), 7.51-7.41 (m, 3H), 7.37-7.28 (m, 2H), 4.57 (s, 1H), 4.01 (s, 2H), 3.69 (s, 2H), 3.12 (s, 3H), 2.47 (s, 3H), 0.81 (d, J = 4.0 Hz, 4H) ppm

161		463.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.66-7.60 (m, 2H), 7.55-7.36 (m, 4H), 7.32-7.24 (m, 1H), 4.19 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.24 (s, 3H), 2.49 (s, 3H), 2.32-2.18 (m, 2H) ppm

162		492.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.65-7.61 (m, 2H), 7.54-7.48 (m, 2H), 7.48-7.36 (m, 2H), 7.33-7.23 (m, 1H), 4.20 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.56- 2.54 (m, 1H), 2.50 (s, 3H), 2.28-2.22 (m, 2H), 1.23 (d, J = 6.8 Hz, 6H) ppm

163		490.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.66-7.59 (m, 2H), 7.55-7.36 (m, 4H), 7.32-7.23 (m, 1H), 4.19 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.05-2.83 (m, 1H), 2.49 (s, 3H), 2.27-2.20 (m, 2H), 1.10-1.03 (m, 4H) ppm

164		446.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.53 (m, 3H), 7.52-7.48 (m, 2H), 7.47-7.40 (m, 1H), 7.36-7.29 (m, 2H), 4.20 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.24 (s, 3H), 2.49 (s, 3H), 2.29- 2.20 (m, 2H) ppm

165		468.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.67-7.62 (m, 2H), 7.55-7.50 (m, 2H), 7.50-7.36 (m, 2H), 7.34-7.23 (m, 1H), 4.24 (t, J = 6.1 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 2.59 (s, 3H), 2.34-2.21 (m, 2H) ppm

166		476.0	¹H NMR (400 MHz, DMSO-d₆): δ 8.05 (s, 1H), 7.64 (d, J = 7.0 Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H), 7.50-7.36 (m, 2H), 7.34-7.24 (m, 1H), 4.23 (t, J = 6.1 Hz, 2H), 3.84 (t, J = 5.8 Hz, 2H), 2.96- 2.88 (m, 1H), 2.31-2.25 (m, 2H), 1.14-1.04 (m, 4H) ppm

167		450.2	¹H NMR (400 MHz, DMSO-d₆): δ 8.06 (s, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.49-7.35 (m, 2H), 7.35-7.22 (m, 1H), 4.22 (t, J = 5.9 Hz, 2H), 3.87- 3.81 (m, 2H), 3.31 (s, 3H), 2.33-2.22 (m, 2H) ppm

168		430.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.63-7.55 (m, 3H), 7.53-7.47 (m, 2H), 7.47-7.39 (m, 1H), 7.38-7.29 (m, 2H), 4.24- 4.17 (m, 2H), 3.88- 3.77 (m, 2H), 2.88 (s, 3H), 2.38 (s, 3H), 2.29- 2.20 (m, 2H) ppm

169		519.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.13 (br s, 2H), 7.68-7.59 (m, 2H), 7.56-7.49 (m, 2H), 7.48- 7.34 (m, 2H), 7.33- 7.21 (m, 1H), 4.22-4.11 (m, 2H), 3.89-3.78 (m, 2H), 2.31-2.19 (m, 2H) ppm

170		501.1	¹H NMR (400 MHz, DMSO-d₆): δ 8.11 (s, 2H), 7.63-7.49 (m, 5H), 7.48-7.39 (m, 1H), 7.39- 7.26 (m, 2H), 4.16 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.32-2.21 (m, 2H) ppm

171		485.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.94-7.81 (m, 2H), 7.64 (d, J = 7.3 Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H), 7.48-7.34 (m, 2H), 7.32-7.25 (m, 1H), 4.14 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.31-2.20 (m, 2H) ppm

172		479.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.51 (d, J = 7.3 Hz, 5H), 7.42-7.34 (m, 3H), 7.32-7.22 (m, 1H), 4.66 (s, 2H), 4.11- 4.03 (m, 2H), 3.44-3.36 (m, 2H), 2.42 (s, 3H), 2.10-1.99 (m, 2H) ppm

173		443.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.69-7.62 (m, 2H), 7.57 (br.s, 2H), 7.55-7.50 (m, 2H), 7.50- 7.42 (m, 3H), 7.41- 7.34 (m, 1H), 7.34-7.27 (m, 1H), 4.66 (s, 2H), 4.10-4.03 (m, 2H), 3.45- 3.36 (m, 2H), 2.42 (s, 3H), 2.09-1.99 (m, 2H) ppm

174		493.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.54-7.31 (m, 8H), 7.31-7.19 (m, 1H), 5.80-5.69 (m, 1H), 4.15-4.02 (m, 1H), 3.98- 3.86 (m, 1H), 3.09- 2.93 (m, 2H), 2.41 (s, 3H), 2.08-1.85 (m, 2H), 1.58 (d, J = 6.8 Hz, 3H) ppm

175	Single enantiomer, arbitrarily assigned stereochemistry	493.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.62-7.31 (m, 8H), 7.33-7.18 (m, 1H), 5.82-5.67 (m, 1H), 4.17-4.00 (m, 1H), 4.01- 3.86 (m, 1H), 3.40-3.30 (m, 1H), 3.09-2.93 (m, 1H), 2.41 (s, 3H), 2.09- 1.83 (m, 2H), 1.57 (d, J = 6.8 Hz, 3H) ppm

176	Single enantiomer, arbitrarily assigned stereochemistry	493.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.57-7.32 (m, 8H), 7.31-7.21 (m, 1H), 5.81-5.69 (m, 1H), 4.14-4.04 (m, 1H), 3.98- 3.87 (m, 1H), 3.40-3.30 (m, 1H), 3.05-2.94 (m, 1H), 2.41 (s, 3H), 2.07- 1.84 (m, 2H), 1.57 (d, J = 6.4 Hz, 3H) ppm

177		475.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.57-7.37 (m, 8H), 7.35-7.27 (m, 2H), 5.76 (q, J = 7.0 Hz, 1H), 4.14-4.04 (m, 1H), 3.97-3.87 (m, 1H), 3.42- 3.33 (m, 1H), 3.09- 2.91 (m, 1H), 2.41 (s, 3H), 2.07-1.85 (m, 2H), 1.57 (d, J = 7.1 Hz, 3H) ppm

178	Single enantiomer, arbitrarily assigned stereochemistry	474.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.57-7.46 (m, 6H), 7.44-7.36 (m, 2H), 7.35-7.27 (m, 2H), 5.76 (q, J = 7.5 Hz, 1H), 4.14-4.05 (m, 1H), 3.96- 3.87 (m, 1H), 3.38- 3.33 (m, 1H), 3.08-2.92 (m, 1H), 2.41 (s, 3H), 2.05-1.97 (m, 1H), 1.94- 1.87 (m, 1H), 1.57 (d, J = 7.1 Hz, 3H) ppm

179	Single enantiomer, arbitrarily assigned stereochemistry	474.9	¹H NMR (400 MHz, DMSO-d₆): δ 7.57-7.37 (m, 8H), 7.34-7.28 (m, 2H), 5.76 (q, J = 7.5 Hz, 1H), 4.13-4.05 (m, 1H), 3.97-3.87 (m, 1H), 3.41- 3.32 (m, 1H), 3.09- 2.92 (m, 1H), 2.41 (s, 3H), 2.07-1.85 (m, 2H), 1.57 (d, J = 7.1 Hz, 3H) ppm

180		519.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.99 (s, 1H), 7.54-7.47 (m, 3H), 7.45-7.34 (m, 3H), 7.34- 7.20 (m, 1H), 4.66 (s, 2H), 4.09 (t, J = 5.9 Hz, 2H), 3.40 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.40- 2.15 (m, 1H), 2.10-2.00 (m, 2H), 0.56-0.47 (m, 2H), 0.47-0.39 (m, 2H) ppm

181		493.2	¹H NMR (400 MHz, DMSO-d₆): δ 7.57-7.46 (m, 4H), 7.46-7.32 (m, 3H), 7.30-7.21 (m, 1H), 4.66 (s, 2H), 4.08 (t, J = 6.0 Hz, 2H), 3.39 (t, J = 5.6 Hz, 2H), 2.48-2.46 (m, 3H), 2.42 (s, 3H), 2.06-2.03 (m, 2H) ppm

182		457.1	¹H NMR (400 MHz, DMSO-d₆): δ 7.65 (d, J = 7.3 Hz, 2H), 7.60-7.52 (m, 3H), 7.50-7.42 (m, 3H), 7.41-7.34 (m, 1H), 7.34-7.27 (m, 1H), 4.66 (s, 2H), 4.08 (t, J = 6.0 Hz, 2H), 3.40 (t, J = 5.6 Hz, 2H), 2.49-2.47 (m, 3H), 2.43 (s, 3H), 2.10- 2.00 (m, 2H) ppm

183		483.0	¹H NMR (400 MHz, DMSO-d₆): δ 7.99 (br s, 1H), 7.68-7.63 (m, 2H), 7.61-7.55 (m, 2H), 7.50- 7.42 (m, 3H), 7.40- 7.34 (m, 1H), 7.33-7.28 (m, 1H), 4.66 (s, 2H), 4.09 (t, J = 5.8 Hz, 2H), 3.43-3.38 (m, 2H), 2.43 (s, 3H), 2.29-2.13 (m, 1H), 2.09-2.01 (m, 2H), 0.59-0.49 (m, 2H), 0.45- 0.39 (m, 2H) ppm

184		444.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (d, J = 8.3 Hz, 2H), 7.80-7.75 (m, 2H), 7.56 (s, 2H), 7.52-7.46 (m, 2H), 7.25- 7.20 (m, 1H), 4.21- 4.13 (m, 2H), 3.86-3.80 (m, 2H), 2.54 (s, 3H), 2.45 (s, 3H), 2.27-2.19 (m, 2H).

185		463.9	¹H NMR (400 MHz, DMSO-d₆) δ 8.65 (d, J = 5.4 Hz, 1H), 8.19-8.14 (m, 3H), 7.56 (s, 2H), 7.54-7.50 (m, 3H), 4.16 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.32-2.15 (m, 2H)

186		481.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.92 (dd, J = 2.3, 7.1 Hz, 1H), 7.79- 7.67 (m, 3H), 7.59-7.46 (m, 5H), 4.16 (t, J = 6.0 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.17 (m, 2H)

187		465.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.66-7.53 (m, 5H), 7.53-7.46 (m, 2H), 7.45-7.34 (m, 1H), 7.27-7.17 (m, 1H), 4.16 (br t, J = 5.6 Hz, 2H), 3.90-3.75 (m, 2H), 2.44 (s, 3H), 2.29-2.17 (m, 2H

188		483.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.88-7.64 (m, 4H), 7.56 (br s, 2H), 7.52-7.47 (m, 2H), 4.20- 4.10 (m, 2H), 3.87- 3.77 (m, 2H), 2.46 (m, 3H), 2.28-2.19 (m, 2H).

189		446.9	¹H NMR (400 MHz, DMSO-d₆) δ 7.76-7.66 (m, 4H), 7.57 (s, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.35-7.27 (m, 2H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.27-2.18 (m, 2H).

190		465.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.85-7.78 (m, 1H), 7.78-7.70 (m, 2H), 7.61-7.51 (m, 4H), 7.51-7.46 (m, 2H), 4.17 (t, J = 5.8 Hz, 2H), 3.85- 3.77 (m, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H).

191		463.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.79-7.72 (m, 3H), 7.67 (d, J = 7.9 Hz, 1H), 7.57 (s, 2H), 7.54-7.42 (m, 4H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.28-2.19 (m, 2H).

192		497.9	¹H NMR (400 MHz, DMSO-d₆) δ 7.87 (s, 1H), 7.83-7.75 (m, 2H), 7.75- 7.63 (m, 2H), 7.60- 7.49 (m, 5H), 6.70 (d, J = 16.8 Hz, 1H), 4.17 (t, J = 5.7 Hz, 2H), 3.86-3.79 (m, 2H), 2.45 (s, 3H), 2.27-2.19 (m, 2H).

193		481.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.66-7.60 (m, 1H), 7.56 (s, 2H), 7.53-7.47 (m, 4H), 7.38- 7.26 (m, 2H), 4.20- 4.13 (m, 2H), 3.87-3.80 (m, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H).

194		497.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.86-7.78 (m, 1H), 7.59-7.48 (m, 4H), 7.48-7.39 (m, 3H), 7.39-7.21 (m, 1H), 6.81 (t, J = 54.4 Hz, 1H), 4.24- 4.12 (m, 2H), 3.89- 3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.21 (m, 2H).

195		457.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.57 (s, 2H), 7.44 (d, J = 7.8 Hz, 2H), 7.40-7.27 (m, 2H), 7.22- 7.13 (m, 2H), 7.06-7.04 (m, 1H), 4.22-4.15 (m, 2H), 3.87-3.79 (m, 2H), 2.46 (s, 3H), 2.31 (s, 3H), 2.28-2.20 (m, 2H), 2.14 (s, 3H).

196		497.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.84 (d, J = 7.9 Hz, 1H), 7.77-7.69 (m, 1H), 7.66-7.57 (m, 1H), 7.54 (s, 2H), 7.49- 7.39 (m, 3H), 7.39-7.29 (m, 2H), 4.19-4.12 (m, 2H), 3.85-3.79 (m, 2H), 2.43 (s, 3H), 2.27-2.18 (m, 2H).

197		485.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J = 7.5 Hz, 1H), 7.56 (s, 2H), 7.51-7.39 (m, 3H), 7.39- 7.32 (m, 1H), 7.30- 7.22 (m, 3H), 4.70-4.59 (m, 2H), 4.57-4.51 (m, 2H), 4.50-4.43 (m, 1H), 4.17 (t, J = 5.7 Hz, 2H), 3.83 (t, J = 5.0 Hz, 2H), 2.45 (s, 3H), 2.29-2.19 (m, 2H).

198		494.6	¹H NMR (400 MHz, DMSO-d₆) δ 7.73 (d, J = 8.3 Hz, 2H), 7.62 (d, J = 7.5 Hz, 1H), 7.56 (s, 2H), 7.54-7.51 (m, 1H), 7.51- 7.46 (m, 3H), 7.45- 7.32 (m, 1H), 4.20-4.13 (m, 2H), 3.84-3.79 (m, 2H), 2.45 (s, 3H), 2.28- 2.17 (m, 2H), 1.82-1.76 (m, 2H), 1.67-1.61 (m, 2H).

199		483.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.73-7.66 (m, 2H), 7.59-7.54 (m, 2H), 7.51-7.44 (m, 4H), 7.42-7.36 (m, 1H), 7.28- 7.20 (m, 1H), 4.21- 4.11 (m, 2H), 3.86-3.77 (m, 2H), 3.67-3.55 (m, 1H), 2.45 (s, 3H), 2.39- 2.28 (m, 2H), 2.28-2.11 (m, 4H), 2.07-1.95 (m, 1H), 1.91-1.78 (m, 1H).

200		483.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.56 (s, 2H), 7.51-7.45 (m, 2H), 7.45- 7.28 (m, 5H), 7.10- 7.03 (m, 1H), 4.20-4.13 (m, 2H), 3.90-3.83 (m, 1H), 3.83-3.77 (m, 2H), 2.44 (s, 3H), 2.27-2.17 (m, 2H), 0.83-0.75 (m, 2H), 0.69-0.62 (m, 2H).

201		507.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.18 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.79-7.73 (m, 1H), 7.59- 7.51 (m, 4H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H). [Note: -3H merged in solvent peak]

202		472.3	¹H NMR (400 MHz, DMSO-d₆) δ 8.13-8.08 (m, 1H), 7.96-7.90 (m, 1H), 7.67-7.61 (m, 2H), 7.60-7.48 (m, 5H), 4.19- 4.12 (m, 2H), 3.84- 3.78 (m, 2H), 2.43 (s, 3H), 2.25-2.18 (m, 2H).

203		477.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.57-7.53 (m, 4H), 7.42 (d, J = 8.3 Hz, 2H), 7.23-7.09 (m, 3H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 3.77 (s, 3H), 2.45 (s, 3H), 2.27-2.18 (m, 2H).

204		503.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.62-7.53 (m, 4H), 7.51-7.46 (m, 4H), 7.28-7.17 (m, 1H), 4.20-4.15 (m, 2H), 3.85- 3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.20 (m, 2H), 1.32 (s, 9H).

205		487.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.62-7.51 (m, 3H), 7.51-7.44 (m, 2H), 7.25-7.06 (m, 4H), 4.22-4.12 (m, 2H), 3.87- 3.77 (m, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H), 2.04-1.94 (m, 1H), 0.96 (d, J = 6.8 Hz, 2H), 0.75- 0.68 (m, 2H).

206		497.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.77 (d, J = 7.3 Hz, 1H), 7.70-7.60 (m, 3H), 7.59-7.47 (m, 5H), 7.09 (t, J = 56 Hz, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.28- 2.19 (m, 2H).

207		527.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.56 (s, 2H), 7.53-7.47 (m, 1H), 7.45- 7.44 (m, 1H), 7.41- 7.36 (m, 2H), 7.28-7.21 (m, 3H), 7.17-7.12 (m, 1H), 6.92 (d, J = 0.7 Hz, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.81 (t, J = 5.7 Hz, 2H), 3.74 (s, 3H), 2.44 (s, 3H), 2.27-2.19 (m, 2H).

208		512.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (d, J = 7.9 Hz, 2H), 7.55 (s, 2H), 7.53-7.47 (m, 2H), 7.44- 7.40 (m, 2H), 7.40- 7.33 (m, 1H), 4.22-4.12 (m, 2H), 3.87-3.76 (m, 2H), 2.45 (s, 3H), 2.28- 2.19 (m, 2H), 1.81-1.70 (m, 2H), 1.66-1.57 (m, 2H).

209		491.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.60-7.51 (m, 3H), 7.51-7.42 (m, 4H), 7.25-7.23 (m, 1H), 7.15 (dd, J = 2.8, 9.9 Hz, 1H), 4.29 (s, 2H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.26 (s, 3H), 2.45 (s, 3H), 2.42- 2.19 (m, 2H).

210		545.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.23 (s, 1H), 7.99 (s, 1H), 7.69-7.60 (m, 3H), 7.58-7.48 (m, 4H), 7.28-7.20 (m, 1H), 4.22-4.12 (m, 2H), 3.91 (s, 3H), 3.87-3.80 (m, 2H), 2.45 (s, 3H), 2.29- 2.20 (m, 2H).

211		548.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.27 (s, 1H), 8.54 (s, 1H), 7.88-7.82 (m, 1H), 7.70-7.65 (m, 2H), 7.60-7.52 (m, 4H), 7.51-7.46 (m, 1H), 4.17 (t, J = 5.8 Hz, 2H), 3.84 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.29-2.20 (m, 2H).

212		542.7	¹H NMR (400 MHz, DMSO-d₆) δ 7.78-7.73 (m, 1H), 7.66-7.60 (m, 2H), 7.57 (s, 2H), 7.55- 7.48 (m, 3H), 4.16 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.27-2.19 (m, 2H).

213		515.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.82 (s, 1H), 7.64 (d, J = 7.3 Hz, 3H), 7.58-7.49 (m, 4H), 4.20- 4.13 (m, 2H), 3.86- 3.79 (m, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H).

214		499.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.81-7.69 (m, 1H), 7.68-7.59 (m, 2H), 7.59-7.47 (m, 5H), 4.21-4.11 (m, 2H), 3.88- 3.78 (m, 2H), 2.45 (s, 3H), 2.27-2.18 (m, 2H).

215		481.0	¹H NMR (400 MHz, DMSO-d₆) δ 9.63 (brs, 1H), 7.65-7.58 (m, 2H), 7.56 (s, 2H), 7.48-7.40 (m, 2H), 7.28-7.19 (m, 1H), 7.08-7.01 (m, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.27-2.18 (m, 2H).

216		495.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.60-7.54 (m, 4H), 7.53-7.43 (m, 2H), 7.41-7.32 (m, 1H), 7.14 (d, J = 9.3 Hz, 1H), 4.16 (t, J = 5.6 Hz, 2H), 3.85-3.78 (m, 2H), 3.68 (s, 3H), 2.45 (s, 3H), 2.28- 2.19 (m, 2H)

217		515.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.74-7.62 (m, 3H), 7.59-7.51 (m, 5H), 7.28 (t, J = 54 Hz, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28- 2.20 (m, 2H).

218		511.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.61 (d, J = 7.8 Hz, 2H), 7.56 (s, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.23-7.18 (m, 1H), 7.07- 7.03 (m, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.82 (s, 3H), 3.81-3.76 (m, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H).

219		547.4	¹H NMR (400 MHz, CD₃OD-d₄) δ 8.50 (s, 1H), 7.92-7.86 (m, 1H), 7.50-7.46 (m, 2H), 7.43- 7.38 (m, 3H), 7.33- 7.23 (m, 2H), 4.28 (t, J = 6.1 Hz, 2H), 3.90 (t, J = 5.7 Hz, 2H), 2.52 (s, 3H), 2.36-2.28 (m, 2H).

220		492.9	¹H NMR (400 MHz, DMSO-d₆) δ 7.60-7.50 (m, 4H), 7.48-7.36 (m, 5H), 7.34-7.27 (m, 1H), 4.18-4.12 (m, 2H), 3.84- 3.77 (m, 2H), 2.43 (s, 3H), 2.27-2.18 (m, 2H), 0.84-0.76 (m, 2H), 0.63- 0.56 (m, 2H).

221		509.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.58-7.47 (m, 6H), 7.41-7.23 (m, 1H), 7.12 (d, J = 8.3 Hz, 1H), 4.27-4.13 (m, 4H), 3.89-3.80 (m, 2H), 3.26 (s, 3H), 2.45 (s, 3H), 2.29- 2.18 (m, 2H).

222		497.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.84-7.75 (m, 4H), 7.56 (s, 2H), 7.54-7.49 (m, 2H), 7.49- 7.40 (m, 1H), 7.11 (t, J = 55.6 Hz, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H)

223		493.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.57 (s, 2H), 7.51-7.36 (m, 5H), 7.30- 7.22 (m, 1H), 7.13 (dd, J = 2.8, 9.4 Hz, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.38 (s, 3H), 2.27- 2.19 (m, 2H)

224		531.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.60-7.49 (m, 7H), 7.49-7.45 (m, 1H), 7.43-7.34 (m, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.28-2.19 (m, 2H)

225		511.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.73 (dd, J = 5.8, 8.9 Hz, 1H), 7.57 (s, 2H), 7.47-7.41 (m, 2H), 7.40-7.32 (m, 3H), 7.13 (dd, J = 2.6, 9.4 Hz, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.29-2.18 (m, 2H), 1.72 (t, J = 19.0 Hz, 3H)

226		502.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.97-7.90 (m, 1H), 7.72 (s, 1H), 7.59-7.51 (m, 4H), 7.51- 7.43 (m, 2H), 4.18- 4.10 (m, 2H), 3.89-3.76 (m, 5H), 2.43 (s, 3H), 2.27-2.16 (m, 2H).

227		545.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.81 (dd, J = 1.9, 11.6 Hz, 1H), 7.62- 7.54 (m, 5H), 7.52-7.48 (m, 2H), 4.17 (t, J = 6.0 Hz, 2H), 3.85 (s, 3H), 3.82-3.79 (m, 2H), 2.45 (s, 3H), 2.32-2.17 (m, 2H).

228		581.1	1H-NMR (400 MHz, DMSO-d6): δ 8.76 (s, 1H), 8.38 (s, 1H), 7.98 (s, 2H), 7.79 (d, J = 3.20 Hz, 2H), 7.54 (d, J = 8.80 Hz, 4H), 7.39 (t, J = 2.80 Hz, 1H), 4.18 (t, J = 5.60 Hz, 2H), 3.85 (t, J = 5.60 Hz, 2H), 2.46 (s, 3H), 8.38 (s, 2H),

229		512.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.24 (s, 1H), 8.35-8.28 (m, 2H), 8.01 (d, J = 7.3 Hz, 1H), 7.79 (d, J = 7.8 Hz, 2H), 7.68 (d, J = 6.8 Hz, 1H), 7.60- 7.47 (m, 5H), 4.21-4.13 (m, 2H), 3.90-3.79 (m, 2H), 2.45 (s, 3H), 2.30- 2.19 (m, 2H).

230		530.2	¹H NMR (400 MHz, DMSO-d₆) δ 9.00 (s, 1H), 7.77 (s, 1H), 7.72-7.60 (m, 2H), 7.55 (s, 2H), 7.42-7.34 (m, 2H), 7.33- 7.22 (m, 3H), 4.14 (t, J = 5.5 Hz, 2H), 3.82-3.76 (m, 2H), 2.45 (s, 3H), 2.26-2.17 (m, 2H).

231		530.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.99 (s, 1H), 7.77 (s, 1H), 7.69-7.64 (m, 1H), 7.56 (br s, 2H), 7.43-7.22 (m, 6H), 4.19- 4.10 (m, 2H), 3.83- 3.75 (m, 2H), 2.44 (s, 3H), 2.26-2.13 (m, 2H).

232		498.0	¹H NMR (400 MHz, DMSO-d₆) δ 8.92 (d, J = 3.9 Hz, 1H), 8.33 (d, J = 7.5 Hz, 1H), 7.73-7.61 (m, 1H), 7.57 (s, 2H), 7.54-7.48 (m, 4H), 4.17 (t, J = 5.7 Hz, 2H), 3.88- 3.81 (m, 2H), 2.45 (s, 3H), 2.31-2.19 (m, 2H).

233		460.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J = 5.8 Hz, 1H), 8.39 (s, 1H), 7.60-7.51 (m, 4H), 7.50- 7.39 (m, 2H), 7.18 (d, J = 5.8 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.88 (s, 3H), 3.81 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.29-2.19 (m, 2H).

234		498.3	¹H NMR (400 MHz, DMSO-d₆) δ 8.83 (s, 1H), 8.41-8.36 (s, 1H), 8.17 (d, J = 7.6 Hz, 2H), 7.63- 7.44 (m, 4H), 4.24-4.10 (m, 2H), 3.88-3.79 (m, 2H), 2.45 (s, 3H), 2.30- 2.16 (m, 2H).

235		466.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.14 (d, J = 8.6 Hz, 2H), 7.99 (d, J = 9.5 Hz, 1H), 7.58-7.52 (m, 4H), 7.23 (d, J = 8.6 Hz, 1H), 4.16 (t, J = 5.8 Hz, 2H), 3.84 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.32-2.16 (m, 2H).

236		496.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.95-7.89 (m, 2H), 7.63-7.59 (m, 1H), 7.58-7.52 (m, 4H), 4.17 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.28-2.19 (m, 2H) [Note: -CH₃ merged in solvent peak].

237		462.6	¹H NMR (400 MHz, DMSO-d₆) δ 8.14 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 10.8 Hz, 1H), 7.55 (s, 2H), 7.53-7.48 (m, 2H), 7.19-7.14 (m, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 2.56 (s, 3H), 2.45 (s, 3H), 2.29- 2.18 (m, 2H)

238		460.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.00-7.85 (m, 2H), 7.70-7.37 (m, 4H), 7.13-6.79 (m, 1H), 6.69-6.29 (m, 1H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.5 Hz, 2H), 2.44 (s, 3H), 2.37 (s, 3H), 2.27- 2.19 (m, 2H). [Note: -OH proton not observed]

239		478.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.18 (d, J = 3.0 Hz, 1H), 7.82 (dd, J = 2.9, 8.8 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.56 (s, 2H), 7.50-7.42 (m, 2H), 4.17 (t, J = 5.8 Hz, 2H), 3.89 (s, 3H), 3.81 (t, J = 5.2 Hz, 2H), 2.44 (s, 3H), 2.32-2.14 (m, 2H).

240		498.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.95 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 8.28-8.22 (m, 2H), 7.78- 7.71 (m, 1H), 7.61- 7.50 (m, 4H), 4.20-4.12 (m, 2H), 3.90-3.81 (m, 2H), 2.45 (s, 3H), 2.30- 2.19 (m, 2H)

241		499.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.84 (s, 1H), 7.75-7.63 (m, 3H), 7.53 (s, 2H), 7.43 (d, J = 7.8 Hz, 2H), 4.18-4.08 (m, 2H), 3.83-3.72 (m, 2H), 2.42 (s, 3H), 2.26-2.15 (m, 2H), 2.01 (t, J = 18.6 Hz, 3H).

242		484.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (d, J = 8.3 Hz, 1H), 8.01 (d, J = 6.8 Hz, 1H), 7.95-7.87 (m, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.56-7.52 (m, 2H), 4.20-4.12 (m, 2H), 3.89-3.80 (m, 2H), 2.43 (s, 3H), 2.27-2.19 (m, 2H).

243		505.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.68 (dd, J = 2.3, 8.5 Hz, 1H), 8.05 (dd, J = 2.3, 9.6 Hz, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.66-7.60 (m, 2H), 7.58 (s, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.87 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.30-2.21 (m, 2H).

244		555.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.61 (s, 1H), 8.13-8.00 (m, 3H), 7.68- 7.45 (m, 4H), 4.27- 4.11 (m, 2H), 3.95-3.76 (m, 2H), 2.44 (s, 3H), 2.29-2.17 (m, 2H).

245		489.0	1H-NMR (400 MHz, DMSO-d₆) 8.17 (d, J = 8.80 Hz, 2H), 7.97-7.94 (m, 2H), 7.63 (d, J = 8.40 Hz, 2H), 7.59 (s, 2H), 4.18 (t, J = 6.00 Hz, 2H), 3.87 (t, J = 6.00 Hz, 2H), 2.46 (s, 3H), 2.26 (t, J = 5.60 Hz, 2H).

246		550.2	(400 MHz, DMSO-d6 ) 7.92 (s, 1H), 7.76 (d, J = 2.00 Hz, 2H), 7.69 (d, J = 2.80 Hz, 1H), 7.55 (t, J = 1.60 Hz, 4H), 7.38 (s, 1H), 6.69 (d, J = 2.40 Hz, 1H), 4.19 (t, J = 6.00 Hz, 2H), 3.95 (s, 3H), 3.87 (t, J = 5.60 Hz, 2H), 2.46 (s, 3H), 2.08 (t, 2H)

247		483.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.02-7.95 (m, 2H), 7.86 (s, 1H), 7.66 (d, J = 9.0 Hz, 1H), 7.54 (d, J = 8.5 Hz, 4H), 7.31-7.23 (m, 1H), 7.00 (d, J = 6.9 Hz, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.86 (t, J = 5.3 Hz, 2H), 2.45 (s, 3H), 2.32 (s, 3H), 2.29- 2.21 (m, 2H).

248		469.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.05-7.97 (m, 3H), 7.74 (d, J = 8.8 Hz, 1H), 7.59-7.52 (m, 4H), 7.36-7.28 (m, 1H), 7.05 (d, J = 6.8 Hz, 1H), 6.77-6.73 (m, 1H), 4.18 (t, J = 5.6 Hz, 2H), 3.86 (t, J = 5.4 Hz, 2H), 2.46 (s, 3H), 2.30-2.21 (m, 2H).

249		487.0	¹H NMR (400 MHz, DMSO-d₆) δ 7.56-7.47 (m, 4H), 7.42-7.34 (m, 2H), 6.90-6.81 (m, 3H), 4.32-4.19 (m, 4H), 4.17- 4.11 (m, 2H), 3.82- 3.75 (m, 2H), 2.43 (s, 3H), 2.26-2.15 (m, 2H).

250		496.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (d, J = 7.8 Hz, 2H), 7.56 (s, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.42-7.36 (m, 1H), 7.24- 7.14 (m, 1H), 7.12- 7.06 (m, 1H), 6.38 (s, 1H), 4.23-4.13 (m, 2H), 3.89-3.79 (m, 2H), 3.71 (s, 3H), 2.45 (s, 3H), 2.43 (s, 3H), 2.29-2.21 (m, 2H).

251		500.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.72 (d, J = 8.4 Hz, 2H), 7.57 (s, 2H), 7.55-7.49 (m, 2H), 7.45- 7.40 (m, 1H), 7.40- 7.31 (m, 1H), 7.02 (dd, J = 2.0, 10.6 Hz, 1H), 6.56 (d, J = 3.1 Hz, 1H), 4.18 (t, J = 5.8 Hz, 2H), 3.84 (t, J = 5.5 Hz, 2H), 3.80 (s, 3H), 2.45 (s, 3H), 2.29- 2.20 (m, 2H).

252		516.0	¹H NMR (400 MHz, DMSO-d₆) δ 9.42 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.66 (s, 1H), 7.62-7.49 (m, 4H), 7.23 (s, 1H), 4.22-4.12 (m, 2H), 3.91 (s, 3H), 3.87-3.80 (m, 2H), 2.44 (s, 3H), 2.30- 2.17 (m, 2H).

253		544.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.79-7.70 (m, 3H), 7.63-7.54 (m, 4H), 7.44 (dd, J = 2.2, 10.1 Hz, 1H), 4.17 (t, J = 5.7 Hz, 2H), 3.85 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 2H), 1.30- 1.24 (m, 2H), 1.19- 1.13 (m, 2H). [Note: -One -CH of cyclopropyl not observed, merged in solvent peak]

254		546.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (s, 1H), 8.13 (s, 1H), 7.86-7.78 (m, 3H), 7.69-7.64 (m, 1H), 7.62-7.53 (m, 4H), 7.51-7.45 (m, 1H), 4.22- 4.15 (m, 2H), 3.91- 3.83 (m, 2H), 2.46 (s, 3H), 2.31-2.21 (m, 2H).

255		504.2	¹H NMR (400 MHz, DMSO-d₆) δ 9.56 (s, 1H), 7.98 (d, J = 9.3 Hz, 1H), 7.85-7.78 (m, 2H), 7.63- 7.52 (m, 5H), 4.22- 4.14 (m, 2H), 3.90-3.83 (m, 2H), 2.46 (s, 3H), 2.30-2.20 (m, 2H).

256		518.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.84-7.74 (m, 3H), 7.61-7.54 (m, 4H), 7.48 (dd, J = 2.2, 10.0 Hz, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.85 (t, J = 5.4 Hz, 2H), 2.83 (s, 3H), 2.45 (s, 3H), 2.29-2.20 (m, 2H).

257		572.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.24 (dd, J = 2.4, 9.0 Hz, 1H), 7.89- 7.81 (m, 3H), 7.65-7.60 (m, 2H), 7.58 (s, 2H), 4.18 (t, J = 6.0 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.30-2.21 (m, 2H)

258		486.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.26 (s, 1H), 8.27 (d, J = 7.3 Hz, 1H), 7.88-7.75 (m, 3H), 7.72- 7.66 (m, 1H), 7.64- 7.55 (m, 4H), 4.23-4.14 (m, 2H), 3.92-3.82 (m, 2H), 2.45 (s, 3H), 2.30- 2.22 (m, 2H).

259		505.6	1H-NMR (400 MHz, DMSO-d6): δ 8.09 (d, J = 2.00 Hz, 2H), 7.93-7.98 (m, 2H), 7.61-7.58 (m, 4H), 4.21-4.18 (m, 2H), 3.89-3.86 (m, 2H), 2.53 (s, 3H), 2.34-2.33 (m, 2H),

260		487.3	¹H NMR (400 MHz, DMSO-d₆) δ 9.75 (s, 1H), 8.80-8.77 (d, J = 5.2 Hz, 1H), 8.08 (d, J = 6.8 Hz, 3H), 7.61 (d, J = 8.3 Hz, 2H), 7.54 (s, 2H), 4.21- 4.12 (m, 2H), 3.90-3.81 (m, 2H), 2.43 (s, 3H), 2.27-2.16 (m, 2H).

261		484.3	¹H NMR (400 MHz, DMSO-d₆): δ 8.51 (s, 1H), 8.49-8.44 (m, 1H), 8.15 (d, J = 8.3 Hz, 2H), 7.65 (d, J = 5.4 Hz, 1H), 7.60- 7.50 (m, 4H), 4.19-4.14 (m, 2H), 4.10 (s, 3H), 3.89-3.79 (m, 2H), 2.43 (s, 3H), 2.28-2.16 (m, 2H).

262		470.3	¹H NMR (400 MHz, CD₃OD-d₄) δ 8.57 (s, 1H), 8.26-8.20 (m, 1H), 8.13-8.06 (m, 2H), 8.01- 7.97 (m, 1H), 7.69- 7.59 (m, 3H), 4.33-4.25 (m, 2H), 3.96-3.90 (m, 2H), 2.52(s, 3H), 2.38- 2.30 (m, 2H). [Note: -NH₂not observed].

263		468.2	¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (d, J = 7.0 Hz, 1H), 8.38 (s, 1H), 7.85 (d, J = 7.9 Hz, 2H), 7.64-7.52 (m, 4H), 7.34- 7.25 (m, 2H), 4.19 (t, J = 5.7 Hz, 2H), 3.91-3.82 (m, 2H), 2.46 (s, 3H), 2.30-2.21 (m, 2H).

264		507.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.42 (m, 7H), 7.11 (d, J = 7.5 Hz, 2H), 4.82 (t, J = 16.9 Hz, 2H), 4.16 (t, J = 4.8 Hz, 2H), 3.83 (t, J = 4.8 Hz, 2H), 2.45 (s, 3H), 2.28-2.18 (m, 2H)

265		518.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.56 (s, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 6.55 (dd, J = 2.9, 11.4 Hz, 1H), 6.38 (dd, J = 2.9, 9.3 Hz, 1H), 4.24- 4.07 (m, 4H), 3.79 (t, J = 5.4 Hz, 2H), 2.89 (s, 3H), 2.44 (s, 3H), 2.27-2.17 (m, 2H). [Note: -Two protons merged in solvent peak]

266		521.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.57 (s, 2H), 7.47-7.35 (m, 5H), 6.99 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 7.5 Hz, 1H), 4.35 (t, J = 5.2 Hz, 2H), 4.16 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.43-2.38 (m, 2H), 2.32-2.16 (m, 2H)

267		521.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.61-7.52 (m, 5H), 7.48 (d, J = 7.5 Hz, 1H), 7.45-7.41 (m, 2H), 7.23-7.11 (m, 1H), 4.38-4.32 (m, 2H), 4.17 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.63- 2.54 (m, 2H), 2.44 (s, 3H), 2.28-2.17 (m, 2H).

268		495.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 1H), 7.62-7.47 (m, 8H), 7.06 (dd, J = 1.1, 6.6 Hz, 1H), 6.69 (s, 1H), 6.01 (s, 2H), 4.18 (t, J = 6.1 Hz, 2H), 3.87 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H), 2.29-2.22 (m, 2H).

269		487.3	¹H NMR (400 MHz, DMSO-d₆) δ 9.60 (s, 1H), 9.38-9.35 (m, 1H), 8.71 (s, 1H), 7.83 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.54 (s, 2H), 4.16 (t, J = 5.6 Hz, 2H), 3.88-3.82 (m, 2H), 2.44 (s, 3H), 2.27-2.20 (m, 2H).

270		484.0	¹H NMR (400 MHz, DMSO-d₆) δ 8.62 (d, J = 4.8 Hz, 1H), 8.20 (d, J = 5.3 Hz, 1H), 8.15-8.06 (m, 2H), 7.99-7.80 (m, 1H), 7.73-7.49 (m, 5H), 4.24-4.14 (m, 2H), 3.94- 3.84 (m, 2H), 2.54 (s, 3H), 2.35-2.20 (m, 2H).

271		484.1	(400 MHz, DMSO-d6): δ 9.14 (s, 1H), 8.77 (s, 1H), 8.29 (s, 1H), 7.84 (d, J = −8.00 Hz, 2H), 7.55-7.58 (m, 4H), 4.30 (s, 3H), 4.09-4.19 (m, 2H), 3.84- 3.87 (m, 2H), 2.50 (s, 3H), 2.20-2.27 (m, 2H),

272		487.0	¹H NMR (400 MHz, DMSO-d₆) δ 9.81 (s, 1H), 8.84 (d, J = 4.9 Hz, 1H), 7.88 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 5.0 Hz, 1H), 7.65 (d, J = 8.6 Hz, 2H), 6.05 (br s, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.87 (t, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.28-2.21 (m, 2H)

273		537.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.80 (d, J = 8.6 Hz, 2H), 7.56 (s, 2H), 7.54-7.46 (m, 2H), 7.34- 7.27 (m, 1H), 7.13 (d, J = 1.6 Hz, 1H), 6.18 (s, 2H), 4.16 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.27- 2.20 (m, 2H), 2.01 (t, J = 18.8 Hz, 3H)

274		510.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.52-8.48 (m, 1H), 8.10-8.04 (m, 1H), 7.79-7.73 (m, 2H), 7.71-7.65 (m, 2H), 7.60- 7.51 (m, 4H), 4.20- 4.12 (m, 2H), 3.88-3.80 (m, 2H), 2.43 (s, 3H), 2.29-2.18 (m, 2H).

275		499.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.83-7.72 (m, 3H), 7.61-7.52 (m, 5H), 7.49-7.43 (m, 2H), 4.21-4.14 (m, 2H), 3.91- 3.82 (m, 2H), 2.48-2.43 (m, 6H), 2.32-2.18 (m, 2H).

276		528.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (s, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 9.8 Hz, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.59-7.55 (m, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.89- 3.84 (m, 2H), 2.46 (s, 3H), 2.30-2.22 (m, 2H).

277		520.2	¹H NMR (400 MHz, DMSO-d₆) δ 9.56 (s, 1H), 8.23 (d, J = 2.0 Hz, 1H), 7.81 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 1.8 Hz, 1H), 7.62-7.60 (m, 1H), 7.59- 7.55 (m, 3H), 4.17 (t, J = 5.6 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.45 (s, 3H), 2.29-2.21 (m, 2H).

278		511.2	¹H NMR (400 MHz, DMSO-d₆) δ 9.69 (s, 1H), 8.70 (d, J = 1.3 Hz, 1H), 8.06 (d, J = 1.2 Hz, 1H), 7.87-7.83 (m, 2H), 7.67- 7.62 (m, 2H), 7.60 (brs, 2H), 4.20 (t, J = 6.0 Hz, 2H), 3.89 (t, J = 5.5 Hz, 2H), 2.47 (s, 3H), 2.34- 2.21 (m, 2H)

279		529.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.23 (dd, J = 2.3, 8.9 Hz, 1H), 7.89- 7.79 (m, 3H), 7.67-7.59 (m, 2H), 7.58 (s, 2H), 4.18 (t, J = 5.8 Hz, 2H), 3.87 (t, J = 5.4 Hz, 2H), 2.44 (s, 3H), 2.31-2.19 (m, 2H).

280		542.0	¹H-NMR (400 MHz, DMSO-d₆): δ 8.38 (d, J = 7.2 Hz, 1H), 8.04 (d, J = 11.2 Hz, 1H), 7.69 (dd, J = 1.6, 8.8 Hz, 2H), 7.58- 7.54 (m, 4H), 4.18 (t, J = 6.0 Hz, 2H), 3.85 (t, J = 6.0 Hz, 2H), 2.67 (s, 3H), 2.50 (s, 3H), 2.34-2.26 (m, 2H).

281		561.0	¹H-NMR (400 MHz, DMSO-d₆): δ 7.79-7.77 (m, 2H), 7.63-7.57 (m, 5H), 7.37-7.31 (m, 1H), 7.30-7.27 (m, 1H), 5.70 (s, 1H), 4.19 (t, J = 6.0 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.46 (s, 3H), 2.33-2.27 (m, 2H), 1.57 (s, 6H).

282		575.1	¹H-NMR (400 MHz, DMSO-d₆): δ 7.78-7.75 (m, 2H), 7.58-7.51 (m, 5H), 7.28 (dd, J = 2.4, 9.6 Hz, 1H), 5.74 (s, 1H), 4.19 (t, J = 6.0 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.53 (s, 6H), 2.47 (t, J = 8.4 Hz, 2H), 1.59 (s, 6H).

283		577.1	¹H-NMR (400 MHz, DMSO-d6) 7.77 (d, J = 2.00 Hz, 2H), 7.58 (d, J = 2.00 Hz, 4H), 4.19 (t, J = 6.00 Hz, 2H), 3.86 (t, J = 6.00 Hz, 2H), 2.46 (s, 6H), 2.26 (s, 2H), 1.84 (s, 3H), 1.79 (s, 3H).

284		563.1	¹H-NMR (400 MHz, DMSO-d₆): δ 7.81-7.78 (m, 2H), 7.71 (dd, J = 2.4, 9.2 Hz, 1H), 7.60- 7.54 (m, 5H), 7.39 (dd, J = 2.4, 10.0 Hz, 1H), 4.19 (t, J = 6.0 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 2.46 (s, 3H), 2.26 (t, J = 5.6 Hz, 2H), 1.85 (s, 3H), 1.80 (s, 3H).

285		485.1	1H-NMR (400 MHz, DMSO-d6): δ 8.06 (d, J = 8.00 Hz, 1H), 7.84 (d, J = 5.60 Hz, 1H), 7.64 (d, J = 8.80 Hz, 2H), 7.48-7.56 (m, 4H), 7.43-7.42 (m, 2H), 7.43 (d, J = 1.20 Hz, 1H), 4.20-4.17 (m, 2H), 3.88-3.85 (m, 2H), 2.50 (s, 3H), 2.31-2.26 (m, 2H)

286		512.1	1H-NMR (400 MHz, DMSO-d6): δ 8.01 (d, J = 7.60 Hz, 1H), 7.51-7.42 (m, 4H), 7.36-7.30 (m, 3H), 4.22-4.19 (m, 2H), 3.80-3.77 (m, 2H), 2.54 (s, 3H), 2.27-2.24 (m, 2H)

287		551.1(	¹H-NMR (400 MHz, DMSO-d₆): δ 8.34 (s, 1H), 8.22 (s, 1H), 7.85 (d, J = 1.60 Hz, 2H), 7.59 (d, J = 1.60 Hz, 4H), 7.52 (s, 1H), 4.21 (s, 5H), 3.87 (t, J = 5.60 Hz, 2H), 2.33 (s, 3H), 2.28-2.25 (m, 2H)

288		484.1	1H-NMR (400 MHz, DMSO-d6): δ 9.20 (s, 1H), 8.45 (s, 1H), 8.37 (s, 1H), 7.88 (d, J = 8.80 Hz, 2H), 7.60-7.58 (m, 4H), 4.25 (s, 3H), 4.20-4.19 (m, 3H), 3.88-3.85 (m, 2H), 2.51 (s, 3H), 2.33- 2.28 (m, 2H)

289		551.4	¹H-NMR (400 MHz, DMSO-d₆): δ 8.76 (s, 1H), 8.07 (s, 1H), 7.84 (d, J = 8.40 Hz, 2H), 7.57 (d, J = 8.80 Hz, 4H), 7.37 (d, J = 1.20 Hz, 1H), 4.27 (s, 3H), 4.21-4.18 (m, 2H), 3.86 (t, J = 6.00 Hz, 2H), 2.46 (s, 3H), 2.26 (t, J = 6.00 Hz, 2H)

290		575.1	1H-NMR (400 MHz, DMSO-d6): δ 8.58 (s, 1H), 8.15 (s, 1H), 7.62 (d, J = 2.00 Hz, 2H), 7.58- 7.53 (m, 4H), 7.45 (d, J = 1.20 Hz, 1H), 4.20-4.02 (m, 2H), 3.98 (s, 3H), 3.86-3.39 (m, 2H), 2.50 (s, 3H), 2.34-2.33 (m, 2H)

291		514.2	1H-NMR (400 MHz, DMSO-d6): δ 7.49 (d, J = 2.00 Hz, 2H), 7.44-7.42 (m, 4H), 7.31 (d, J = 2.00 Hz, 1H), 7.28 (s, 2H), 6.73 (d, J = 2.40 Hz, 1H), 6.74-6.71 (m, 2H), 3.86- 3.83 (m, 2H), 3.73 (s, 3H), 2.51 (s, 3H), 2.34- 2.25 (m, 2H),

292		580.0	1H-NMR (400 MHz, DMSO-d6): δ 7.88 (s, 1H), 7.49-7.54 (m, 7H), 7.10 (s, 1H), 4.75-4.72 (m, 1H), 4.20-4.18 (m, 4H), 3.91 (s, 3H), 3.88- 3.85 (m, 2H), 2.56 (s, 3H), 2.57-2.52 (m, 2H),

293		525.0	¹H-NMR (400 MHz, DMSO-d₆) 7.75 (d, J = 8.80 Hz, 2H), 7.61- 7.54 (m, 7H), 4.19 (t, J = 6.00 Hz, 2H), 3.93 (s, 3H), 3.85 (t, J = 4.80 Hz, 2H), 2.46 (s, 3H), 2.26 (d, J = 5.20 Hz, 2H).

294		525.1	1H-NMR (400 MHz, DMSO-d6): δ 8.36 (s, 1H), 7.63-7.51 (m, 7H), 7.12 (d, J = 1.60 Hz, 1H), 4.20-4.17 (m, 2H), 3.89 (s, 3H), 3.86-3.83 (m, 2H), 2.51 (s, 3H), 2.05- 2.08 (m, 2H),

295		518.1	1H-NMR (400 MHz, DMSO-d6): δ 7.62-7.58 (m, 4H), 7.50-7.46 (m, 3H), 7.41 (d, J = 2.40 Hz, 1H), 6.98 (d, J = 2.40 Hz, 1H), 4.19-4.16 (m, 2H), 3.86-3.83 (m, 2H), 3.75 (s, 3H), 2.46 (s, 3H), 2.34-2.25 (m, 2H),

296		512.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (d, J = 8.3 Hz, 2H), 7.58-7.51 (m, 2H), 7.45 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 2.9 Hz, 1H), 7.02 (d, J = 7.8 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.49 (d, J = 2.9 Hz, 1H), 4.18 (t, J = 5.9 Hz, 2H), 4.04 (s, 3H), 3.93 (s, 3H), 3.86-3.79 (m, 2H), 2.45 (s, 3H), 2.29-2.19 (m, 2H).

297		568.1	1H-NMR (400 MHz, DMSO-d6): δ 7.97 (d, J = 2.00 Hz, 1H), 7.74 (d, J = 2.00 Hz, 1H), 7.63 (d, J = 3.20 Hz, 2H), 7.65 (d, J = 2.80 Hz, 2H), 7.55 (d, J = 23.20 Hz, 2H), 7.30 (d, J = 0.80 Hz, 1H), 4.20- 4.17 (m, 2H), 3.89 (s, 3H), 3.87-3.84 (m, 2H), 2.52 (s, 3H), 2.34-2.27 (m, 2H),

298		560.1	1H-NMR (400 MHz, DMSO-d6): δ 7.74 (d, J = 2.00 Hz, 1H), 7.72-7.71 (m, 2H), 7.58-7.51 (m, 4H), 7.10 (d, J = 2.00 Hz, 1H), 4.19-4.16 (m, 2H), 3.93 (s, 3H), 3.87-3.85 (m, 2H), 2.51 (s, 3H), 2.51 (m, 2H),

299		536.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.05 (t, J = 59.6 Hz, 1H), 7.77-7.68 (m, 3H), 7.59-7.53 (m, 5H), 7.23 (dd, J = 1.9, 10.4 Hz, 1H), 6.80 (d, J = 3.5 Hz, 1H), 4.18 (t, J = 5.6 Hz, 2H), 3.85 (t, J = 5.2 Hz, 2H), 2.45 (s, 3H), 2.31-2.19 (m, 2H)

300		507.0	¹H NMR (400 MHz, DMSO-d₆) δ 7.77-7.68 (m, 2H), 7.58-7.54 (m, 4H), 7.28 (d, J = 7.8 Hz, 1H), 6.70 (d, J = 3.0 Hz, 1H), 4.17-4.16 (m, 2H), 4.13 (s, 3H), 3.88-3.82 (m, 2H), 2.45 (s, 3H), 2.29-2.18 (m, 2H). [NH₂ not observed]

301		512.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.75-7.66 (m, 2H), 7.57 (s, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 3.3 Hz, 1H), 7.01 (d, J = 1.6 Hz, 1H), 6.79 (d, J = 2.1 Hz, 1H), 6.46 (dd, J = 0.6, 3.3 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.86 (s, 3H), 3.85- 3.81 (m, 2H), 3.78 (s, 3H), 2.45 (s, 3H), 2.31- 2.17 (m, 2H)

302		507.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.15-8.08 (m, 1H), 7.80-7.69 (m, 3H), 7.60-7.42 (m, 5H), 6.73-6.66 (m, 1H), 4.24- 4.12 (m, 2H), 3.92 (s, 3H), 3.87-3.81 (m, 2H), 2.46 (s, 3H), 2.30-2.20 (m, 2H).

303		516.9	¹H NMR (400 MHz, DMSO-d₆) δ 8.07-7.97 (m, 2H), 7.62-7.44 (m, 6H), 4.24-4.13 (m, 2H), 3.97 (s, 3H), 3.91-3.80 (m, 2H), 2.46 (s, 3H), 2.32-2.21 (m, 2H)

304		512.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.87 (d, J = 1.3 Hz, 1H), 8.19 (d, J = 1.3 Hz, 1H), 8.09 (d, J = 8.7 Hz, 2H), 7.62-7.55 (m, 4H), 4.18 (t, J = 6.1 Hz, 2H), 3.87 (t, J = 5.3 Hz, 2H), 2.45 (s, 3H), 2.30-2.21 (m, 2H)

305		486.0	¹H NMR (400 MHz, DMSO-d₆) δ 8.02-7.97 (m, 1H), 7.88-7.80 (m, 3H), 7.69-7.63 (m, 2H), 7.59-7.53 (m, 3H), 7.42- 7.35 (m, 1H), 4.23- 4.15 (m, 2H), 3.91-3.84 (m, 2H), 2.45 (s, 3H), 2.31-2.22 (m, 2H).

306		522.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.86 (d, J = 8.5 Hz, 2H), 7.68-7.57 (m, 6H), 4.18 (t, J = 5.9 Hz, 2H), 3.87 (t, J = 5.5 Hz, 2H), 2.46 (s, 3H), 2.29-2.22 (m, 2H).

307		522.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.82-7.70 (m, 2H), 7.63-7.58 (m, 2H), 7.56 (s, 2H), 7.45- 7.27 (m, 1H), 7.13-7.00 (m, 1H), 4.16 (t, J = 5.7 Hz, 2H), 3.86 (t, J = 4.8 Hz, 2H), 2.44 (s, 3H), 2.29-2.18 (m, 2H).

308		539.8	¹H NMR (400 MHz, DMSO-d₆) δ 7.94-7.71 (m, 3H), 7.67-7.51 (m, 4H), 4.23-4.08 (m, 2H), 3.91-3.78 (m, 2H), 2.28- 2.17 (m, 2H). [Note: -Methyl proton merged in solvent peak]

309		562.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.11 (s, 1H), 7.97-7.88 (m, 4H), 7.87- 7.74 (m, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.57 (s, 2H), 7.55-7.47 (m, 2H), 7.47-7.38 (m, 1H), 4.22- 4.14 (m, 2H), 3.92- 3.83 (m, 2H), 2.47 (s, 3H), 2.30-2.21 (m, 2H).

310		486.3	¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (dd, J = 8.3, 17.1 Hz, 2H), 7.95 (d, J = 7.9 Hz, 2H), 7.73- 7.51 (m, 6H), 4.24-4.12 (m, 2H), 3.94-3.80 (m, 2H), 2.45 (s, 3H), 2.30- 2.22 (m, 2H).

311		522.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.47 (s, 1H), 7.73-7.61 (m, 2H), 7.61- 7.37 (m, 5H), 4.32- 4.20 (m, 2H), 3.96-3.84 (m, 2H), 2.37-2.24 (m, 2H), [Note: -CH₃ merged with solvent peak, not observed]

312		486.3	¹H NMR (400 MHz, DMSO-d₆) δ 9.19 (s, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.81-7.76 (m, 2H), 7.69- 7.48 (m, 6H), 4.31- 4.22 (m, 2H), 3.97-3.88 (m, 2H), 2.46 (s, 3H), 2.34-2.30 (m, 2H)

313		519.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.08 (d, J = 7.8 Hz, 2H), 7.99-7.89 (m, 2H), 7.62-7.50 (m, 4H), 4.31-4.23 (m, 2H), 3.90-3.80 (m, 2H), 2.46 (s, 3H), 2.06-1.96 (m, 2H), 1.91-1.81 (m, 2H).

314		491.3	¹H NMR (400 MHz, DMSO-d₆) δ 8.15 (d, J = 8.9 Hz, 2H), 7.95-7.89 (m, 2H), 7.85 (d, J = 8.8 Hz, 2H), 7.67 (s, 2H), 4.18 (s, 4H), 2.47 (s, 3H).

315		461.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.63-7.53 (m, 5H), 7.52-7.46 (m, 2H), 7.46-7.40 (m, 1H), 7.39-7.27 (m, 2H), 4.43- 4.34 (m, 1H), 3.81- 3.73 (m, 1H), 3.71-3.57 (m, 2H), 2.45 (s, 3H), 1.12 (d, J = 6.6 Hz, 3H). [Note: one proton not observed]

316		460.1	¹H NMR (400 MHz, CD₃OD-d₄) δ 7.66-7.56 (m, 2H), 7.53-7.42 (m, 3H), 7.42-7.33 (m, 1H), 7.29-7.15 (m, 2H), 4.56- 4.48 (m, 1H), 3.84- 3.58 (m, 3H), 2.59-2.49 (m, 4H), 1.21 (d, J = 6.4 Hz, 3H). [Note: -NH₂ protons not observed].

317	Single enantiomer, arbitrarily assigned stereochemistry	460.1	¹H NMR (400 MHz, CD₃OD-d₄) δ 7.61 (d, J = 7.8 Hz, 2H), 7.53-7.42 (m, 3H), 7.41-7.33 (m, 1H), 7.30-7.14 (m, 2H), 4.56-4.48 (m, 1H), 3.84- 3.58 (m, 3H), 2.59- 2.49 (m, 4H), 1.21 (d, J = 6.4 Hz, 3H). [Note: -NH₂ protons not observed].

318		479.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.64-7.57 (m, 2H), 7.57-7.45 (m, 4H), 7.44-7.32 (m, 2H), 7.30-7.20 (m, 1H), 4.40- 4.32 (m, 1H), 3.78- 3.70 (m, 1H), 3.68-3.55 (m, 2H), 2.42 (s, 3H), 1.09 (d, J = 5.9 Hz, 3H). [Note: -One proton merged in solvent peak]

319	Single enantiomer, arbitrarily assigned stereochemistry	479.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (d, J = 8.3 Hz, 2H), 7.56 (brs, 2H), 7.53-7.48 (m, 2H), 7.47-7.35 (m, 2H), 7.33- 7.23 (m, 1H), 4.43- 4.35 (m, 1H), 3.80-3.73 (m, 1H), 3.70-3.57 (m, 2H), 2.45 (s, 3H), 1.12 (d, J = 6.4 Hz, 3H). [Note: -one proton merged in solvent peak].

320	Single enantiomer, arbitrarily assigned stereochemistry	479.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (d, J = 6.8 Hz, 2H), 7.56 (brs, 2H), 7.53-7.47 (m, 2H), 7.46-7.34 (m, 2H), 7.31- 7.22 (m, 1H), 4.44- 4.33 (m, 1H), 3.83-3.73 (m, 1H), 3.69-3.55 (m, 2H), 2.45 (s, 3H), 1.11 (d, J = 5.2 Hz, 3H). [Note: -one proton merged in solvent peak].

321		477.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.60-7.53 (m, 3H), 7.49-7.37 (m, 7H), 4.42-4.32 (m, 1H), 3.81-3.72 (m, 1H), 3.69- 3.56 (m, 2H), 2.43 (s, 3H), 1.10 (d, J = 6.5 Hz, 3H). [Note: -One proton merged in solvent peak].

322	Single enantiomer, arbitrarily assigned stereochemistry	477.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.61-7.55 (m, 1H), 7.51-7.38 (m, 9H), 4.38 (dd, J = 3.3, 12.6 Hz, 1H), 3.77 (dd, J = 2.7, 11.6 Hz, 1H), 3.70- 3.58 (m, 2H), 2.44 (s, 3H), 1.12 (d, J = 6.6 Hz, 3H). [Note: One proton merged in solvent peak]

323	Single enantiomer, arbitrarily assigned stereochemistry	477.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.60-7.56 (m, 1H), 7.51-7.38 (m, 9H), 4.38 (dd, J = 4.9, 12.0 Hz, 1H), 3.80-3.73 (m, 1H), 3.69-3.57 (m, 2H), 2.44 (s, 3H), 1.12 (d, J = 6.8 Hz, 3H). [Note: One proton merged in solvent peak].

324	Single enantiomer, arbitrarily assigned stereochemistry	459.2	¹H NMR (400 MHz, CD₃OD-d₄) δ 7.66-7.56 (m, 2H), 7.53-7.42 (m, 3H), 7.42-7.33 (m, 1H), 7.29-7.15 (m, 2H), 4.56- 4.48 (m, 1H), 3.84- 3.58 (m, 3H), 2.59-2.49 (m, 4H), 1.21 (d, J = 6.4 Hz, 3H). [Note: -NH₂ protons not observed].

325	Single enantiomer, arbitrarily assigned stereochemistry	459.2	¹H NMR (400 MHz, CD₃OD-d₄) δ 7.61 (d, J = 7.8 Hz, 2H), 7.53-7.42 (m, 3H), 7.41-7.33 (m, 1H), 7.30-7.14 (m, 2H), 4.56-4.48 (m, 1H), 3.84- 3.58 (m, 3H), 2.59- 2.49 (m, 4H), 1.21 (d, J = 6.4 Hz, 3H). [Note: -NH₂ protons not observed].

326		443.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.81-7.71 (m, 4H), 7.64 (s, 2H), 7.59-7.50 (m, 4H), 7.47- 7.42 (m, 1H), 4.49- 4.41 (m, 1H), 3.85-3.78 (m, 1H), 3.76-3.62 (m, 2H), 2.51 (s, 3H), 1.18 (d, J = 6.6 Hz, 3H). [Note: -One proton merged in solvent peak]

327	Single enantiomer, arbitrarily assigned stereochemistry	443.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.73-7.66 (m, 4H), 7.54-7.44 (m, 6H), 7.41-7.35 (m, 1H), 4.42-4.34 (m, 1H), 3.79- 3.72 (m, 1H), 3.69- 3.56 (m, 2H), 2.44 (s, 3H), 1.11 (d, J = 6.6 Hz, 3H). [Note: -One proton merged in solvent peak].

328	Single enantiomer, arbitrarily assigned stereochemistry	443.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.73-7.64 (m, 4H), 7.56-7.44 (m, 6H), 7.41-7.33 (m, 1H), 4.42-4.34 (m, 1H), 3.80- 3.72 (m, 1H), 3.70- 3.55 (m, 2H), 2.44 (s, 3H), 1.11 (d, J = 6.6 Hz, 3H). [Note: -One proton merged in solvent peak]

329		491.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.54 (d, J = 7.9 Hz, 2H), 7.47-7.35 (m, 2H), 7.24-7.08 (m, 5H), 4.42-4.32 (m, 1H), 3.77 (s, 3H), 3.75-3.71 (m, 1H), 3.69-3.53 (m, 2H), 2.43 (s, 3H), 1.11 (d, J = 6.5 Hz, 3H). [Note: -One proton merged in solvent peak].

330	Single enantiomer, arbitrarily assigned stereochemistry	491.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.55-7.51 (m, 2H), 7.41 (d, J = 8.6 Hz, 2H), 7.21-7.07 (m, 5H), 4.41-4.32 (m, 1H), 3.77 (s, 3H), 3.76-3.71 (m, 1H), 3.68-3.55 (m, 2H), 2.42 (s, 3H), 1.11 (d, J = 6.6 Hz, 3H). [Note: -One proton merged in solvent peak].

331	Single enantiomer, arbitrarily assigned stereochemistry	491.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.54 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.21-7.06 (m, 5H), 4.41-4.31 (m, 1H), 3.77 (s, 3H), 3.74- 3.71 (m, 1H), 3.67-3.55 (m, 2H), 2.42 (s, 3H), 1.11 (d, J = 6.4 Hz, 3H). [Note: -One proton merged in solvent peak].

332		478.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J = 7.8 Hz, 2H), 7.54 (s, 2H), 7.50-7.35 (m, 4H), 7.33- 7.24 (m, 1H), 4.38- 4.27 (m, 1H), 4.20-4.04 (m, 2H), 2.45 (s, 3H), 2.10-2.02 (m, 2H), 1.16 (d, J = 6.4 Hz, 3H).

333	Single enantiomer, arbitrarily assigned stereochemistry	479.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J = 7.4 Hz, 2H), 7.55 (s, 2H), 7.49-7.35 (m, 4H), 7.33- 7.24 (m, 1H), 4.37- 4.26 (m, 1H), 4.19-4.04 (m, 2H), 2.45 (s, 3H), 2.40-2.37 (m, 1H), 2.11- 2.01 (m, 1H), 1.16 (d, J = 6.5 Hz, 3H).

334	Single enantiomer, arbitrarily assigned stereochemistry	479.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.62 (m, 2H), 7.55 (s, 2H), 7.50-7.36 (m, 4H), 7.34- 7.21 (m, 1H), 4.38- 4.27 (m, 1H), 4.20-4.03 (m, 2H), 2.45 (s, 3H), 2.42-2.34 (m, 1H), 2.10- 2.00 (m, 1H), 1.16 (d, J = 6.5 Hz, 3H).

335		447.0	¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 1H), 8.05 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.6 Hz, 2H), 7.61-7.56 (s, 2H), 4.01 (s, 2H), 3.72 (s, 2H), 2.43 (s, 3H), 0.87-0.74 (m, 4H)

336		519.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.63-7.57 (m, 2H), 7.56-7.50 (m, 2H), 7.49-7.32 (m, 4H), 7.30-7.21 (m, 1H), 3.99 (s, 2H), 3.64 (s, 2H), 2.43 (s, 3H), 1.74-1.54 (m, 8H).

337		540.3	¹H NMR (400 MHz, DMSO-d₆) δ 9.47 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.8 Hz, 2H), 7.73-7.66 (m, 1H), 7.65- 7.52 (m, 5H), 4.03 (s, 2H), 3.70 (s, 2H), 2.45 (s, 3H), 1.76-1.57 (m, 8H).

338		548.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.62 (m, 4H), 7.53 (dd, J = 2.00, 6.80 Hz, 2H), 7.49- 7.46 (m, 1H), 7.45-7.38 (m, 1H), 7.32-7.27 (m, 1H), 4.41 (d, J = 12.40 Hz, 1H), 4.30 (d, J= 12.40 Hz, 1H), 4.15-4.06 (m, 2H), 4.03-3.98 (m, 2H), 3.82 (s, 2H), 2.47 (s, 3H), 1.78 (s, 3H),

339		507.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J = 8.0 Hz, 2H), 7.60 (br s, 2H), 7.55-7.49 (m, 2H), 7.49-7.44 (m, 1H), 7.44- 7.34 (m, 1H), 7.34- 7.25 (m, 1H), 4.55 (s, 4H), 4.47-4.40 (s, 2H), 4.08 (s, 2H). [Note: -Methyl merged in solvent peak]

340		546.8	¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (d, J = 8.6 Hz, 2H), 7.99-7.92 (m, 2H), 7.60 (d, J = 8.7 Hz, 4H), 4.57 (s, 4H), 4.46 (s, 2H), 4.12 (s, 2H). [Note: -CH₃merged in solvent peak]

341		531.0	1H-NMR (400 MHz, DMSO-d6): δ 8.19 (d, J = 8.80 Hz, 2H), 7.99-7.95 (m, 2H), 7.65-7.62 (m, 4H), 4.57 (s, 4H), 4.46 (s, 2H), 4.13 (s, 2H), 2.51 (s, 3H)

342		623.0	1H-NMR (400 MHz, DMSO-d6): δ 8.76 (d, J = 1.60 Hz, 1H), 8.47 (s, 1H), 8.39 (s, 1H), 8.06- 7.76 (m, 2H), 7.70 (d, J = 6.80 Hz, 2H), 7.61-7.54 (m, 4H), 7.41-7.38 (m, 1H), 4.57 (s, 4H), 4.45 (s, 2H), 4.10 (s, 2H), 2.51 (s, 3H).

343	Single enantiomer, arbitrarily assigned stereochemistry	523.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (d, J = 7.8 Hz, 2H), 7.59-7.34 (m, 6H), 7.33-7.24 (m, 1H), 4.78 (s, 1H), 4.62- 4.52 (m, 1H), 3.90-3.80 (m, 1H), 3.79-3.65 (m, 2H), 2.46 (s, 3H), 2.39- 2.28 (m, 1H), 1.20 (d, J = 10.4 Hz, 6H).

344	Single enantiomer, arbitrarily assigned stereochemistry	523.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.65-7.61 (m, 2H), 7.60-7.49 (m, 4H), 7.48-7.36 (m, 2H), 7.33-7.23 (m, 1H), 4.78 (s, 1H), 4.60-4.53 (m, 1H), 3.89-3.81 (m, 1H), 3.79-3.66 (m, 2H), 2.46 (s, 3H), 2.39-2.29 (m, 1H), 1.20 (d, J = 10.4 Hz, 6H).

345		553.2	¹H NMR (400 MHz, CD₃OD-d₄) δ 7.63-7.57 (m, 2H), 7.51-7.43 (m, 2H), 7.06-6.94 (m, 2H), 4.77-4.65 (m, 1H), 4.58 (s, 1H), 3.95-3.75 (m, 3H), 3.66 (s, 3H), 2.53 (s, 3H), 2.50-2.36 (m, 1H), 1.33 (s, 6H).

346	Single enantiomer, arbitrarily assigned stereochemistry	553.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.62-7.54 (m, 4H), 7.53-7.47 (m, 2H), 7.41-7.33 (m, 1H), 7.17-7.11 (m, 1H), 4.77 (s, 1H), 4.61-4.53 (m, 1H), 3.89-3.82 (m, 2H), 3.78-3.70 (m, 2H), 3.67 (s, 3H), 2.49 (s, 3H), 1.23- 1.17 (m, 6H).

347	Single enantiomer, arbitrarily assigned stereochemistry	553.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.62-7.54 (m, 4H), 7.53-7.47 (m, 2H), 7.41-7.33 (m, 1H), 7.17-7.11 (m, 1H), 4.77 (s, 1H), 4.61-4.53 (m, 1H), 3.89-3.82 (m, 2H), 3.78-3.70 (m, 2H), 3.67 (s, 3H), 2.49 (s, 3H), 1.23- 1.17 (m, 6H).

348		544.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.05-7.76 (m, 4H), 7.71-7.47 (m, 5H), 7.43-7.32 (m, 1H), 4.84-4.79 (m, 1H), 4.57 (d, J = 9.3 Hz, 1H), 3.90 (t, J = 10.5 Hz, 1H), 3.82- 3.70 (m, 2H), 1.22 (d, J = 8.8 Hz, 6H). [Note: Methyl merged in solvent peak]

349		515.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.62 (m, 2H), 7.60 (br s, 2H), 7.56-7.37 (m, 4H), 7.32- 7.25 (m, 1H), 6.64- 6.27 (m, 1H), 4.42-4.34 (m, 1H), 4.23-4.12 (m, 1H), 4.06-3.95 (m, 1H), 3.91-3.82 (m, 1H), 3.13- 3.00 (m, 1H), 2.46 (s, 3H)

350	Single enantiomer, arbitrarily assigned stereochemistry	515.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.66-7.62 (m, 2H), 7.60 (s, 2H), 7.56-7.37 (m, 4H), 7.34- 7.24 (m, 1H), 6.62- 6.26 (m, 1H), 4.42-4.34 (m, 1H), 4.23-4.12 (m, 1H), 4.04-3.97 (m, 1H), 3.91-3.82 (m, 1H), 3.15- 2.97 (m, 1H), 2.46 (s, 3H)

351	Single enantiomer, arbitrarily assigned stereochemistry	525.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.66-7.61 (m, 2H), 7.59 (s, 2H), 7.56-7.51 (m, 2H), 7.49- 7.36 (m, 2H), 7.34- 7.23 (m, 1H), 4.59-4.52 (m, 1H), 3.95-3.81 (m, 2H), 3.81-3.70 (m, 1H), 2.78-2.68 (m, 1H), 2.46 (s, 3H), 1.47 (d, J = 9.6 Hz, 3H), 1.42 (d, J = 9.6 Hz, 3H).

352	Single enantiomer, arbitrarily assigned stereochemistry	525.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.68-7.63 (m, 2H), 7.62 (s, 2H), 7.54-7.37 (m, 4H), 7.32- 7.26 (m, 1H), 4.47- 4.41 (m, 1H), 4.38-4.32 (m, 1H), 4.15-4.09 (m, 1H), 4.02-3.96 (m, 1H), 3.76-3.64 (m, 1H), 2.47 (s, 3H).

353		481.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.65-7.61 (m, 2H), 7.57 (s, 2H), 7.54-7.36 (m, 4H), 7.31- 7.25 (m, 1H), 6.63 (s, 1H), 5.61 (d, J = 2.9 Hz, 1H), 4.37-4.31 (m, 2H), 4.06-3.99 (m, 2H), 2.45 (s, 3H).

354	Single enantiomer, arbitrarily assigned stereochemistry	481.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.65-7.61 (m, 2H), 7.57 (s, 2H), 7.52-7.34 (m, 4H), 7.32- 7.25 (m, 1H), 5.62- 5.59 (m, 1H), 4.37-4.31 (m, 2H), 4.08-3.98 (m, 2H), 3.66-3.59 (m, 1H), 2.45 (s, 3H).

355	Single enantiomer, arbitrarily assigned stereochemistry	481.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.65-7.61 (m, 2H), 7.57 (s, 2H), 7.52-7.34 (m, 4H), 7.32- 7.22 (m, 1H), 5.62- 5.59 (m, 1H), 4.38-4.30 (m, 2H), 4.09-3.97 (m, 2H), 3.67-3.59 (m, 1H), 2.45 (s, 3H).

356		495.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (d, J = 8.3 Hz, 2H), 7.57 (s, 2H), 7.53-7.35 (m, 4H), 7.35- 7.21 (m, 1H), 5.01- 4.94 (m, 1H), 4.42-4.32 (m, 1H), 3.90-3.77 (m, 2H), 3.77-3.66 (m, 1H), 3.60-3.52 (m, 2H), 2.45 (s, 3H). [Note: -One proton merged in solvent peak].

357		495.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.72-7.58 (m, 4H), 7.47-7.16 (m, 5H), 5.09-4.99 (m, 1H), 4.24 (t, J = 8.8 Hz, 1H), 3.92-3.87 (m, 3H), 3.12 (s, 3H), 2.33 (s, 3H).

358	Single enantiomer, arbitrarily assigned stereochemistry	495.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.73-7.57 (m, 4H), 7.48-7.31 (m, 4H), 7.29-7.18 (m, 1H), 5.09-4.98 (m, 1H), 4.30- 4.17 (m, 1H), 3.94-3.80 (m, 3H), 3.12 (s, 3H), 2.33 (s, 3H).

359	Single enantiomer, arbitrarily assigned stereochemistry	495.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.72-7.57 (m, 4H), 7.48-7.32 (m, 4H), 7.30-7.19 (m, 1H), 5.09-4.99 (m, 1H), 4.28- 4.19 (m, 1H), 3.93- 3.82 (m, 3H), 3.12 (s, 3H), 2.33 (s, 3H).

360		489.9	¹H NMR (400 MHz, DMSO-d₆) δ 7.67 (d, J = 7.8 Hz, 2H), 7.61 (s, 2H), 7.51-7.36 (m, 4H), 7.33- 7.24 (m, 1H), 4.71-4.62 (m, 1H), 4.27-4.16 (m, 2H), 4.06-3.96 (m, 2H), 2.47 (s, 3H).

361	Single enantiomer, arbitrarily assigned stereochemistry	490.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.70-7.64 (m, 2H), 7.59 (brs, 2H), 7.52-7.35 (m, 4H), 7.33- 7.23 (m, 1H), 4.70- 4.61 (m, 1H), 4.26-4.16 (m, 2H), 4.05-3.98 (m, 2H), 2.47 (s, 3H).

362	Single enantiomer, arbitrarily assigned stereochemistry	490.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.71-7.63 (m, 2H), 7.59 (s, 2H), 7.52-7.35 (m, 4H), 7.34- 7.24 (m, 1H), 4.71- 4.61 (m, 1H), 4.27-4.14 (m, 2H), 4.05-3.95 (m, 2H), 2.47 (s, 3H).

363		483.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.69-7.56 (m, 4H), 7.54-7.33 (m, 4H), 7.33-7.24 (m, 1H), 5.63-5.38 (m, 1H), 4.78- 4.64 (m, 1H), 4.36-3.90 (m, 3H), 2.46 (s, 3H).

364	Single enantiomer, arbitrarily assigned stereochemistry	483.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.69-7.64 (m, 2H), 7.60 (s, 2H), 7.55-7.36 (m, 4H), 7.32- 7.24 (m, 1H), 5.51 (d, J = 45.6 Hz, 1H), 4.80- 4.63 (m, 1H), 4.36-4.13 (m, 2H), 4.12-3.91 (m, 1H). [Note: -CH₃ merged in solvent peak].

365	Single enantiomer, arbitrarily assigned stereochemistry	483.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.68-7.63 (m, 2H), 7.61 (s, 2H), 7.52-7.37 (m, 4H), 7.32- 7.23 (m, 1H), 5.51 (d, J = 46.8 Hz, 1H), 4.78- 4.64 (m, 1H), 4.36-4.13 (m, 2H), 4.12-3.91 (m, 1H), 2.46 (s, 3H).

366		511.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.64-7.58 (m, 4H), 7.50-7.44 (m, 2H), 7.41-7.34 (m, 1H), 7.15 (d, J = 8.1 Hz, 1H), 5.60-5.42 (m, 1H), 4.71 (t, J = 11.2 Hz, 1H), 4.37- 4.03 (m, 2H), 4.02- 3.90 (m, 1H), 3.68 (s, 3H), 2.46 (s, 3H).

367		501.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.70-7.64 (m, 4H), 7.51 (d, J = 8.3 Hz, 2H), 7.48-7.35 (m, 2H), 7.33-7.24 (m, 1H), 4.60 (t, J = 12.5 Hz, 2H), 4.36 (t, J = 11.7 Hz, 2H), 2.47 (s, 3H).

368		533.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.68-7.61 (m, 4H), 7.52-7.37 (m, 4H), 7.32-7.25 (m, 1H), 4.44 (dd, J = 4.9, 13.1 Hz, 1H), 4.40-4.30 (m, 1H), 4.15-4.08 (m, 1H), 4.03-3.96 (m, 1H), 3.76- 3.65 (m, 1H), 2.46 (s, 3H)

369		525.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.66-7.60 (m, 2H), 7.58 (s, 2H), 7.56-7.51 (m, 2H), 7.49- 7.36 (m, 2H), 7.33- 7.23 (m, 1H), 4.55 (dd, J = 3.1, 12.6 Hz, 1H), 3.93- 3.82 (m, 2H), 3.78- 3.71 (m, 1H), 2.79-2.68 (m, 1H), 2.46 (s, 3H), 1.47 (d, J = 9.9 Hz, 3H), 1.42 (d, J = 9.9 Hz, 3H)

370	Single enantiomer, arbitrarily assigned stereochemistry	515.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.62 (m, 2H), 7.60 (s, 2H), 7.54-7.48 (m, 2H), 7.48- 7.36 (m, 2H), 7.34- 7.24 (m, 1H), 6.60-6.25 (m, 1H), 4.42-4.33 (m, 1H), 4.22-4.14 (m, 1H), 4.03-3.96 (m, 1H), 3.91- 3.84 (m, 1H), 3.13- 3.00 (m, 1H), 2.46 (s, 3H).

371	Single enantiomer, arbitrarily assigned stereochemistry	533.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.68-7.63 (m, 2H), 7.62 (s, 2H), 7.54-7.37 (m, 4H), 7.32- 7.26 (m, 1H), 4.47- 4.41 (m, 1H), 4.38-4.32 (m, 1H), 4.15-4.09 (m, 1H), 3.99 (dd, J = 6.8, 12.2 Hz, 1H), 3.75-3.67 (m, 1H), 2.47 (s, 3H).

372		563.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.61 (d, J = 8.4 Hz, 4H), 7.47 (d, J = 8.5 Hz, 2H), 7.43-7.35 (m, 1H), 7.20-7.11 (m, 1H), 4.44 (dd, J = 4.9, 12.9 Hz, 1H), 4.39-4.31 (m, 1H), 4.15-4.08 (m, 1H), 4.03-3.96 (m, 1H), 3.68 (s, 3H), 2.46 (s, 3H). [Note: -One proton merged in solvent peak]

373	Single enantiomer, arbitrarily assigned stereochemistry	563.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.64-7.59 (m, 4H), 7.47 (d, J = 8.6 Hz, 2H), 7.41-7.34 (m, 1H), 7.15 (dd, J = 1.9, 9.2 Hz, 1H), 4.45 (dd, J = 5.1, 13.2 Hz, 1H), 4.39- 4.32 (m, 1H), 4.12 (dd, J = 4.6, 12.2 Hz, 1H), 3.99 (dd, J = 6.5, 12.0 Hz, 1H), 3.77-3.69 (m, 1H), 3.68 (s, 3H), 2.47 (s, 3H).

374	Single enantiomer, arbitrarily assigned stereochemistry	563.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.65-7.57 (m, 4H), 7.47 (d, J = 8.6 Hz, 2H), 7.42-7.34 (m, 1H), 7.17-7.12 (m, 1H), 4.44 (dd, J = 4.9, 13.1 Hz, 1H), 4.39-4.32 (m, 1H), 4.15-4.08 (m, 1H), 4.03-3.96 (m, 1H), 3.78- 3.69 (m, 1H), 3.68 (s, 3H), 2.47 (s, 3H).

375		531.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (s, 2H), 7.65-7.59 (m, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.46- 7.32 (m, 1H), 7.18-7.11 (m, 1H), 4.60 (t, J = 12.7 Hz, 2H), 4.36 (t, J = 11.8 Hz, 2H), 3.68 (s, 3H), 2.47 (s, 3H)

376	Single enantiomer, arbitrarily assigned stereochemistry	490.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.70-7.64 (m, 2H), 7.59 (brs, 2H), 7.52-7.35 (m, 4H), 7.33- 7.23 (m, 1H), 4.70- 4.61 (m, 1H), 4.26-4.16 (m, 2H), 4.05-3.98 (m, 2H), 2.47 (s, 3H).

377	Single enantiomer, arbitrarily assigned stereochemistry	490.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.71-7.63 (m, 2H), 7.59 (s, 2H), 7.52-7.35 (m, 4H), 7.34- 7.24 (m, 1H), 4.71- 4.61 (m, 1H), 4.27-4.14 (m, 2H), 4.05-3.95 (m, 2H), 2.47 (s, 3H).

378		519.1	1H-NMR (400 MHz, DMSO-d6) δ 7.60-7.56 (m, 3H), 7.44 (dd, J = 2.00, 6.80 Hz, 2H), 7.22- 7.20 (m, 2H), 7.19-7.13 (m, 2H), 4.56 (s, 4H), 4.44 (s, 2H), 4.07 (s, 2H), 3.79 (s, 3H), 2.50 (s, 3H)

379		490.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.71 (dd, J = 5.7, 9.2 Hz, 1H), 8.19 (d, J = 8.6 Hz, 2H), 7.97 (dd, J = 2.3, 11.1 Hz, 1H), 7.59 (s, 2H), 7.57-7.50 (m, 2H), 7.35-7.24 (m, 1H), 4.56 (s, 4H), 4.44 (s, 2H), 4.09 (s, 2H), 2.48 (s, 3H).

380		509.3	¹H NMR (400 MHz, DMSO-d₆) δ 13.13 (brs, 1H), 7.63 (d, J = 7.4 Hz, 2H), 7.60-7.54 (m, 2H), 7.52-7.36 (m, 4H), 7.32- 7.24 (m, 1H), 4.52- 4.42 (m, 1H), 4.28-4.20 (m, 1H), 4.06-3.93 (m, 2H), 3.47-3.38 (m, 1H), 2.46 (s, 3H).

381		508.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.71 (brs, 1H), 7.66-7.62 (m, 2H), 7.58 (s, 2H), 7.52-7.37 (m, 4H), 7.32-7.24 (m, 2H), 4.37-4.21 (m, 2H), 4.00 (d, J = 5.9 Hz, 2H), 3.27-3.20 (m, 1H), 2.46 (s, 3H).

382	Single enantiomer, arbitrarily assigned stereochemistry	508.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.70 (s, 1H), 7.63 (d, J = 7.8 Hz, 2H), 7.57 (s, 2H). 7.52-7.36 (m, 4H), 7.33-7.20 (m, 2H), 4.37-4.29 (m, 1H), 4.27-4.19 (m, 1H), 3.99 (d, J = 5.4 Hz, 2H), 3.26- 3.19 (m, 1H), 2.46 (s, 3H).

383	Single enantiomer, arbitrarily assigned stereochemistry	508.0	¹H NMR (400 MHz, DMSO-d₆) δ 7.70 (s, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.59-7.53 (m, 1H), 7.52- 7.35 (m, 5H), 7.32- 7.20 (m, 2H), 4.38-4.29 (m, 1H), 4.29-4.19 (m, 1H), 3.99 (d, J = 4.9 Hz, 2H), 3.26-3.19 (m, 1H), 2.46 (s, 3H).

384		523.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (d, J = 7.3 Hz, 2H), 7.58 (s, 2H), 7.49-7.36 (m, 4H), 7.33- 7.24 (m, 1H), 4.52- 4.43 (m, 1H), 4.34-4.26 (m, 1H), 4.13-4.06 (m, 1H), 4.03-3.96 (m, 1H), 3.71 (s, 3H), 3.66-3.58 (m, 1H), 2.47 (s, 3H)

385		481.1	¹H NMR (400 MHz, DMSO-d₆) δ 9.62 (s, 1H), 9.51 (s, 1H), 7.63 (d, J = 7.8 Hz, 2H), 7.54-7.49 (m, 2H), 7.48-7.35 (m, 2H), 7.32-7.23 (m, 1H), 4.19 (t, J = 5.6 Hz, 2H), 3.83 (t, J = 5.1 Hz, 2H), 2.29-2.20 (m, 2H). [Note: -CH₃merged in solvent peak].

386		494.9	¹H NMR (400 MHz, DMSO-d₆) δ 10.46 (s, 1H), 7.63 (d, J = 7.3 Hz, 2H), 7.55-7.49 (m, 2H), 7.48-7.36 (m, 2H), 7.33- 7.25 (m, 1H), 4.19 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.5 Hz, 2H), 3.67 (s, 3H), 2.28-2.21 (m, 2H). [Note: -CH₃merged in solvent peak].

387		523.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.91 (s, 1H), 7.65-7.60 (m, 2H), 7.53- 7.48 (m, 2H), 7.48- 7.42 (m, 1H), 7.42-7.36 (m, 1H), 7.31-7.24 (m, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.19 (s, 3H), 2.96 (t, J = 5.8 Hz, 2H), 2.45 (s, 3H), 2.27-2.19 (m, 2H). [Note: -Two protons merged in solvent peak].

388		509.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.80-7.73 (m, 1H), 7.65-7.59 (m, 2H), 7.53-7.49 (m, 2H), 7.48-7.35 (m, 2H), 7.32- 7.24 (m, 1H), 4.68 (t, J = 5.6 Hz, 1H), 4.17 (t, J = 6 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.39 (q, J = 6.4 Hz, 2H), 2.90-2.83 (m, 2H), 2.45 (s, 3H), 2.28- 2.20 (m, 2H).

389		537.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.77-7.69 (m, 1H), 7.62 (d, J = 7.3 Hz, 2H), 7.54-7.48 (m, 2H), 7.47-7.35 (m, 2H), 7.33-7.23 (m, 1H), 4.37 (t, J = 5.1 Hz, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.88- 3.74 (m, 2H), 3.41-3.33 (m, 2H), 2.88-2.73 (m, 2H), 2.45 (s, 3H), 2.28- 2.19 (m, 2H), 1.48-1.33 (m, 4H)

390		551.0	¹H NMR (400 MHz, DMSO-d₆) δ 7.78-7.70 (m, 1H), 7.63 (d, J = 7.1 Hz, 2H), 7.56-7.36 (m, 4H), 7.32-7.24 (m, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.82 (t, J = 5.4 Hz, 2H), 3.28-3.23 (m, 2H), 3.18 (s, 3H), 2.85-2.78 (m, 2H), 2.45 (s, 3H), 2.30- 2.17 (m, 2H), 1.55-1.35 (m, 4H).

391		525.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.84 (s, 1H), 7.63 (d, J = 7.1 Hz, 2H), 7.54-7.36 (m, 4H), 7.31- 7.24 (m, 1H), 4.51 (t, J = 5.7 Hz, 1H), 4.39 (t, J = 5.8 Hz, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.4 Hz, 2H), 2.92 (t, J = 6.7 Hz, 2H), 2.46 (s, 3H), 2.31-2.17 (m, 2H), 1.86- 1.71 (m, 2H).

392		559.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (brs, 1H), 7.63 (d, J = 7.1 Hz, 2H), 7.56-7.36 (m, 4H), 7.33-7.24 (m, 1H), 5.48 (t, J = 6.2 Hz, 1H), 4.17 (t, J = 5.7 Hz, 2H), 3.82 (t, J = 5.5 Hz, 2H), 3.65- 3.53 (m, 2H), 2.46 (s, 3H), 2.32-2.16 (m, 2H). [Note: -2H merged in solvent peak]

393		551.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.57 (m, 3H), 7.54-7.36 (m, 4H), 7.31-7.25 (m, 1H), 4.31 (s, 1H), 4.18 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.93-2.85 (m, 2H), 2.45 (s, 3H), 2.32-2.17 (m, 2H), 1.57- 1.48 (m, 2H), 1.04 (s, 6H).

394		537.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.72-7.65 (m, 1H), 7.65-7.60 (m, 2H), 7.57-7.36 (m, 4H), 7.36-7.20 (m, 1H), 4.48 (t, J = 5.2 Hz, 1H), 4.23- 4.11 (m, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.28-3.18 (m, 2H), 2.93-2.84 (m, 1H), 2.61-2.54 (m, 1H), 2.45 (s, 3H), 2.32-2.17 (m, 2H), 1.72-1.57 (m, 1H), 0.80 (d, J = 6.8 Hz, 3H).

395		537.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.72-7.66 (m, 1H), 7.66-7.59 (m, 2H), 7.56-7.36 (m, 4H), 7.36-7.20 (m, 1H), 4.48 (t, J = 5.2 Hz, 1H), 4.23- 4.11 (m, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.28-3.18 (m, 2H), 2.93-2.84 (m, 1H), 2.61-2.54 (m, 1H), 2.45 (s, 3H), 2.32-2.17 (m, 2H), 1.69-1.60 (m, 1H), 0.80 (d, J = 6.8 Hz, 3H).

396		537.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.71-7.66 (m, 1H), 7.65-7.59 (m, 2H), 7.56-7.36 (m, 4H), 7.33-7.23 (m, 1H), 4.48 (t, J = 5.2 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.28- 3.18 (m, 2H), 2.92-2.85 (m, 1H), 2.61-2.54 (m, 1H), 2.45 (s, 3H), 2.29- 2.20 (m, 2H), 1.71-1.59 (m, 1H), 0.80 (d, J = 6.8 Hz, 3H).

397		534.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (d, J = 7.2 Hz, 2H), 7.55-7.36 (m, 4H), 7.32-7.25 (m, 1H), 4.19 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.4 Hz, 2H), 3.38-3.35 (m, 2H), 3.24-3.15 (m, 1H), 2.88- 2.73 (m, 1H), 2.28- 2.21 (m, 2H), 1.93-1.82 (m, 2H), 1.54-1.45 (m, 1H) [Note: -CH₃and 2H merged in solvent peak]

398		534.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (d, J = 7.8 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.48-7.35 (m, 2H), 7.33-7.24 (m, 1H), 4.25-4.16 (m, 2H), 3.88-3.79 (m, 2H), 3.43- 3.34 (m, 2H), 3.24- 3.15 (m, 1H), 2.88-2.74 (m, 1H), 2.31-2.18 (m, 2H), 2.00-1.80 (m, 2H), 1.59-1.45 (m, 1H). [Note: -CH₃and 2H merged in solvent peak]

399		534.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.59 (m, 2H), 7.55-7.34 (m, 4H), 7.33-7.23 (m, 1H), 4.24-4.15 (m, 2H), 3.88- 3.78 (m, 2H), 2.98- 2.87 (m, 1H), 2.30-2.21 (m, 2H), 2.03-1.89 (m, 1H), 1.66-1.53 (m, 1H). [Note: -NH₂and -CH₃ merged in solvent peak]

400		549.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.81 (d, J = 7.7 Hz, 1H), 7.63 (d, J = 7.1 Hz, 2H), 7.53-7.49 (m, 2H), 7.48-7.35 (m, 2H), 7.31-7.25 (m, 1H), 4.47 (d, J = 3.7 Hz, 1H), 4.18 (t, J = 5.7 Hz, 2H), 4.11-4.04 (m, 1H), 3.82 (t, J = 5.6 Hz, 2H), 3.70- 3.64 (m, 1H), 2.45 (s, 3H), 2.29-2.19 (m, 2H), 1.88-1.75 (m, 2H), 1.67- 1.59 (m, 1H), 1.50-
			1.42 (m, 1H), 1.38-1.26
			(m, 2H).

401		549.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.83 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 7.1 Hz, 2H), 7.54-7.48 (m, 2H), 7.48-7.35 (m, 2H), 7.31-7.25 (m, 1H), 4.58 (d, J = 4.2 Hz, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.97-3.90 (m, 1H), 3.82 (t, J = 5.5 Hz, 2H), 3.50- 3.37 (m, 2H), 2.44 (s, 3H), 2.27-2.21 (m, 2H), 2.01-1.91 (m, 1H), 1.69- 1.40 (m, 3H), 1.30- 1.22 (m, 1H).

402		537.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (d, J = 7.1 Hz, 2H), 7.55-7.36 (m, 5H), 7.32-7.24 (m, 1H), 4.77 (t, J = 5.8 Hz, 1H), 4.17 (t, J = 5.8 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.21 (d, J = 6.0 Hz, 2H), 2.44 (s, 3H), 2.29- 2.18 (m, 2H), 1.08 (s, 6H).

403		547.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.65-7.62 (m, 2H), 7.53-7.37 (m, 4H), 7.31-7.25 (m, 1H), 4.57 (s, 4H), 4.21 (t, J = 5.9 Hz, 2H), 3.92 (s, 4H), 3.87-3.81 (m, 2H), 2.29- 2.21 (m, 2H). [Note: -Methyl merged in solvent peak]

404		535.3	¹H NMR (400 MHz, DMSO-d₆) δ 7.98-7.91 (m, 1H), 7.64-7.61 (m, 2H), 7.52-7.36 (m, 4H), 7.31-7.25 (m, 1H), 4.56 (dd, J = 6.2, 7.6 Hz, 2H), 4.21-4.16 (m, 4H), 3.82 (t, J = 5.5 Hz, 2H), 3.13- 3.06 (m, 2H), 3.06-2.92 (m, 1H), 2.46 (s, 3H), 2.28-2.19 (m, 2H)

405		480.1	¹H-NMR (400 MHz, DMSO-d6) 8.42 (s, 1H), 7.64 (d, J = 6.80 Hz, 2H), 7.51 (d, J = 8.40 Hz, 2H), 7.40- 7.46 (m, 2H), 7.30-7.29 (m, 1H), 4.19 (t, J = 5.60 Hz, 4H), 3.83 (t, J = 5.60 Hz, 2H) , 2.48 (s, 3H), 2.08 (s, 2H).

406		542.1	¹H NMR (400 MHz, DMSO-d₆) δ 8.06-7.94 (m, 1H), 7.82-7.68 (m, 1H), 7.62 (d, J = 7.6 Hz, 2H), 7.54-7.35 (m, 4H), 7.33-7.25 (m, 1H), 7.17- 7.08 (m, 1H), 6.93- 6.77 (m, 1H), 4.12 (t, J = 5.7 Hz, 2H), 3.84-3.71 (m, 2H), 2.46 (s, 3H), 2.24-2.17 (m, 2H). [Note: -NH proton not observed]

407		580.2	¹H NMR (400 MHz, DMSO-d₆) δ 11.04 (s, 1H), 10.10 (s, 1H), 7.60 (d, J = 7.1 Hz, 2H), 7.50- 7.35 (m, 5H), 7.31-7.21 (m, 3H), 6.79 (dd, J = 1.8, 8.4 Hz, 1H), 6.36- 6.30 (m, 1H), 4.07 (t, J = 5.9 Hz, 2H), 3.76 (t, J = 5.5 Hz, 2H), 2.28 (s, 3H), 2.23-2.12 (m, 2H)

408		488.6	¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (dd, J = 5.7, 8.8 Hz, 1H), 8.17 (d, J = 8.3 Hz, 2H), 8.02 (s, 1H), 7.99-7.91 (m, 1H), 7.53 (d, J = 8.3 Hz, 2H), 7.40-7.19 (m, 1H), 4.24- 4.14 (m, 2H), 3.89- 3.79 (m, 2H), 2.47 (s, 3H), 2.36-2.12 (m, 3H), 0.56-0.49 (m, 2H), 0.45- 0.40 (m, 2H).

409		488.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.56 (s, 1H), 8.03 (s, 1H), 7.97 (d, J = 7.8 Hz, 2H), 7.89-7.79 (m, 1H), 7.58-7.52 (m, 2H), 7.52-7.46 (m, 1H), 4.19 (t, J = 5.6 Hz, 2H), 3.89-3.79 (m, 2H), 2.47 (s, 3H), 2.29-2.17 (m, 3H), 0.56-0.49 (m, 2H), 0.46-0.37 (m, 2H).

410		485.2	¹H NMR (400 MHz, DMSO-d₆) δ 8.00 (d, J = 8.3 Hz, 3H), 7.55-7.34 (m, 3H), 7.07 (d, J = 7.0 Hz, 1H), 6.42 (d, J = 8.3 Hz, 1H), 5.97 (s, 2H), 4.26-4.11 (m, 2H), 3.88- 3.74 (m, 2H), 2.46 (s, 3H), 2.28-2.17 (m, 3H), 0.56-0.49 (m, 2H), 0.46- 0.38 (m, 2H).

411		508.9	¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 1H), 7.63-7.46 (m, 7H), 7.06 (d, J = 6.4 Hz, 1H), 6.71- 6.68 (m, 1H), 5.98 (s, 2H), 4.20 (t, J = 5.4 Hz, 2H), 3.87 (t, J = 4.4 Hz, 2H), 2.46 (s, 3H), 2.30- 2.23 (m, 2H). [Note: One -CH₃merged in solvent peak]

412		482.0	1H NMR (400 MHz, DMSO-d6): δ 7.63-7.58 (m, 3H), 7.57-7.51 (m, 2H), 7.37-7.29 (m, 4H), 4.24 (t, J = 6.40 Hz, 2H), 3.85 (t, J = 6.00 Hz, 2H), 2.55 (s, 3H), 2.50-2.27 (m, 2H),

413		527.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.81 (s, 1H), 7.65 (d, J = 7.1 Hz, 2H), 7.53-7.42 (m, 3H), 7.41- 7.36 (m, 1H), 7.32- 7.25 (m, 1H), 5.61-5.42 (m, 1H), 4.76-4.65 (m, 2H), 4.35-4.05 (m, 2H), 4.01-3.91 (m, 1H), 3.43- 3.35 (m, 2H), 2.88 (t, J = 6.4 Hz, 2H), 2.46 (s, 3H).

414	Single enantiomer, arbitrarily assigned stereochemistry	527.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.85-7.78 (m, 1H), 7.65 (dd, J = 1.5, 8.4 Hz, 2H), 7.53- 7.37 (m, 4H), 7.32-7.25 (m, 1H), 5.61-5.44 (m, 1H), 4.76-4.66 (m, 2H), 4.35-4.05 (m, 2H), 4.01- 3.90 (m, 1H), 3.43- 3.34 (m, 2H), 2.88 (q, J = 6.3 Hz, 2H), 2.46 (s, 3H).

415	Single enantiomer, arbitrarily assigned stereochemistry	527.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.86-7.78 (m, 1H), 7.65 (dd, J = 1.5, 8.6 Hz, 2H), 7.51- 7.37 (m, 4H), 7.37-7.21 (m, 1H), 5.65-5.42 (m, 1H), 4.76-4.66 (m, 2H), 4.42-4.03 (m, 2H), 4.01- 3.90 (m, 1H), 3.43- 3.35 (m, 2H), 2.88 (q, J = 6.4 Hz, 2H), 2.46 (s, 3H).

416		537.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.78-7.71 (m, 1H), 7.63 (dd, J = 1.4, 8.5 Hz, 2H), 7.51 (d, J = 8.6 Hz, 2H), 7.48- 7.42 (m, 1H), 7.42-7.35 (m, 1H), 7.32-7.25 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.30-3.28 (m, 2H), 3.17 (s, 3H), 2.92-2.80 (m, 2H), 2.45 (s, 3H), 2.30-2.18 (m, 2H), 1.62 (quin, J = 6.6 Hz, 2H).

417		523.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.70-7.58 (m, 3H), 7.56-7.35 (m, 4H), 7.35-7.21 (m, 1H), 4.43 (t, J = 4.9 Hz, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.82 (t, J = 5.4 Hz, 2H), 3.41-3.35 (m, 2H), 2.98- 2.76 (m, 2H), 2.45 (s, 3H), 2.29-2.20 (m, 2H), 1.55 (quin, J = 6.7 Hz, 2H)

418		563.5	¹H NMR (400 MHz, DMSO-d₆) δ 8.07 (d, J = 6.8 Hz, 2H), 7.97-7.87 (m, 2H), 7.71-7.63 (m, 1H), 7.57 (d, J = 6.8 Hz, 2H), 4.45-4.36 (m, 1H), 4.22-4.13 (m, 2H), 3.89- 3.80 (m, 2H), 3.40- 3.34 (m, 2H), 2.90-2.81 (m, 2H), 2.44 (s, 3H), 2.28-2.21 (m, 2H), 1.62- 1.44 (m, 2H).

419		577.3	¹H NMR (400 MHz, DMSO-d₆) δ 8.09 (d, J = 6.4 Hz, 2H), 7.96-7.91 (m, 2H), 7.77-7.68 (m, 1H), 7.59 (d, J = 6.8 Hz, 2H), 4.26-4.13 (m, 2H), 3.91-3.82 (m, 2H), 3.18 (s, 3H), 2.93-2.82 (m, 2H), 2.37-2.29 (m, 5H), 2.28-2.20 (m, 2H), 1.67- 1.57 (m, 2H).

420		621.6	¹H NMR (400 MHz, DMSO-d₆) δ 7.75-7.70 (m, 1H), 7.65-7.60 (m, 2H), 7.50 (d, J = 8.7 Hz, 2H), 7.47-7.36 (m, 2H), 7.32-7.24 (m, 1H), 4.29 (t, J = 5.2 Hz, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.39- 3.33 (m, 2H), 2.80 (q, J = 6.8 Hz, 2H), 2.45 (s, 3H), 2.27-2.20 (m, 2H), 1.43- 1.33 (m, 4H), 1.27- 1.16 (m, 12H).

421		635.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.74-7.66 (m, 1H), 7.65-7.57 (m, 2H), 7.54-7.31 (m, 4H), 7.30-7.21 (m, 1H), 4.20- 4.10 (m, 2H), 3.85- 3.76 (m, 2H), 3.17 (s, 3H), 2.83-2.73 (m, 2H), 2.43 (s, 3H), 2.26-2.16 (m, 2H), 1.50-1.40 (m, 2H), 1.38-1.29 (m, 2H), 1.28-1.10 (m, 12H). [Note: -two protons are merged in solvent peak]

422		651.5	¹H NMR (400 MHz, DMSO-d₆) δ 7.77-7.66 (m, 1H), 7.61-7.56 (m, 2H), 7.51-7.45 (m, 2H), 7.45-7.30 (m, 1H), 7.19- 7.08 (m, 1H), 4.30 (t, J = 5.1 Hz, 1H), 4.17 (t, J = 5.8 Hz, 2H), 3.82 (t, J = 5.4 Hz, 2H), 3.67 (s, 3H), 3.41-3.34 (m, 2H), 2.84- 2.76 (m, 2H), 2.45 (s, 3H), 2.30-2.17 (m, 2H), 1.43-1.33 (m, 4H), 1.29- 1.12 (m, 12H).

423		509.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J = 7.3 Hz, 2H), 7.60-7.50 (m, 3H), 7.39-7.32 (m, 1H), 4.54 (s, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.83 (t, J = 5.1 Hz, 2H), 3.19-3.11 (m, 2H), 2.28-2.19 (m, 2H), 1.70-1.55 (m, 2H), 0.92 (t, J = 7.6 Hz, 3H). [Note: -CH₃merged in solvent peak]

424	Single enantiomer, arbitrarily assigned stereochemistry	509.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (dd, J = 1.5, 8.5 Hz, 2H), 7.61- 7.51 (m, 3H), 7.38-7.33 (m, 1H), 4.54 (s, 1H), 4.17 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.14 (dd, J = 6.4, 9.4 Hz, 2H), 2.32-2.16 (m, 2H), 1.68-1.57 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). [Note: -CH₃merged in solvent peak]

425	Single enantiomer, arbitrarily assigned stereochemistry	509.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.68-7.62 (m, 2H), 7.60-7.51 (m, 3H), 7.38-7.32 (m, 1H), 4.54 (s, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.83-3.83 (m, 2H), 3.18-3.10 (m, 2H), 2.32-2.15 (m, 2H), 1.69-1.55 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). [Note: -CH₃merged in solvent peak]

426	Single enantiomer, arbitrarily assigned stereochemistry	477.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (d, J = 7.8 Hz, 2H), 7.52-7.35 (m, 4H), 7.31-7.24 (m, 1H), 4.58 (s, 1H), 4.32- 4.20 (m, 2H), 3.88-3.76 (m, 2H), 3.13 (s, 3H), 2.02-1.93 (m, 2H), 1.91- 1.81 (m, 2H). [Note: -Methyl protons merged in solvent peak].

427	Single enantiomer, arbitrarily assigned stereochemistry	477.4	¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (d, J = 7.1 Hz, 2H), 7.52-7.35 (m, 4H), 7.31-7.23 (m, 1H), 4.60 (s, 1H), 4.28- 4.21 (m, 2H), 3.84-3.78 (m, 2H), 3.12 (s, 3H), 2.01-1.93 (m, 2H), 1.90- 1.81 (m, 2H). [Note: -Methyl protons merged in solvent peak].

428		498.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.47 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.8 Hz, 2H), 7.73-7.66 (m, 1H), 7.65- 7.61 (m, 1H), 7.59- 7.53 (m, 2H), 4.58 (s, 1H), 4.30-4.23 (m, 2H), 3.89-3.80 (m, 2H), 3.13 (s, 3H), 2.05-1.94 (m, 2H), 1.93-1.84 (m, 2H). [Note: -Methyl proton merged in solvent peak].

429	Single enantiomer, arbitrarily assigned stereochemistry	498.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.48 (s, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.73-7.65 (m, 1H), 7.65- 7.61 (m, 1H), 7.60- 7.53 (m, 2H), 4.59 (s, 1H), 4.31-4.21 (m, 2H), 3.89-3.79 (m, 2H), 3.13 (s, 3H), 2.05-1.94 (m, 2H), 1.93-1.79 (m, 2H). [Note: -Methyl protons merged in solvent peak].

430	Single enantiomer, arbitrarily assigned stereochemistry	498.4	¹H NMR (400 MHz, DMSO-d₆) δ 9.45 (s, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.79-7.72 (m, 2H), 7.70- 7.63 (m, 1H), 7.63- 7.57 (m, 1H), 7.57-7.51 (m, 2H), 4.56 (s, 1H), 4.27-4.21 (m, 2H), 3.86- 3.79 (m, 2H), 3.11 (s, 3H), 2.02-1.91 (m, 2H), 1.91-1.81 (m, 2H). [Note: -Methyl protons merged in solvent peak].

431		505.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.68-7.63 (m, 2H), 7.56-7.50 (m, 2H), 7.48-7.35 (m, 2H), 7.32-7.25 (m, 1H), 4.60 (s, 1H), 4.55 (s, 4H), 4.44 (s, 2H), 4.08 (s, 2H), 3.13 (s, 3H), 2.52 (s, 3H).

432	Single enantiomer, arbitrarily assigned stereochemistry	505.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.67-7.62 (m, 2H), 7.54-7.37 (m, 4H), 7.32-7.26 (m, 1H), 4.55 (s, 4H), 4.44 (s, 2H), 4.09 (s, 2H), 3.13 (s, 3H), 2.52 (s, 3H)

433	Single enantiomer, arbitrarily assigned stereochemistry	505.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J = 7.2 Hz, 2H), 7.54-7.37 (m, 4H), 7.32-7.26 (m, 1H), 4.55 (s, 4H), 4.44 (s, 2H), 4.08 (s, 2H), 3.14 (s, 3H), 2.53 (s, 3H).

434		622.0	1H-NMR (400 MHz, DMSO-d6): δ 8.76 (d, J = 1.20 Hz, 1H), 8.39 (s, 1H), 7.91 (s, 1H), 7.82- 7.77 (m, 1H), 7.71 (d, J = 7.20 Hz, 2H), 7.55 (d, J = 8.40 Hz, 2H), 7.42-7.38 (m, 1H), 4.58 (s, 4H), 4.48 (s, 2H), 4.11 (s, 2H), 3.28 (s, 3H), 2.55 (s, 3H),

435		518.1	1H-NMR (400 MHz, DMSO-d6): δ 7.59-7.56 (m, 2H), 7.45-7.43 (m, 2H), 7.22-7.20 (m, 1H), 7.19-7.13 (m, 2H), 4.57 (s, 4H), 4.47 (s, 2H), 4.08 (s, 2H), 3.79 (s, 3H), 3.27 (s, 3H), 2.54 (s, 3H)

436		506.1	1H-NMR (400 MHz, DMSO-d6): δ 7.67-7.65 (m, 2H), 7.54-7.48 (m, 2H), 7.47-7.42 (m, 1H), 7.41-7.38 (m, 1H), 7.32- 7.30 (m, 1H), 4.57 (s, 4H), 4.47 (s, 2H), 4.10 (s, 2H), 3.27 (s, 3H), 2.55 (s, 3H)

437		549.4	¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (s, 2H), 7.63-7.56 (m, 2H), 7.54- 7.47 (m, 2H), 7.41- 7.32 (m, 1H), 7.18-7.11 (m, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 3.67 (s, 3H), 2.31-2.21 (m, 2H).

438		559.3	¹H NMR (400 MHz, CD₃OD-d₄) δ 8.02 (d, J = 8.5 Hz, 2H), 7.63-7.47 (m, 2H), 7.44-7.36 (m, 1H), 7.25 (d, J = 7.9 Hz, 1H), 4.25 (t, J = 6.1 Hz, 2H), 3.82 (t, J = 5.6 Hz, 2H), 2.33-2.21 (m, 2H)

439		475.1	¹H NMR (400 MHz, DMSO-d₆) δ 7.80 (s, 2H), 7.63 (d, J = 7.1 Hz, 2H), 7.55-7.49 (m, 2H), 7.48- 7.36 (m, 2H), 7.32- 7.26 (m, 1H), 4.61 (s, 1H), 4.15 (t, J = 5.9 Hz, 2H), 3.83 (t, J = 5.5 Hz, 2H), 2.28-2.20 (m, 2H)

440		481.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (d, J = 8.3 Hz, 2H), 7.55-7.49 (m, 4H), 7.49-7.36 (m, 2H), 7.33-7.23 (m, 1H), 5.06 (br.s, 1H), 4.64 (br.s, 2H), 4.21 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.32-2.20 (m, 2H).

441		483.2	¹H NMR (400 MHz, DMSO-d₆) δ 7.83 (s, 2H), 7.63 (d, J = 7.1 Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H), 7.50-7.36 (m, 2H), 7.32- 7.25 (m, 1H), 5.54 (d, J = 47.2 Hz, 2H), 4.20 (t, J = 5.9 Hz, 2H), 3.84 (t, J = 5.7 Hz, 2H), 2.30-2.22 (m, 2H)

Biological Assay Data

Cell Culture

[0445] Vero cells were cultured in Dulbecco's Modified Eagle Medium (DMVEM) supplemented with 1000 fetal bovine serum and 100 units/mL penicillin and streptomycin. The cells were passaged 2-3 times per week to maintain sub-confluent densities.

Assays

HSV-1 Antiviral Assay

[0446] Vero cells were seeded into 96-well plates at a density of 2.5×10³cells per well and allowed to attach overnight. Following attachment, the media was replaced with 50 μL of infection medium (DMVEM supplemented with 2% fetal bovine serum and 100 units/mL penicillin and streptomycin). A Tecan D300e digital dispenser was then used to add compounds to the culture using an 8-point 3-fold serial dilution format. The DMSO concentration was normalized to 0.5% for all treatments. Following compound addition, 50 μL of infection medium containing 80 TCID₅₀HSV-1 was added to the cells and incubated at 37° C. for 4 days. After the incubation, the plates were equilibrated to room temperature, the media was removed, and 60 of a 1:1 dilution of Cell titer glow and phosphate buffered saline was added to the cells. Following a 5-minute incubation, cell viability was quantified by measuring luminance using a Tecan Infinite M1000 Pro plate reader.

HSV-2 Antiviral Assay

[0447] Vero cells were seeded into 96-well plates at a density of 1.0×10⁴cells per well and allowed to attach overnight. Following attachment, the media was replaced with 50 μL of infection medium (DMEM supplemented with 2% fetal bovine serum and 100 units/mL penicillin and streptomycin). A Tecan D300e digital dispenser was then used to add compounds to the culture using an 8-point 3-fold serial dilution format. The DMSO concentration was normalized to 0.5% for all treatments. Following compound addition, 50 μL of infection medium containing 160 TCID₅₀HSV-2 G strain was added to the cells and incubated at 37° C. for 5 days. After the incubation, 10 μL/well of WST-8 chromogenic reagent was added and the plates incubated at 37° C. for 3 hours. Following the incubation, cell viability was quantified by measuring the absorbance at 460 nm and 620 nm using a Tecan Infinite M1000 Pro plate reader.

[0448] Table 2 provides assay data for exemplified compounds of the invention grouped in the following ranges: A indicates EC₅₀<100 nM; B indicates EC₅₀of ≥100 to <1,000 nM; C indicates EC₅₀of ≥1,000 to <5,000 nM; NA indicates not available.

TABLE 2

Assay data for exemplified compounds of the invention.
Compound
Number	HSV-1	HSV-2

1	A	A
2	B	B
3	B	B
4	B	B
5	A	A
6	A	A
7	A	A
8	A	A
9	A	A
10	A	A
11	NA	A
12	A	A
13	A	A
14	A	A
15	B	NA
16	B	B
17	A	A
18	A	A
19	NA	C
20	NA	B
21	NA	B
22	A	A
23	NA	C
24	A	A
25	A	A
26	A	A
27	NA	A
28	C	C
29	C	NA
30	NA	A
31	NA	A
32	NA	B
33	B	NA
34	B	NA
35	A	A
36	A	A
37	NA	B
38	NA	C
39	B	NA
40	C	C
41	B	B
42	A	A
43	A	A
44	C	NA
45	C	C
46	B	NA
47	NA	B
48	NA	A
49	NA	B
50	NA	B
51	C	NA
52	C	C
53	B	NA
54	B	B
55	A	A
56	B	B
57	NA	C
58	NA	A
59	C	C
60	C	C
61	B	NA
62	C	NA
63	A	NA
64	NA	B
65	NA	B
66	A	NA
67	A	A
68	A	A
69	NA	A
70	NA	A
71	A	NA
72	NA	A
73	A	A
74	B	B
75	C	C
76	C	NA
77	B	B
78	B	B
79	A	A
80	A	A
81	NA	B
82	B	NA
83	A	NA
84	B	A
85	A	A
86	B	B
87	C	NA
88	B	C
89	C	C
90	B	B
91	B	NA
92	NA	A
93	A	NA
94	NA	C
95	B	B
96	A	A
97	A	A
98	A	A
99	A	A
100	C	NA
101	A	A
102	A	A
103	A	A
104	C	NA
105	A	A
106	A	NA
107	NA	A
108	NA	A
109	NA	A
110	A	A
111	A	NA
112	NA	A
113	C	C
114	NA	A
115	C	NA
116	A	A
117	A	A
118	A	A
119	A	A
120	A	A
121	A	A
122	A	A
123	A	A
124	A	A
125	B	NA
126	A	A
127	A	A
128	A	A
129	B	NA
130	A	A
131	B	B
132	B	A
133	A	A
134	B	NA
135	B	NA
136	B	NA
137	C	NA
138	A	A
139	B	NA
140	B	B
141	A	A
142	NA	B
143	NA	A
144	NA	B
145	NA	B
146	NA	B
147	NA	A
148	A	NA
149	B	NA
150	A	NA
151	NA	B
152	NA	C
153	NA	B
154	NA	A
155	A	A
156	A	A
157	B	A
158	B	NA
159	B	NA
160	B	NA
161	A	A
162	B	NA
163	B	B
164	A	A
165	C	NA
166	B	B
167	B	NA
168	B	NA
169	A	NA
170	A	NA
171	A	A
172	A	A
173	A	A
174	C	C
175	C	C
176	C	C
177	C	NA
178	C	C
179	C	NA
180	B	NA
181	A	B
182	A	A
183	B	NA
184	NA	A
185	NA	A
186	NA	B
187	NA	B
188	NA	B
189	NA	B
190	NA	B
191	NA	A
192	NA	A
193	A	A
194	A	A
195	NA	A
196	NA	A
197	NA	C
198	NA	A
199	NA	B
200	NA	B
201	NA	C
202	NA	A
203	NA	A
204	NA	C
205	NA	B
206	NA	A
207	NA	B
208	NA	A
209	A	A
210	A	A
211	A	A
212	A	A
213	NA	A
214	NA	A
215	NA	A
216	A	A
217	NA	A
218	NA	A
219	NA	B
220	NA	A
221	NA	A
222	NA	A
223	NA	A
224	NA	A
225	NA	A
226	NA	B
227	NA	B
228	A	A
229	NA	A
230	NA	B
231	NA	B
232	NA	B
233	NA	B
234	NA	A
235	A	A
236	NA	A
237	NA	A
238	NA	C
239	NA	A
240	NA	B
241	NA	C
242	A	A
243	A	A
244	NA	A
245	A	A
246	NA	A
247	NA	A
248	NA	A
249	NA	A
250	NA	A
251	A	A
252	NA	A
253	NA	A
254	NA	B
255	A	A
256	NA	A
257	NA	A
258	NA	A
259	A	A
260	NA	A
261	NA	B
262	NA	C
263	NA	B
264	NA	A
265	NA	A
266	NA	B
267	NA	B
268	NA	A
269	NA	B
270	NA	A
271	NA	C
272	NA	C
273	NA	B
274	A	A
275	NA	A
276	NA	A
277	A	A
278	NA	B
279	NA	B
280	NA	C
281	NA	B
282	NA	B
283	NA	B
284	NA	B
285	NA	A
286	NA	C
287	NA	A
288	NA	B
289	NA	C
290	NA	C
291	NA	A
292	NA	C
293	A	A
294	NA	B
295	NA	A
296	NA	B
297	NA	B
298	NA	A
299	NA	A
300	NA	B
301	NA	A
302	NA	B
303	NA	A
304	NA	A
305	A	A
306	NA	A
307	NA	B
308	NA	B
309	NA	A
310	A	A
311	NA	B
312	NA	C
313	NA	A
314	NA	A
315	NA	A
316	A	A
317	NA	a
318	A	A
319	NA	A
320	NA	A
321	NA	A
322	A	A
323	A	A
324	A	A
325	NA	A
326	NA	A
327	NA	A
328	NA	A
329	NA	A
330	NA	A
331	NA	A
332	NA	A
333	NA	A
334	NA	A
335	NA	C
336	NA	A
337	NA	A
338	B	B
339	A	A
340	NA	A
341	NA	A
342	A	A
343	A	A
344	NA	A
345	NA	B
346	NA	B
347	NA	B
348	NA	B
349	NA	A
350	NA	A
351	NA	A
352	NA	A
353	NA	A
354	NA	A
355	NA	A
356	NA	A
357	NA	C
358	NA	C
359	NA	C
360	NA	A
361	A	A
362	NA	A
363	A	A
364	NA	A
365	NA	A
366	NA	A
367	NA	A
368	NA	A
369	A	A
370	NA	A
371	NA	A
372	NA	A
373	NA	A
374	NA	A
375	NA	A
376	A	A
377	NA	A
378	NA	A
379	NA	A
380	NA	C
381	NA	B
382	NA	B
383	NA	B
384	NA	A
385	NA	B
386	NA	A
387	NA	A
388	NA	A
389	NA	A
390	NA	A
391	NA	A
392	NA	A
393	NA	A
394	NA	A
395	NA	A
396	NA	A
397	NA	B
398	NA	B
399	NA	B
400	NA	A
401	NA	A
402	NA	B
403	NA	A
404	NA	A
405	NA	B
406	NA	A
407	NA	B
408	NA	A
409	NA	A
410	NA	A
411	NA	A
412	NA	B
413	NA	A
414	NA	A
415	NA	A
416	NA	A
417	A	A
418	NA	A
419	NA	A
420	NA	A
421	NA	A
422	NA	A
423	NA	A
424	NA	A
425	NA	A
426	NA	A
427	NA	A
428	NA	A
429	NA	A
430	NA	A
431	NA	A
432	NA	A
433	NA	A
434	A	A
435	NA	A
436	A	A
437	NA	A
438	NA	C
439	NA	A
440	NA	A
441	A	A

[0449] It will be understood that various details of the presently disclosed subject matter may be changed without departing from the scope of the presently disclosed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.

[0450] All publications, patents, and patent applications cited in this specification are incorporated herein by reference for the teaching to which such citation is used.

[0451] Test compounds for the experiments described herein were employed in free or salt form.

[0452] The specific responses observed may vary according to and depending on the particular active compound selected or whether there are present carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with practice of the present disclosure.

[0453] Although specific embodiments of the present disclosure are herein illustrated and described in detail, the disclosure is not limited thereto. The above detailed descriptions are provided as exemplary of the present disclosure and should not be construed as constituting any limitation of the disclosure. Modifications will be obvious to those skilled in the art, and all modifications that do not depart from the spirit of the disclosure are intended to be included with the scope of the appended claims.

Claims

1. A compound, wherein the compound is:


Com-
pound
Num-	Structure
ber


1

5

6

7

8

13

35

36

235

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein the compound is:


Com-
pound
Num-	Structure
ber


1

5

6

7

8

13

35

36

	or

235

3. The compound of claim 1, wherein the compound is:


Com-
pound
Num-	Structure
ber

5

6

7

8

13

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, wherein the compound is:


Com-
pound
Num-	Structure
ber

5

6

7

8

	or

13

5. The compound of claim 1, wherein the compound is:


Com-
pound
Num-	Structure
ber

1

35

36

235

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5, wherein the compound is:


Com-
pound
Num-	Structure
ber

1

35

36

	or

235

7. A compound, wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. A compound, wherein the compound is:

9. A pharmaceutical composition comprising:

a compound:

and a pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising a compound according to claim 7, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

11. A method for the treatment or prophylaxis of a herpes virus infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of claim 7, or a pharmaceutically acceptable salt thereof.

12. A method for suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of claim 7, or a pharmaceutically acceptable salt thereof.

13. A method for the treatment or prophylaxis of a herpes virus infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 10.

14. A method for the suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 10.

15. The method of claim 11, wherein the herpes virus infection is an HSV-1 infection, an HSV-2 infection, a varicella zoster virus (VZV) infection, an Epstein-Barr virus (EBV) infection, a cytomegalovirus (CMV) infection, a human herpes virus 6 (HHV-6) infection, a human herpes virus 7 (HHV-7) infection, or a human herpes virus 8 (HHV-8) infection.

16. The method of claim 13, wherein the herpes virus infection is an HSV-1 infection, an HSV-2 infection, a VZV infection, an EBV infection, a CMV infection, an HHV-6 infection, an HHV-7 infection, or an HHV-8 infection.

17. The method of claim 15, wherein the herpes virus infection is an HSV-1 infection or an HSV-2 infection.

18. The method of claim 16, wherein the herpes virus infection is an HSV-1 infection or an HSV-2 infection.

19. The method of claim 12, wherein the HSV symptoms or outbreaks are associated with an HSV-2 infection.

20. The method of claim 14, wherein the HSV symptoms or outbreaks are associated with an HSV-2 infection.

21. A method for the treatment or prophylaxis of a herpes virus infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of claim 8.

22. A method for suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound of claim 8.

23. A method for the treatment or prophylaxis of a herpes virus infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 9.

24. A method for suppressing recurrence of HSV symptoms or outbreaks in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 9.

25. The method of claim 21, wherein the herpes virus infection is an HSV-1 infection, an HSV-2 infection, a VZV infection, an EBV infection, a CMV infection, an HHV-6 infection, an HHV-7 infection, or an HHV-8 infection.

26. The method of claim 23, wherein the herpes virus infection is an HSV-1 infection, an HSV-2 infection, a VZV infection, an EBV infection, a CMV infection, an HHV-6 infection, an HHV-7 infection, or an HHV-8 infection.

27. The method of claim 25, wherein the herpes virus infection is an HSV-1 infection or an HSV-2 infection.

28. The method of claim 26, wherein the herpes virus infection is an HSV-1 infection or an HSV-2 infection.

29. The method of claim 22, wherein the HSV symptoms or outbreaks are associated with an HSV-2 infection.

30. The method of claim 24, wherein the HSV symptoms or outbreaks are associated with an HSV-2 infection.